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Madeirolide A (1) is a structurally novel polyketide natural product first isolated from the 
deep-sea sponge Leiodermatium sp. by Wright in 2009. Initial biological investigations of 
madeirolide A revealed potent inhibition of the fungal pathogen Candida albicans but failed to 
determine any appreciable cytotoxicity when tested against a limited range of cancer cell 
lines.  
The unusual bioactivity of madeirolide A coupled with uncertainty over the true 
stereostructure of the natural product makes it a compelling target for synthesis. This thesis 
discloses synthetic efforts towards the total synthesis of madeirolide A with an emphasis on 
the construction of the all-cis C21 – C27 eastern tetrahydropyran.  
 
Chapters 1 and 2 provide an introduction to the importance of natural products in drug 
discovery and outline the context of this project with details of the isolation and biological 
activity of madeirolide A (1). Previous synthetic efforts are also reviewed including those from 
within the group which formed the basis of the present studies.  
Chapter 3 describes the synthesis of a fully elaborated C1 - C11 fragment (A), building upon 


















































modified approach designed to avoid some of the major challenges previously encountered 
such as undesired migration of protecting groups and challenges in selectively installing an 
(E)-vinyl iodide.  
Chapter 4 discusses ongoing efforts towards the challenging C12 - C27 fragment of 
madeirolide A. The stereocontrolled synthesis of several linear C19 – C27 precursors (B) is 
outlined, followed by details of screening reactions conducted to affect the desired oxy-
Michael cyclisation. Additionally, extensive computational studies have been undertaken in 
an attempt to rationalise the frustrating lack of reactivity observed with the goal of developing 
a substrate suitably elaborated to cyclise. Finally, the asymmetric synthesis of the C13 – C17 
subfragment (C) is outlined, which will provide eventual access to the eastern 
tetrahydrofuran.  
Chapter 5  summarises the synthetic work carried out thus far and explores potential 
strategies for the future completion of the natural product with a focus on alternative 
disconnections of the eastern tetrahydropyran.   
Finally, the appendices contain full experimental details and copies of NMR spectra for key 
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COMPOUND NUMBERING  
The naming and numbering of compounds follows priorities laid out by IUPAC. For the 
purposes of clarity, madeirolide A 1 and fragments derived from it are numbered in 
accordance with the system proposed by the isolation group. To avoid ambiguity, this 
numbering is used for assignment of resonances in NMR spectra. Additional numbers (32 – 
37) have been used for the cinerulose sugar to avoid confusion with the assignment of 
diastereotopic protons.  
 
RELATIVE STEREOCHEMICAL RELATIONSHIPS  
As defined by Masamune, syn- and anti- nomenclature is used in this thesis to define the 
relative stereochemistry of two substituent groups along a carbon chain. Groups are 
considered syn if they point in the same direction out of the plane of the paper, conversely, 






























































Metal enolates are described as E- and Z-enolates on the basis of IUPAC recommendations. 
The metal-oxygen bond is taken to have the highest priority in all cases, irrespective of the R- 




The relative stereochemistry of THP rings is described as either 2.6-cis or 2,6-trans based 
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bp boiling point  
br broad or broadened (spectra) 
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Bz benzoyl 
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c concentration 
calcd calculated 
CI chemical ionisation  
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COSY  correlation spectroscopy, 1H – 1H  
concd concentrated  
cryst crystalline  
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1. INTRODUCTION: NATURAL 
PRODUCTS & ORGANIC SYNTHESIS   
1.1 BIOACTIVE NATURAL PRODUCTS  
The use of natural products in traditional medicine has been extensively documented, with 
records of crude extracts from plant, animal and marine sources dating back as far as 2100 
BC.1 The development of modern synthetic and medicinal chemistry has gradually enabled 
the active components of these traditional remedies to be isolated in their pure forms allowing 
thorough evaluation of their biological properties.  
While many traditional medicines have now been shown to have minimal efficacy, there are 
numerous examples of natural products that have progressed through clinical trials and are 
still widely used, either in their original form or as synthetic analogues. Morphine 1, cocaine 
2 and quinine 3 (Figure 1.1) are all examples of naturally occurring molecules known to 
humankind for hundreds of years, yet only isolated as pure compounds in recent history.  
The systematic study of traditional medicines is still ongoing, a prime example being 
cannabinol 4 which has received significant interest in recent years owing to its potential uses 
for the treatment of pain, nausea, arthritis and addiction.2 
 
Figure 1.1: Structures of natural products used in traditional medicine that have subsequently been 



















1: Morphine 2: Cocaine 3: Quinine 4: Cannabinol





1.1.1 NATURAL PRODUCTS OF MARINE ORIGIN  
Despite accounting for more than 70% of the earth’s surface,3 there are remarkably few 
representations of marine derived natural products in traditional medicine. This can be 
attributed to the fact that the marine environment remained largely unexplored prior to the 
development of underwater breathing apparatus and deep-sea submersibles in the 20th 
century.  
Sustained scientific interest in marine natural products has permitted the isolation of over 
18000 unique chemical entities,4 many of which possess novel modes of action5 and structural 
motifs not found terrestrially.4 Currently, seven marine natural products (or analogues 
derived from them) have been approved for use in humans by the FDA,6 with around 20 at 
various stages of clinical trials, mostly for oncological targets. One example of a successful 
marine natural product now used extensively in the clinic is Yondelis® 5 (trabedectin, 
Pharmamar)7, first isolated from the marine tunicate Ecteinascidia turbinata in 1984 and 
approved by the FDA in 2015 for the treatment of soft tissue sarcoma.  
With estimates suggesting that as little as 5% of the marine environment has been explored, 
the ocean represents a significant untapped potential in the discovery of new medicines. As 
analytical tools and deep-sea exploration techniques advance, an ever-increasing number of 
new chemical entities are sure to be discovered.  
 
Figure 1.2: Structure of Yondelis® 5, an example of a marine natural product approved by the FDA for 
the treatment of cancer (Pharmamar).  
1.1.2 NATURAL PRODUCTS AS DRUG DISCOVERY LEADS    
In recent years, there has been a resurgence of interest in natural products as lead-like 
compounds for drug discovery owing to the failure of ‘modern’ methods such as 
combinatorial synthesis and high-throughput screening (HTS) to deliver significant numbers 
of drug candidates. Indeed, annual FDA approvals have remained steady despite substantial 
increases in funding, suggesting that new medicines may be becoming harder to find. The 























to its target, and only its target. This binding is difficult to achieve artificially, with most 
synthetic drugs occupying vastly different chemical space than natural products.8,9 In 
contrast, evolution has meant that natural products are necessarily ‘drug-like’ – organisms 
would not continue to produce them as secondary metabolites if they imparted no advantage. 
The ability to harness this source of biological activity is of key importance for the discovery 
of new drugs.  
The future of drug discovery likely lies at the intersection between natural products and 
synthetic medicines: natural product-like screening libraries offer the possibility of finding 
more diverse hits, diversity-oriented synthesis (DOS) offers the possibility of generating large 
numbers of stereochemically diverse fragments, and genomics offers the possibility of 
manipulating biosynthetic pathways to offer new possibilities for drug design.  
1.2 THE ROLE OF ORGANIC SYNTHESIS IN NATURAL PRODUCT CHEMISTRY  
1.2.1 SYNTHESIS AS A SOURCE OF MATERIAL  
One of the greatest challenges when considering the use of natural products and their 
derivatives in drug discovery is the sustainable supply of material, with multi-gram quantities 
required to progress a molecule through clinical trials and into the clinic. While some 
secondary metabolites such as opium and quinine are produced abundantly in nature, others 
are produced in such low concentrations that isolation from natural sources is neither 
economically nor environmentally sustainable. Despite the significant improvements in 
bioengineering that have allowed an increasing number of secondary metabolites to be 
produced artificially through culture, synthesis is still often the only tractable way to reliably 
obtain the necessary material.  
The Novartis total synthesis of (+)-discodermolide 6 was a landmark achievement in process 
chemistry, demonstrating the viability of carrying out academic synthesis in an industrial 
context.10–14 Reported in 2004, Mickel and co-workers at Novartis successfully synthesised 64 
g of (+)-discodermolide via a route that took advantage of the best aspects of the syntheses 
developed independently by Paterson and Smith, including several challenging asymmetric 
aldol reactions. Although the clinical development of discodermolide was halted during 
clinical trials owing to unexpected levels of toxicity, it remains to this day one of the most 
complex molecules to be produced on a process scale, and validated the plausibility of using 
total synthesis to access significant quantities of a natural product.  
A more recent example is eribulin mesylate 11 (Eisai Co.), a simplified analogue of the marine 
natural product halichondrin B 10 that was approved for the treatment of breast cancer in 





2010.15 The stereoselective synthesis of 11 takes 62 steps,16 making it the most complex non-
peptide drug to be obtained using organic synthesis to date.   
 
Scheme 1.1: The Novartis route to (+)-discodermolide 6 demonstrating the possibility of carrying out 
complex asymmetric synthesis on an industrial scale (Novartis/Mickel).  
 





















































































Semi-synthesis is also an important discipline in which abundant natural occurring molecules 
are chemically elaborated into more complex, higher value products. Two key examples of 
this are the synthesis of taxol 12 from 10-deacetylbaccatin 13, and trabectedin 14 from 
cyanosafracin B 15,17 both of which are approved by the FDA as chemotherapeutic agents.   
 
Figure 1.4: Semi-synthetic routes used in the process scale synthesis of taxol 12 and trabedectin 14.  
Ultimately, chemical synthesis is often the only viable way to produce natural product drugs 
reliably, and with new methodology constantly pushing the boundaries of what is possible, 
ever more complex molecules can be evaluated as potential drugs. 
1.2.2 SYNTHESIS AS A METHOD FOR STRUCTURE DETERMINATION   
The structural elucidation of new natural products facilitates interdisciplinary research 
across chemistry, biology and medicine.  In the formative years of natural product research, 
structure elucidation of complex metabolites required multi-gram quantities of material to be 
isolated in order to enable chemical degradation and derivatisation studies which aimed to 
produce known fragments from which the complete structure of the molecule could be pieced 
together. This process was time consuming, and the unambiguous assignment of structure 



























































With the development of X-ray crystallography, high-resolution NMR, and advanced MS 
techniques, it is now common for structural elucidation to be carried out on milligram scales, 
significantly reducing the burden of isolation. Moreover, many of the above analytical 
techniques are non-destructive, allowing the material to be reused in subsequent biological 
assays. These techniques, coupled with advances in computational structure prediction and 
verification tools, make it possible to deduce the structure of even the most challenging 
metabolites with high-levels of confidence.  
To put this in context, erythromycin A 16 was isolated in 1952 from the bacteria Streptomyces 
erythreus, but not until 1957 after exhaustive studies, was the complete structure able to be 
established, several years after its widespread adoption as a broad-spectrum antibiotic 
(Figure 1.5). In contrast, the structure of a similarly  complex polyketide natural product, 
hemi-phorboxazole A 17, isolated in trace amounts from Phorbas sp. was able to be elucidated 
fully using only 16.5 μg of material.18 Both natural products have subsequently had their 
structures verified through total synthesis, with synthetic material correlating well to the 
authentic samples.19,20 
 
Figure 1.5: Structures of erythromycin 16 and hemi-phorboxazole A 17.  
While these developments in technology may suggest that any metabolite may be defined 
unambiguously without the requirement for structure verification (i.e. through synthesis), 
some challenges still exist, often due to ambiguity arising in spectroscopic data around 
isolated stereocentres, or in highly flexible chains where the conformation is unpredictable. 
In recent analyses by Nicolaou21 (covering 1990 – 2005) and McPhail22 (covering 2005 – 2010), 
over 600 natural products were identified that subsequently required structural revision.* 
These ambiguities may be resolved through the total synthesis of molecules with defined 
connectivity and stereochemistry, allowing for comparison between synthetic and authentic 
 
* The true number of incorrectly assigned structures is likely significantly higher since many reported 
natural products are never investigated further due to a lack of biological activity or interesting 





























samples of the natural product. Leiodermatolide A 21 and amphidinolide A 19 (Figure 1.6) 
were both able to be correctly identified through detailed NMR studies and synthetic efforts 
by Paterson23 and Trost24 respectively after the synthesis of several (of the many) possible 
diastereomers.   
 
Figure 1.6: Representative examples of polyketide natural products reassigned using total synthesis. 
Stereocentres inverted relative to the initial assignment are highlighted. 
Baulamycin A 23, reported in 2014,25 exemplifies the challenges associated with the complete 
structural elucidation  of a natural product using spectroscopic methods alone (Figure 1.7). 
The natural product is highly conformationally flexible, casting doubt on the original 
stereochemical assignment of the natural product 22 which was established using Murata’s 
empirical J-based configurational analysis known to be inaccurate for isolated 
stereocentres.26 Recent work by Aggarwal27 established that synthetic baulamycin A did not 
correlate with the proposed structure 22, however the spectroscopic data did not offer any 
clues as to where the error may be. The true structure of baulamycin A 23 was eventually 
discovered after significant synthetic efforts, resulting in an impressive five stereocentres 













































Figure 1.7: Structural reassignment of baulamycin A (Aggarwal).  
1.3 SUMMARY & ANALYSIS  
The discovery of new medicines is of critical importance to society. Despite significant 
progress, many diseases still have no effective treatment, and drug-resistance has led to many 
widely-used drugs rendered useless.  
While nature is often able to provide inspiration for new drugs, synthesis is still deeply 
important in the search for novel and biologically active molecules. The above discussion aims 
to highlight the role of chemical synthesis as a central science to the disciplines of drug 
discovery and medicinal chemistry, providing examples in the contexts of structural 
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2. INTRODUCTION PART II: 
MADEIROLIDE A  
 
2.1 MADEIROLIDE A 
Madeirolide A 1 (Figure 2.1) is a structurally unique marine polyketide isolated from the 
lithisthid sponge Leiodermatium sp. At the time of discovery, only three other natural products 
had been isolated from a sponge of this genus: leiodermatolide A 20,23 and the leiodelides A 
25 and B 26.28 Due to continued efforts, two additional congeners of leiodermatolide have 
recently been identified (leiodermatolide B 27 and C 28).29 
Of the known natural products isolated from Leiodermatium sp., only leiodermatolide A 20 
has had its structure confirmed conclusively through total synthesis,30 with the complete 
stereostructures of the leiodelides still elusive despite synthetic studies and computational 
investigations by several research groups.31–33  
2.1.1 ISOLATION & STRUCTURE ELUCIDATION  
The isolation and structure elucidation of madeirolide A 1 was carried out by Winder and 
Wright at the Harbor Branch Oceanographic Institute (HBOI) in 2009. A 1 kg sample of 
Leiodermatium sp. was collected at a depth of 656 m off the southwest coast of Porto Santo 
(Madeira, Portugal). Exhaustive extraction of the sponge followed by normal and reverse 
phase chromatography allowed the isolation of madeirolide A 1 (1.2 mg), and a similarly 
complex congener, madeirolide B 24 (1.3 mg), both as amorphous white solids. 
The amorphous form and resistance to crystallisation of madeirolide A 1 meant that extensive 
1D- and 2D-NMR spectroscopy had to be relied upon for the purposes of structure elucidation. 
The 2D structure of madeirolide A was assigned to fit with the HR-ESI-MS and 13C NMR data, 
which suggested a molecular formula of C37H56O11 (m/z observed [M+Na]+ 699.3735, 
calculated 699.3715) and required ten degrees of unsaturation be present within the molecule.  






Figure 2.1: Structures of madeirolide A 1, madeirolide B 24, and other natural products isolated from 
Leiodermatium sp. Undefined stereocentres marked with (*) represent currently unknown 
configuration. 
Closer inspection of the 13C NMR shifts indicated the presence of three carbonyl groups: one 
ester (δC 170.9 ppm) and two ketones (δC 211.0, 208.2 ppm).  Two olefins (δC 122.8, 127.5, 130.8, 
142.3 ppm) were also present, accounting for five degrees of unsaturation in total.  The 
remaining five degrees of unsaturation would later be identified as cyclic structures: two 
tetrahydropyrans (THP), a tetrahydrofuran (THF), a pyranose sugar, and the macrolactone 
itself. 	
The connectivity of madeirolide A 1 was established based on six isolated proton spin systems, 
determined using 1H-1H-COSY and 1H-13C-gHSQC relationships (Figure 2.2), with 1H-13C-
HMBC correlations used to connect them into a single structure. A bis-acetate derivative was 
also prepared during the elucidation work to confirm the positions of the free hydroxyl groups 









20: leiodermatolide A (R = OH)
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Figure 2.2: Planar 2D structure of madeirolide A showing relevant COSY and HMBC correlations. 
The 16 stereocentres present in madeirolide A 1 are arranged in three relatively isolated 
clusters: A, containing the tetrahydrofuran and diene; B, containing the sugar and the western 
tetrahydropyran; and C, containing the all-cis eastern tetrahydropyran. The relative 
configuration within each stereocluster of madeirolide A was proposed on the basis of scalar 
3JH-H couplings and NOESY correlations. Key NOESY correlations within each stereocluster 
are shown in Figure 2.3.  
 
Figure 2.3: Key reciprocal nOe enhancements used to assign relative stereochemical relationships 
within the three heterocycles.  
The relative stereochemistry of the six-membered rings is unambiguous; nOe analysis is higly 
accurate owing to the well-defined conformations adopted. For five-membered rings, nOe 
analysis can lead to ambiguity as the through-space cis and trans couplings often have similar 
magnitudes.34Additional NOESY experiments allowed for the observation of transannular 






































































































three stereoclusters to be determined. Crucially, the proposed assignment of relative 
stereochemistry was based upon a correlation between the C29-methyl group and H22/H23*. 
The absolute configuration of madeirolide A has yet to be determined conclusively, with 
attempts at derivatisation to generate the corresponding MTPA esters unsuccessful. As 
depicted, the absolute configuration of madeirolide A 1 is defined based on that of l-
cinerulose, which is the naturally occurring isomer of the sugar, and found in other natural 
products such as aclacinomycin A 29 (Figure 2.4).35 The completed total synthesis of 
mandelalide A (see §2.2.1.1) provides additional support for the proposed configuration, 
having the same absolute configuration as madeirolide A.  
 
Figure 2.4:  Structure of aclacinomycin A 29 showing the l-cinerulose moiety.  
2.1.2 STRUCTURE REASSIGNMENT   
Although the 2D connectivity was established unambiguously by Winder and Wright, it is now 
believed that an error was made in assigning the overall relative stereochemistry, due to a mix-
up of a crucial transannular NOESY correlation across the macrolactone. The error is thought 
to have occurred when the working 3D diagrams produced during the elucidation work 
(Figure 2.3) were translated into standard 2D skeletal representations (Figure 2.5). 
Madeirolide A was initially depicted as shown in 30, requiring that the C29-methyl group be 
drawn pointing downwards in order that the transannular NOESY correlations between the 
C29-methyl group and H22/23 were preserved. This depiction led to the C9-stereocentre 
ending up with an (S) configuration, in conflict with the (R) configuration of Winder’s 3D 
diagrams.  
 
* While the observation of the transannular NOESY correlation was correct, the interpretation led to an 
incorrect assignment of the stereochemistry at C9 due to the way in which the macrolactone was 





















Figure 2.5: Comparison of madeirolide A 1 with the C9-epimer proposed by Winder and Wright in its 
initial representation 30. The stereocentre inverted relative to Winder’s initial assignment is 
highlighted.  
Winder’s error can be appreciated by considering the calculated lowest energy conformations 
of the two C9-epimers of madeirolide A in chloroform (Figure 2.6): 1 and 30. In 1, the C29 
protons and H22/23 are in close proximity, allowing an nOe enhancement to be observed. This 
is not the case for C9-epi-madeirolide A 30, where the more distant protons in question are 




Figure 2.6: Lowest energy conformations of C9-epi-madeirolide A 30 and madeirolide A 1. Protons 
involved in the observed transannular nOe enhancements are highlighted in yellow. Some hydrogens 






















30: Winder and Wright’s representation 
of putative Madeirolide A




























2.1.3 STRUCTURE VERIFICATION USING THE DP4 PARAMETER    
With remaining uncertainty over the relative stereochemistry of madeirolide A, and in order 
to further validate our proposed reassignment, the molecule was considered a suitable 
candidate for computational studies using the DP4 methodology reported by Goodman and 
Smith in 2010.36 Initial DP4 calculations on madeirolide A were carried out by Dr Guy 
Naylor,37 a former member of the Paterson group.   
The DP4 parameter allows for the identification of the most probable relative stereochemistry 
of a compound by comparison of calculated NMR shifts to experimentally measured values. 
Given that the NMR spectrum of two enantiomers is necessarily identical, DP4 is able only to 
assist in assignment of relative stereochemistry, with other methods such as chiral 
derivatisation necessary to gain insight into the absolute configuration.  Since its initial 
publication, the DP4 methodology has been widely adopted, finding extensive use in the 
structure determination of complex natural products. Recently, several developments have 
been made to the process, notably allowing for automation of the process using Python,38 and 
improvement of accuracy when studying  small molecules using DP4+. 39  
To utilise the DP4 parameter, a conformational search using molecular mechanics is first run 
on all diastereomers to be considered in the analysis*.  Low energy conformers within 10 kJ 
mol-1 of the minimum†  are then used in a calculation of NMR shielding tensors from which 
solvent specific chemical shifts may be derived (Figure 2.7). One unique feature of the DP4 
methodology is that the calculated NMR shifts for each conformer are subjected to Boltzmann 
weighting in order to determine the averaged overall chemical shifts – in doing this, the 
calculation more accurately represents the distribution of conformers in solution, but also 
avoids computationally costly DFT optimisations of every conformer in the ensemble which 




* To give an example, a molecule with 10 stereocentres would have 512 possible diastereomers, excluding 
enantiomers, which may be ignored during DP4 analysis as the calculated NMR shifts will necessarily 
be identical. This would involve 512 individual conformational searches to be conducted, with the low-
energy conformers generated from each diastereomer then used in subsequent DFT calculations.  
† 10 kJ mol-1 was chosen as an arbitrary cut-off, providing a high enough threshold to ensure all low 
energy conformers are found, while minimising the computational expense.  Previous studies in the 
Goodman group have shown that raising the cutoff to 25 kJ mol-1 does not provide a significant 
enhancement in results.  








Figure 2.7: Computational workflow for assignment of relative stereochemistry using the DP4 
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In Naylor’s analysis of madeirolide A, the six-membered rings were considered as single 
variables with defined relative stereochemistry, while the stereocentres around the five-
membered ring were considered separately along with the isolated stereocentres – this 
simplification was made as six-membered rings adopt predictable conformations and nOe 
analysis is generally considered reliable.  In total, only eight variables were considered, 
reducing the number of diastereomers considered in the calculation from 32 768 to a more 
manageable 128.  
 
 
Figure 2.8: Regions considered in the DP4 analysis of madeirolide A (Naylor).37 
In total, the calculations on madeirolide A took six weeks to run distributed across multiple 
CPUs to generate 1285 low-energy conformations which were used in GIAO NMR 
calculations. The two diastereomers with the highest probability by DP4 based on 1H, 13C, and 
the combined 1H/13C calculations are show in Figure 2.9. Diastereomer 1 (madeirolide A) was 
found to have the highest probability in all cases (1H: 61.06%, 13C: 93.59%. 1H/13C: 99.65%)*. 
Notably, Winder and Wright’s C9 epimer does not appear in the results, with the next most 
likely diastereomer being the C18 epimer 31 (1H/13C: 0.35%), inverting the relative 
stereochemistry across the tetrahydrofuran ring. The results of the DP4 calculations coupled 
with careful re-analysis of the NMR data gives strong support to 1 being the true 
stereostructure of madeirolide A, providing a strong basis for which a total synthesis can be 
carried out. Only completion of the synthesis will allow the absolute configuration of the 
molecule to be determined.  
 
* Empirical results from within the Goodman group suggest that a combined 1H/13C weighted average 
provides the most reliable DP4 probabilities.  During the GAIO DFT calculations, shielding tensors are 
calculated for all atoms, meaning calculation of 1H, 13C and 1H/13C probabilities does not require any 
additional computational resources.  
1: Madeirolide A
Regions considered

















Figure 2.9: Results of the DP4 analysis of madeirolide A showing the two most probable diastereomers 
based on 1H, 13C or combined 1H/13C calculations. Centres inverted relative to the proposed structure of 
madeirolide A are highlighted. 3D structures represent the DFT optimised lowest energy conformation 




































































1: 93.59% 32: 3.87%
1: 99.65% 31: 0.35%





2.1.4 BIOLOGICAL ACTIVITY  
Biological evaluation of the madeirolides was carried out by Winder at the time of isolation. 
Due to the low isolation yield (1.2 mg and 1.3 mg for madeirolide A and B respectively from 1 
kg of wet sponge) and material lost to derivatisation attempts, only preliminary biological 
studies were able to be conducted, severely limiting the conclusions able to be drawn. 
Madeirolide A 1, madeirolide B 24, and the bis-acetyl derivative prepared during the structure 
elucidation work were all evaluated. The results of these studies are summarised below in 
Table 2.1:  
Table 2.1: Summary of biological data reported for madeirolides A and B, and the bis-acetyl derivative of 
madeirolide A (Wright).40 






 ZOI  (mm) 
Fungistatic MIC  
(ug/mL) 
Fungicidal MIC  
(ug/mL) 
Madeirolide A  22 44  25 6.2 12.5 
Madeirolide B  21 45  28 6.2 21 
bis-acetyl 
madeirolide A 
 10 -4b  - >50c >50c 
a: Cytotoxicity measured at a concentration of 10 μg/mL of compound 
b: Cell proliferation was greater than the drug-free control sample 
c: The assay was run at concentrations of up-to 50 μg/mL, no MIC was reached below this point 
 
2.1.5 CYTOTOXICITY  
Madeirolides A 1 and B 24, along with the bis-acetyl derivative prepared during the structure 
elucidation work were tested using standard MTT cell proliferation assays at a concentration 
of 10 μg/mL.  The choice of cell lines used was directed by the Wright groups continued 
interest and funding in the discovery of novel anti-tumour agents against pancreatic cancer. 
Two adenocarcinoma cell lines were investigated: AsPC-1, obtained from a 62-year-old 
female, and PANC-1, isolated from a 56-year-old male. In both cases the cancer was found to 
be highly aggressive, with significant metastases to local abdominal organs.41 Despite marine 
polyketide natural products often showing significant levels of cytotoxicity,42  the above 
assays using the madeirolides suggests minimal inhibition of cancer cell growth, albeit against 
a limited range of cell-lines.   
2.1.6 FUNGISTATIC/FUNGICIDAL PROPERTIES  
In recent years, interest in small molecules active against Candida albicans and other fungal 
pathogens has increased due to the evolution of drug resistance towards currently used 





pharmaceuticals, the most common class of which, the azoles, are rapidly becoming 
obsolete.43  
The fungicidal and fungistatic properties of the madeirolides, and the bis-acetyl derivative 
were evaluated used a disk diffusion assay. As previously, the bis-acetyl derivative showed 
zero activity, however both madeirolide A and B were shown to be potent inhibitors of 
pathogen growth, having large zones of inhibition (ZOI) at micromolar concentrations. * 
2.2 RELATED NATURAL PRODUCTS – THE MANDELALIDES 
Three years after the isolation and characterisation of the madeirolides, McPhail reported the 
discovery of mandelalide A 33 (Figure 2.10) along with three structurally related congeners.44 
Despite being isolated from a marine sponge of a different genus (Lissoclinum ascidian) that 
was collected over 5000 miles away off the coast of Port Elizabeth (South Africa), the 
proposed structures of the mandelalides show a remarkable degree of homology to those of 
the madeirolides.   The shared western tetrahydropyran motif (differentially glycosylated and 
lacking the methyl group) is evident, along with the eastern tetrahydrofuran. Given the clear 
structural similarities between the two polyketides, it would not be unreasonable to suggest a 
common biogenic origin 
 
Figure 2.10: Comparison of madeirolide A 1 to McPhail’s originally proposed structure of mandelalide 
A 33.  
2.2.1 STRUCTURAL REASSIGNMENT  
The first total synthesis of putative mandelalide A 33 was completed by Fürstner and co-
workers in 2014.45 Disappointingly, comparison between synthetic and natural samples of the 
natural product revealed small but irreconcilable differences in the spectral data, suggesting 
either an error in the relative stereochemistry proposed by McPhail, or in the synthetic 
 
* Fluconazole, one of the current treatments in use for the treatment of C. Albicans has reported MIC 















































route.44 An independent synthesis of the same putative structure by Ye and co-workers ruled 
out the possibility of a synthetic error, arriving at the same spectral discrepancies via a unique 
synthetic route.46  
McPhail’s error was initially attributed to the inversion of a single stereocentre at C11 based 
upon the magnitude of the errors observed in the 13C NMR spectra (C11 ∆δC  = +1.4 ppm; C25 
∆δC  = -1.8 ppm) with Fürstner also suggesting that the same ROESY correlations could be 
observed from either C11 epimer. *  Unfortunately, preparation of the C11 epimer and 
comparison of the 1H and 13C NMR spectra again showed significant differences (C25 ∆δC  = 
+3.7 ppm) suggesting that more significant errors existed in McPhail’s originally proposed 
structure.47 
Ye was the first to identify the true structure of mandelalide A 34, completing the total 
synthesis and structural reassignment in 2014.46 Shortly after, Fürstner published synthetic 
and computational studies which identified the same diastereomer as Ye,48 thus allowing the 
stereostructure of mandelalide A 34 to be reassigned with confidence, bringing the 
stereochemistry into agreement with that proposed for madeirolide A.  
 
Figure 2.11: Structural reassignment of mandelalide A 34. Stereocentres inverted relative to McPhail’s 
initial assignment are highlighted.  
2.2.2 BIOLOGICAL ACTIVITY  
Biological evaluation of mandelalide A 34 and mandelalide B at the time of isolation revealed 
promising nanomolar cytotoxicity against two cancer cell-lines involved in small-cell lung 
carcinoma (NCI-H460) and mouse neuroblastoma (Neuro-2A) (Table 2.2).44 Additional 
evaluation using the same samples was conducted in 2017.49 
 
* The suggestion that both epimers could produce the same ROESY correlations was based on a simple 
ball-and-stick model constructed by Fürstner and has since been shown to be invalid following 
computational studies.47 











































Table 2.2: Summary of biological data reported for natural mandelalide A and mandelalide B. 
(McPhail)44,49,50 








 Mandelalide A (2012)  12 44 - 
Mandelalide B (2012)   29 84 - 
Mandelalide A (2017)  11 - 9.9 
Mandelalide B (2017)  44 - 16 
a: Cell viability determined via MTT analysis, using linear regression to compute the IC50 values 
 
Despite the initially promising biologically activity reported by McPhail,  independent 
biological evaluation of synthetic mandelalide A has failed to replicate these results. Notably, 
Ye screened the synthetic material against ten cell-lines, observing only micromolar 
cytotoxicity in all cases.46 The only direct comparison available is the Neuro-2A cell line, with 
McPhail reporting an IC50 of 44 nM, but Ye observing no decrease in proliferation.46 
A recent study by McPhail and Smith aimed to resolve the conflicting cytotoxicity data for 
mandelalide A, resulting in the discovery that several members of the mandelalide family 
(including mandelalide A) inhibit ATP synthase.49 This inhibition causes cancer cell death by 
interruption of a key step in the aerobic glycolysis pathway used by rapidly proliferating cells 
to derive ATP (a source of ‘cellular energy’); this is in direct contrast to normally 
differentiated cells which predominantly use oxidative phosphorylation to generate ATP 
(Figure 2.12).51 
 
Figure 2.12: Glucose metabolism in cancer cells. Aerobic glycosysis accounts for over 85% of the energy 
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Ostensibly, mandelalide A 34 acts through a similar mechanism to that of oligomycin A 35and 
apoptolidin A, with several structural motifs conserved between the two natural products, 
namely the unsaturated ester and the planar diene (Figure 2.13).49 
 
Figure 2.13: Mandelalide A 34 and oligomycin A 35 highlighting key structural features present in both 
natural products that may be responsible for the observed cytotoxicity.  
The α,β-unsaturated carbonyl moiety may be especially important in explaining the 
cytotoxicity of mandelalide A 34, especially when comparing it to madeirolide A 1 which lacks 
this group, instead incorporating an additional THP. α,β-Unsaturated carbonyl containing 
molecules are well-known to exhibit cytotoxicity owing to the ease at which sulfur containing 
residues such as cysteine can undergo 1,4-addition reactions.52 Figure 2.14 shows several 
pharmaceutically relevant small-molecules incorporating the α,β-unsaturated carbonyl motif.  
 
































































2.3 PREVIOUS SYNTHETIC STUDIES TOWARDS MADEIROLIDE A  
Synthetic campaigns towards madeirolide A are known to have been initiated by several 
groups. To date, a completed total synthesis of madeirolide A is yet to be forthcoming, 
however multiple fragment syntheses have been reported, initially by Paterson53 with a C1 – 
C11 fragment synthesis 38, and subsequently of C1 – C12 and C1 – C10  fragments by Carter54 
39 and Lee55 40  respectively (Scheme 2.1).  
 
Scheme 2.1: Fragments of madeirolide A currently reported in the literature.  
Notably, the Paterson C1 - C11 fragment 38 is the only reported compound suitably 
functionalised to complete a total synthesis, with the Carter and Lee approaches both 
requiring additional redox manipulations to convert their fragments into a form amenable for 
fragment coupling.  The step-count and yields of the three reported fragments are tabulated 
below in Table 2.3:  
Table 2.3: Comparison of synthetic approaches to the western fragment of madeirolide A . 
 Steps (LLS) Yield 
Paterson53,56 19 (20) 13% 
Carter54 10 (16) 8% 
Lee55 13 (18) 15% 
Values in parentheses include the steps required to obtain the starting 







































38: Paterson C1 - C11 fragment 39: Carter C1 - C12 fragment 40: Lee C1 - C10 fragment
CO2Et





2.3.1 PREVIOUS SYNTHETIC STUDIES WITHIN THE PATERSON GROUP   
Following Wright’s initial report of madeirolide A, synthetic investigations were initiated 
within the Paterson group with the dual aim of validating Naylor’s proposed structural 
reassignment37 and providing material for thorough biological evaluation. These studies by 
Haslett culminated in the synthesis of the fully elaborated C1–C11 fragment 38 and several 
advanced linear precursors to the C18 – C27 THP.53  
The synthetic strategy was guided by the need for flexibility and convergence, given the 
unanswered questions about the C9 stereocentre (see §2.1.2). Directed by this, two key points 
of scission were identified, exploiting the C11 – C12 diene and C1 – OC23 lactone linkages as 
convenient points for fragment union (Scheme 2.2).  These disconnections result in two 
fragments of roughly equal size: the C1 – C11 western fragment 38, containing the cinerulose 
moiety and the simpler 2,6-cis THP; and the C12 – C27 eastern fragment 41, containing the 
THF and the remaining 2,6-cis THP. In a forward sense, an esterification followed by Stille 
macrocyclisation was anticipated to join the two advanced fragments to complete the natural 
product. 
 
Scheme 2.2: Retrosynthetic strategy for fragment union of the C1 – C11 western fragment 38 and the 











































38: C1 - C11 fragment (Haslett) 41: Proposed C12 - C27 fragment





The general features of Haslett’s synthesis of the C1 – C11 western fragment are illustrated in 
Scheme 2.3. Initial simplification reveals aglycone 43 which may be further disconnected to 
reveal linear precursor 44; in a forward sense, treatment of 44 with catalytic p-TsOH would 
affect the desired oxy-Michael cyclisation. Analysis of the linear precursor 44 reveals a 1,2-
syn relationship between the C5-hydroxyl and C6-methyl group and a 1,3-anti relationship 
between the C5 and C7 hydroxyl groups. This stereochemical pattern is accessible using a 
reagent-controlled 1,2-syn selective boron aldol reaction developed in the Paterson group57 
followed by substrate-directed 1,3-anti Evans-Tischenko reduction. The olefin may also be 
disconnected using a Horner-Wadsworth-Emmons olefination, revealing three readily 
accessible starting materials: Roche ester derived ethyl ketone 45, aldehyde 46, and 
phosphonate 47.  This route enabled the successful synthesis of 38 in 13% yield and 19 steps 
(LLS) starting from PMB protected (S)-Roche ester. The forward synthesis is discussed in 
more detail in §3.1 in the context of the development of an improved C1 – C11 fragment.  
 










































































2.3.1.1 PREVIOUS STUDIES TOWARDS THE C12 – C27 EASTERN FRAGMENT  
Concurrent with work on the western fragment 1 of madeirolide A, Haslett begun 
investigations into the synthesis of the C12 - C27 eastern fragment 48. The initial strategy for 
the construction of 48 is outlined retrosynthetically in Scheme 2.4. Following disconnection 
of the (Z)-vinyl stannane, the THF may be introduced using a cycloetherification of 50 using 
a known procedure from Ghosh in the context of mandelalide A.58 Recognising that the C18 – 
C19 diol could be introduced using a Sharpless asymmetric dihydroxylation (SAD) reveals the 
key intermediate 51 which was anticipated to arise from an sp2 - sp3 Suzuki cross-coupling 
reaction between vinyl iodide 53 and organoborane 52.  
 
Scheme 2.4: Retrosynthetic analysis for the C12 – C27 eastern fragment 48.  
With the two heterocycles now isolated, Haslett was able to focus attention on the 
construction of the challenging all-cis THP present in 53. It was initially anticipated that the 
C25-O-C21 bond could be forged via a Tsuji-Trost-type reaction of allylic acetate 56 (Scheme 
2.5).56 Mechanistically, treatment of 56 with a source of Pd(ii) should generate an 
electrophilic π-allyl palladium species 54 which may be intercepted by the C21 hydroxyl 
group to form the THP, with the stereochemistry controlled due to double inversion of the 
C25 stereocentre.  



























































Scheme 2.5: π-allyl palladium cyclisation strategy (Haslett). 56 
In the event, treatment of 56 with a variety of Pd(ii) sources and conditions returned only 
starting material. The lack of reactivity is not unexpected, and may be attributed to two 
factors: firstly, the C21 alkoxide is a poor nucleophile for the soft π-allyl palladium species, 
and secondly, the loss of acetate to generate the π-allyl palladium species is reversible. 
Attempts at fixing these issues (formation of a softer zinc alkoxide, use of a carbonate leaving 
group which would irreversibly decarboxylate) were unsuccessful, prompting an alternate 
tactic to be explored.  
Taking inspiration from the Paterson groups approach to phorboxazole A, in which oxazole 
60 unexpectedly cyclised to give THP 61 (Scheme 2.6),59 it was proposed that treatment of  63 
with a suitable Lewis acid would affect cyclisation to afford 62. Again, despite successful 
synthesis of the linear precursor, Haslett was unable to find conditions that enabled the 
desired heterocycle to be closed.  
 
Scheme 2.6: A Unexpected cyclisation of oxazole 60 during the Paterson synthesis of phorboxazole A.59 


































































Although the desired THP could conceivably be assembled through cyclisation of a suitably 
functionalised linear precursor, the on-going difficulties encountered by Haslett prompted an 
alternative approach to be investigated in which a simplified dihydropyran was accessed, 
anticipating it could be elaborated to give the fully substituted THP. This work was carried 
out by Fearnley, a postdoctoral researcher in the Paterson group. It was projected that the C21 
– C22 syn-diol could be installed at a late stage using an asymmetric dihydroxylation, thus 
revealing dihydropyran 64 as a key intermediate which could itself be derived from a hetero-
Diels Alder between diene 68 and aldehyde 69.60 While DHP 64 was able to be accessed 
successful, Fearnley was unable to find a suitable set of reagents/conditions to install the diol 
with the required stereochemistry – substrate control dominated over reagent control, failing 
to procure access to the desired all-cis configured THP. 
 
Scheme 2.7: Retrosynthetic analysis of dihydropyran 64, which was anticipated to undergo elaboration 
to the fully substituted THP using an asymmetric dihydoxylation (Fearnley).61   
2.3.2 OTHER SYNTHETIC STUDIES TOWARDS MADEIROLIDE A  
2.3.2.1 CARTER  
In 2016, Carter disclosed a total synthesis of mandelalide A, highlighting the power of silver 
catalysed cyclisation (AgCC) of a propargylic benzoate to install the requisite tetrahydropyran 
(Scheme 2.8).62 Recognising the homology between the western fragments of madeirolide A 1 
and mandelalide A 34, Carter was able to exploit his group’s previous synthesis to give facile 
access to a C1 – C12 fragment 39, shown retrosynthetically in  Scheme 2.9. * 
 
*  Note that at present, details of the proposed fragment union have not been revealed, however by 
analogy to their work on mandelalide A,62 it could be suggested that a series of protecting group and 
oxidation state manipulations would enable an esterification to form the lactone functionality followed 































Scheme 2.8: Precedence for THP formation using Carter’s AgCC methodology in the context of 
mandelalide A (Carter). 62 
Initial retrosynthetic scission of the cinerulose moiety and enoate reveals the pivotal 
dihydropyran 73; accessed in the forward sense via AgCC of the corresponding propargylic 
benzoate 74. Other salient disconnections include the introduction of the C6 - C7 anti 
relationship through opening of chiral epoxide 75, and the scission of the C5 - C6 bond using 
a Sonogashira cross-coupling to reveal Carter’s starting materials, 77 and 78.  
 
 Scheme 2.9: Retrosynthetic analysis of a C1 – C12 fragment of madeirolide A 39 (Carter).62 
Carter’s synthetic efforts towards 39 commenced with the preparation of a suitably 
functionalised propargylic benzoate 74 which was anticipated to undergo AgCC to forge the 
C3 – O7 bond of the THP.  The core skeleton was formed through the union of 77 and 78 using 





















































































known compounds, readily accessible from commercial achiral starting materials in four and 
six steps respectively.63,64 
With 76 in hand, attention was turned to the introduction of the required C6 and C7 
stereocentres, which, given the distal nature of the existing chirality within the molecule 
would necessitate the use of a chiral oxidant. Accordingly, 76 was treated with fructose 
derived catalyst 79 using conditions developed by Shi to provide access to epoxide 75 as a 
single diastereomer. Subsequent treatment of 75with LiAlMe4 and BF3･Et2O established the 
1,2-anti relationship in 74 as required, with the choice of Lewis acid and nucleophile crucial 
to obtaining the desired product without loss of the benzoate or pivalate esters.  
 
Reagents and conditions: [a] Pd(PPh3)4, CuI, i-Pr2NH, rt. [b] 79, Oxone, pH 9.3 buffer, MeCN, H2O, 0 °C. [c] LiAlMe4, 
BF3 Et2O･CH2Cl2, -78 °C. [d] AgBF4, 100 °C.  






























































Reagents and conditions:  [a] AgBF4 (20 mol%), PhMe, 100 °C. [b] NaOMe, MeOH, 0 °C ⟶	rt. [c] NaBH4, CeCl3, MeOH, 
-20 °C. [d] BF3･Et2O, CH2Cl2, 0 °C. [e] TBAF, HOAc, THF, 0 °C. [f] DMP, NaHCO3, CH2Cl2, rt. [g] Ph3P=CHCO2Et, CH2Cl2, 
-78 °C.  
Scheme 2.11: Cyclisation of the C1 – C10 propargylic benzoate 74 using AgCC and elaboration to the full 
C1 – C12 fragment 39 (Carter).54 
The stage was now set to test the pivotal AgCC step. Disappointingly, upon treatment of 74 
with catalytic AgBF4 in refluxing toluene a mixture of products was obtained, with formation 
of both 73 and an undesired dihydrofuran 80 in a 1.4:1.0 ratio. This result contrasts with 
Carter’s previous work on mandelalide A in which a single product was obtained in excellent 
yield.  Carter rationalises the outcome via competitive 6-endo-dig (red) and 5-exo-dig (green) 
cyclisations leading to the mixture of products, however no additional mechanistic studies 















































dr 5:1 74% (3 steps)






Scheme 2.12: Mechanistic rationale for competing dihydropyran 86 and dihydrofuran 87 formation 
during the AgCC of propargylic benzoates (Carter).54 
In the event, the desired DHP 73 was in 43% yield and >20:1 dr, providing sufficient material 
the advance the synthesis. Subsequent cleavage of the enol benzoate under basic conditions 
followed by diastereoselective reduction of the ensuing ketone guided by the proximal C9-
methyl group provided alcohol 72. The remaining steps to the completion of the fragment 
were straightforward and followed the same synthetic route as had previously been 
demonstrated in the context of mandelalide A.  Thus, under Lewis acid catalysis, the 
cinerulose moiety was installed via acetate donor 42, with a reproducible 5:1 d.r. at the 
anomeric position. Elaboration of the TIPS ether via a three step deprotection, oxidation, 
Wittig olefination sequence furnished 39, the completed C1 – C12 fragment, in 13% yield and 
10 steps (LLS) from propargylic benzoate 77.* 
2.3.2.2 LEE  
Lee and co-workers reported their synthetic endeavours towards madeirolide A in 2016 with 
a C1 – C10 fragment 40 synthesis, outlined retrosynthetically in Scheme 2.13.55 Pivotal to their 
strategy was the use of an iridium-catalysed visible light mediated radical cyclisation to form 
the THP, with disconnection of the C3 – C4 bond of 82 in the manor illustrated revealing 83 
as the key intermediate.  
 
* Carter’s yield does not account for the unselective AgCC, counting the yield for that step as the mixture 


































Scheme 2.13: Retrosynthetic analysis of a C1 – C10 fragment 40 (Lee).55 
Although the Lee group had previously demonstrated the formation of saturated heterocycles 
using this photoredox methodology, only two examples of THP formation were reported 
(Scheme 2.14).65  In both examples, the cyclisation was carried out on racemic substrates 
lacking any sensitive functionality and as such the application of this methodology in the 
context of madeirolide A was anticipated to be a significantly more demanding test of the 
reaction.   
 
Scheme 2.14: Previous examples of THP formation using visible-light-induced photocatalytic reductive 





















































































Lee’s route commenced from the Masamune aldol adduct  86, accessed in five steps from 
crotonaldehyde (Scheme 2.15).66 Initial cleavage of the pseudoephedrine derived auxiliary 
followed by regioselective TBDPS protection of the C10 hydroxyl and installation of the 2-
benzyloxyacetate moiety at C8 provided 85 which was suitably functionalised to undergo the 
proposed Ireland-Claisen rearrangement.  
Accordingly, treatment of 85 with LiHMDS and TMSCl formed a silyl enol ether, which, upon 
warming to room temperature rearranged to give 91 with concomitant introduction of the C5 
and C6 stereocentres. The remaining C7 oxymethine was installed in a three-step sequence, 
making use of an iodolactonisation reaction, affording with  9:1 dr.  The C7 ß-alkoxy acrylate 
was subsequently installed to give the key pre-cyclisation intermediate 83.  
 
Reagents and conditions: [a] LiAlH4, THF, rt. [b] TBDPSCl, imidazole, CH2Cl2, 0 °C. [c] BnOCH2CO2H, EDAC, DMAP, 
CH2Cl2, rt. [d] KHMDS, TMSCl, THF, -78 °C. [e] I2, NaHCO3, MeCN, -40 °C. [f] [Ir(ppy)2(dtbbpy)]PF6, i-Pr2NEt, MeCN, 2 
W blue LED, rt. [g] LiBH4, THF, 50 °C. [h] 92, PPTS, PhMe, 110 °C. [i] LiHMDS, THF, -78 °C. [j] I2, PPh3, imidazole, THF, 
0 °C.  
Scheme 2.15: Synthesis of the C1 – C10 linear precursor (Lee).55  
Having successfully prepared the linear precursor 83, the stage was set for Lee to test the 
ambitious cyclisation. In the event, treatment of 83 with [Ir(ppy)2(dtbbpy)]PF6 and blue LED 
light enabled aglycone 82 to be obtained as a single diastereomer in 70%  yield, exemplifying 
the power of Lee’s methodology. Finally, the installation of the cinerulose sugar was achieved 
in two steps, using dehydrocinerulose donor 93 which was reduced post-glycosylation to 
provide Lee’s C1 – C10 fragment 40 in 13% yield over 15 steps starting from Masamune aldol 






















































Reagents and conditions: [a] [Ir(ppy)2(dtbbpy)]PF6, i-Pr2NEt, MeCN, 2 W blue LED, rt. [b] 93, Pd2(dba)3･CHCl3, PPh3, 
CH2Cl2, 0 °C. [c] Pd/C, H2 , EtOAc, rt.   
Scheme 2.16: Iridium photoredox cyclisation of 83 and elaboration to the C1 – C10 fragment 40 (Lee).55 
2.4 SUMMARY & ANALYSIS  
Madeirolide A 1 is a novel polyketide natural product. The unique structural features coupled 
with unanswered questions over biological activity have made it a compelling target for total 
synthesis, with several research groups actively engaged in research. Despite this, the natural 
product has thus far proved a formidable challenge, with the eastern THP causing significant 
synthetic challenges. The completion of a total synthesis will facilitate thorough biological 
evaluation of madeirolide A, and, with a robust route to hand, may enable SAR studies to probe 





















































3. RESULTS & DISCUSSION I:   SYNTHESIS 
OF A MODIFIED WESTERN FRAGMENT   
3.1 AIMS AND RATIONALE FOR MODIFICATION OF THE STRATEGY  
The route developed by Haslett (see §2.3.1) successfully accessed a fully elaborated C1 – C11 
fragment 38 in 13% yield over 19 steps (LLS).53 Despite this success, several issues persisted at 
the end stages of the route, namely with the cyclisation and subsequent elaboration to the (E)-
vinyl iodide necessitated by the proposed macro-Stille fragment union (Scheme 3.1). These 
issues were not investigated further at the time as attention was focused on construction of 
the remaining C12 – C27 eastern fragment 48.   
 


























































At the outset of this project, it was acknowledged that a more tractable end-game would be 
beneficial for material throughout as required for fragment coupling when the synthesis of 
the C12 – C27 fragment is completed. While considering the evolution of our strategy several 
lessons were learnt from the aforementioned ‘first-generation’ route:  
§ Protecting group strategy and chemoselectivity 
The C10 PMB ether 94 is unstable under the conditions used to effect cyclisation (p-
TsOH, CH2Cl2, rt). While treatment of the crude cyclisation mixture with DDQ side-
steps the problem, a new issue of chemoselectivity is introduced: selective oxidation 
of a 1º alcohol in the presence of a 2º alcohol. The need for this selective oxidation 
limits the available options (TEMPO, BAIB), especially given the propensity for 
epimerisation of the C10 stereocentre observed by Haslett.  
§ Takai olefination 
The Takai olefination of aldehyde 97 was found to be highly capricious, often failing 
to provide the desired (E)-vinyl iodide even when the same batch of reagents was used. 
The unpredictable nature of this reaction, coupled with the inability to recover the 
aldehyde without epimerisation makes this a challenging step which needs 
improvement.  
In the event, the above issues were able to be resolved through a single change in the overall 
strategy for fragment union: a Heck macrocyclisation reaction would be used in place of the 
original Stille macrocyclisation reaction (Scheme 3.2). This leads to a modified C1 – C11 
western fragment 99 bearing a synthetically more accessible terminal olefin 99 instead of the 
(E)-vinyl iodide 38 previously used by Haslett.  
Despite this, the use of a Heck reaction for macrocyclisation has the potential to introduce 
some additional issues of selectivity. Unlike Suzuki and Stille cross-coupling reactions, which 
use geometrically defined organometallic species (organoboron and organotin species 
respectively), the Heck reaction uses a terminal olefin as the coupling partner. This olefin has 
no inherent selectivity, but rather the geometry of the product is determined during the β-












Scheme 3.2: Comparison of C11 – C12 bond forming strategies showing the original C1 – C11 fragment 










































































In the context of macrocyclisation reactions, the use of a Heck reaction has the potential to 
cause two problems: 
§ Regioselectivity of insertion (ring closure)  
The initial insertion (carbopalladation) step in which the organopalladium species 
adds across the terminal olefin may lead to either the endo- or exo- regioisomer. For 
large ring formation (>13 atoms), the intramolecular Heck reaction is often endo 
selective, as is required for macrocyclisation.68 
§ Reductive elimination (olefin formation)  
When using terminal olefins as coupling partners in Heck reactions, two hydrogens 
are available for elimination, leading to the formation of both (E) and (Z) isomers of 
the resulting olefin. This is largely a thermodynamic property, and the (E) isomer is 
usually favoured through minimisation of steric clash across the C=C bond.67 
Given the complexity of the cyclisation, it is difficult to predict a priori which isomer of the 
diene is likely to prevail. Based on a simple thermodynamic argument, the desired (E,Z) 
isomer is lower in energy by 5.9 kcal mol-1, which may limit formation of the strained (Z,Z) 
diene given the reversibility of the preceding steps (Figure 3.1).  
 
Figure 3.1: Relative energies of the (E,Z) and (Z,Z) isomers of madeirolide A showing the 
thermodynamic preference for the (E,Z) diene as found in the natural product. [DFT-B3LYP/6-31G**, 
gas-phase].  
Encouragingly, Smith and co-workers have recently validated a Heck macrocyclisation 
approach in the context of mandelalide A 34, with cyclisation of 104 furnishing 105 with 
complete selectivity for the desired (Z,E)-diene (Scheme 3.4).69 Although the substrate used 
by Smith is not directly comparable to the proposed intermediate in the madeirolide A 












Scheme 3.4: Application of a ring-closing macro-Heck reaction in the context of mandelalide A leading 
to the desired (E,Z) geometry  of the diene (Smith).69 
As with the original endgame strategy, the modified Heck macrocyclisation route leaves some 
flexibility to the order of steps. Should the cyclisation not give the desired macrocycle, the 
order of steps could be reversed to first conduct an intermolecular Heck coupling followed by 
standard Yamaguchi macrolactonisation. More drastically, the terminal olefin provides a 
useful functional handle, enabling conversion to the vinyl iodide via ozonolysis and Takai 
olefination of the resultant aldehyde; this is somewhat circuitous and therefore undesirable. 
3.1.1 RETROSYNTHESIS  
In considering the synthesis of 99, it was desirable to retain as many of the successful elements 
from the original synthesis as possible in order to avoid optimisation of an entirely new route. 
Accordingly, the modified route was developed to diverge from acetonide 106 (Scheme 3.5). 
This intermediate was preferred as it contains all of the necessary stereochemistry (excluding 
the C7 oxymethine formed upon cyclisation) and is at a sufficiently late stage that it would be 
possible to quickly determine whether the Heck macrocyclisation approach would confer any 








































105: Protected mandelalide A
Glycosylation and protecting 
group manipulations






Scheme 3.5: Divergent synthesis from common acetonide 106 showing the original C1 – C11 fragment 38 
(Haslett) and the proposed C1 – C11 fragment 99.   
The modified retrosynthetic strategy is shown in Scheme 3.6. Accordingly, initial scission of 
the cinerulose donor 42 reveals the C1-C11 aglycone 107; envisioned to be accessible via acid-
catalysed cyclisation of the corresponding linear precursor 108. 108 may be further 
disconnected back to the common C3 – C10 intermediate 106 through two consecutive 
deprotection-oxidation-olefination sequences: a Wittig reaction to install the terminal olefin 
followed by a Horner-Wadsworth-Emmons reaction to install the α,β-unsaturated thioester.   
 
 
Scheme 3.6: Retrosynthesis for completion of the modified C1 – C11 fragment 99 from common 














99: Modified C1 - C11 western fragment
38: C1 - C11 western fragment (Haslett)





















































3.2 SYNTHESIS OF THE C3 - C10 ACETONIDE  
The work carried out in §3.2 builds on chemistry originally performed by Haslett.56 Unless 
otherwise noted, all reactions/yields refer to those carried out by the author. 
Acetonide 106 can be accessed in eight steps starting from PMB-protected (S)-Roche ester 111; 
shown retrosynthetically in Scheme 3.7. Key to strategy is the use of an (–)-Ipc2BOTf 
mediated aldol reaction between ketone 110 and aldehyde 59 to install the C5 and C6 
stereocentres with control of the absolute and relative configuration. Ketone 110 may be 
further disconnected to PMB protected (S)-Roche ester 111, using a Corey-Seebach 
homologation to introduce the necessary methylene (CH2) unit between the C9 stereocentre 
and the carbonyl.  
 
Scheme 3.7: Retrosynthesis for the preparation of the C3 – C10 acetonide 106.  
3.2.1 SYNTHESIS OF THE C6 – C10 ETHYL KETONE  
Preparation of the C6 – C10 ethyl ketone 110 began with the reduction of ester 111 to alcohol 
113 (LiAlH4, 83%) followed by conversion to the analogous alkyl iodide 114 under modified 
Appel conditions (PPh3, I2, imidazole, 70%) to introduce a good leaving group. Subsequent 
displacement of the iodide with lithiated dithiane 112 (t-BuLi, HMPA, 94%), derived from 
propanal as shown in Scheme 3.8 B, delivered the 1,3-dithiane 115. One of the major 
drawbacks to dithiane chemistry in general is the need for the toxic stochiometric mercury 
(ii) salts that are commonly employed to unmask the ketone; this was avoided using 


















acetonide formation Asymmetric boronaldol
PMBO
O O OTBS


















Overall, ethyl ketone 110 was prepared in 34% yield over 4 steps from ester 111.  Through this 
route, over 35 g of ketone 110 has been accessed, demonstrating the tractability of these early 
steps of the synthesis and providing material for future studies.  
   
Reagents and conditions: [a] LiAlH4, THF, 0 °C ⟶	rt. [b] PPh3, imidazole, I2, CH2Cl2, rt. [c] t-BuLi, HMPA, 112, THF, -
78 °C; 114.  [d] I2, NaHCO3, MeCN, rt. [e] BF3·Et2O, HS-CH2-CH2-CH2-SH, THF, -78 °C 
Scheme 3.8: A Preparation of ethyl ketone 110 from chiral ester 111 using a Corey-Seebach 
homologation. B Synthesis of dithiane intermediate 112.  
3.2.2 INSTALLATION OF THE C5 – C7 STEREOTRIAD 
With substantial stocks of ethyl ketone 110 to hand the remaining stereocentres needed to 
complete the linear C1 – C11 precursor could be introduced. This was accomplished using a 
reagent-controlled enantio- and diastereoselective boron aldol reaction followed by a 
substrate-directed 1,3-anti reduction, the combination of which enabled all of the 
stereocentres in the linear C3 – C10 fragment to be introduced with exquisite selectivity. 
3.2.2.1 BORON ALDOL REACTION  
The C3 – C5 aldehyde 59 needed for the aldol was prepared following standard literature 
procedures from either 3-buten-1-ol 116 or propan-1,3-diol 118,71–73 however the latter route 
was preferred owing to the availability of 118 and the extended time needed to effect 
ozonolysis of 117.  Thus, diol 118 was mono-protected as the corresponding TBS ether (NaH, 















































C3 – C5 aldehyde 59.   Note that in both cases, the aldehyde 59 was sufficiently clean to be 
used crude in the subsequent aldol reaction, without any appreciable deterioration of yield.  
 
Reagents and conditions:  [a] TBSCl, imidazole, CH2Cl2, rt. [b] O3, NaHCO3, CH2Cl2, MeOH, -78 °C. [c] NaH, THF, 0 
°C; TBSCl, rt. [d] (COCl) 2, DMSO, -78 °C; Et3N, -78 °C ⟶	 rt.  [e] (–)-Ipc2BOTf, i-Pr2NEt, CH2Cl2, -78 °C; 59, CH2Cl2, -78 
°C ⟶	-30 °C.  
Scheme 3.9: A Preparation of the C3 – C5 aldehyde 59. B Boron aldol reaction between aldehyde 59 
and ethyl ketone 110.  
To carry out the aldol reaction, ketone 110 was first enolised with (–)-Ipc2BOTf and i-Pr2NEt 
in CH2Cl2 at -78 °C. Slow addition of aldehyde 59 at -78 °C followed by warming to -30 °C and 
oxidative workup (H2O2) afforded the desired 1,2-syn aldol adduct 109 as a single 
diastereomer (as determined by 1H NMR spectroscopy of the crude reaction mixture) in 65% 
yield (Scheme 3.9). These results are consistent with those reported by Haslett.53 
Rationalisation of the enantio- and diastereoselectivity requires consideration of both the 
enolate geometry and the transition state.  The (Z)-enolate 120 is formed with high levels of 
selectivity using (–)-Ipc2BOTf/i-Pr2NEt as depicted in Scheme 3.10. Using boron triflate 
reagents, the B-OTf bond is completely dissociated prior to enolisation taking place, allowing 
the trigonal boron group to orient itself away from the developing enolate; the use of a 
sterically demanding base (i-Pr2NEt) reinforces this preference. The most favourable 
enolisation transition state has the methyl group eclipsing the carbonyl to minimise A1,2 strain 
with the R group of the ketone.74 Deprotonation thus takes place via TS-121, with the σ-C-H 
perpendicular to the π-C=O to allow good orbital overlap as the enolate develops. This results 
in the stereoselective formation of the (Z)-enolate 120, leading ultimately to the required 1,2-
syn diastereomer of  the aldol adduct 109. The diastereomeric anti aldol adduct is accessible 
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Scheme 3.10: Mechanistic rationale for the stereodivergent formation of (E)- and (Z)-boron enolates 
from ethyl ketones.75 
Once formed, the (Z)-enolate 120 reacts with aldehyde 59 via a highly-ordered six-membered 
transition state (Scheme 3.11). By virtue of the enolate geometry, the C28-methyl group is 
forced into a pseudo-axial position, with the aldehyde orientating itself such that the R group 
is in the thermodynamically favourable equatorial position. The stereofacial discrimination is 
a consequence of the chiral controlling groups on boron, with the Si face attack via TS-126 
favoured for the (Z)-enolate as it minimises steric clash between the R-group of the enolate 
with the methyl group on the iso-pinocampheyl ligands on boron. This qualitative transition 
state model has been validated by extensive DFT studies by Goodman and Paton (Figure 










■ sterically demanding chiral ligands (Ipc)
■ excellent leaving group (OTf)
Brown conditions
Ipc2BCl, Et3N
■ sterically demanding chiral ligands (Ipc)


















































Scheme 3.11: Mechanistic rationale for the observed facial selectivity when using (–)-ipc2BOTf.  
 
TS-129 
Si-face attack  
 
TS-130 
Re-face attack  
Figure 3.2: Calculated transition states for the Ipc aldol (Goodman/Paton).76 Some hydrogens have been 
omitted for clarity. [DFT-B3LYP/6-31G**, gas-phase] 
The 1,2-syn stereochemistry between the C5-OH and C6-Me substituents in 109 was 
confirmed by inspection of the vicinal  3JH5-H6 coupling constant in the 1H NMR spectrum 













































hydroxyketones adopt chair-like conformations held together via internal hydrogen bonding. 
In this conformation, 1,2-syn aldol adducts are expected to have smaller coupling constants 
than 1,3-anti aldol adducts based on dihedral angles (θ) of ca. 60° and 180° respectively. The 
observed 4.6 Hz coupling between H5 and H6 thus suggests a syn relationship with a dihedral 
angle of ca. 53°, in keeping with the expected stereochemical outcome of the reaction.  
 
Figure 3.3: Confirmation of 1,2-anti stereochemistry via 1H NMR analysis.  
To determine the absolute configuration at the newly formed C5 oxymethine stereocentre, 
aldol adduct 109 was derivatised as the corresponding α-methoxy-α-
trifluoromethylphenylacetic acid (MTPA) esters 134 and 135 using Steiglich conditions (DCC, 
DMAP) (Scheme 3.12).   
 
Scheme 3.12: Preparation of MTPA esters for determination of absolute configuration.  
Experimental and computational investigations suggest that MTPA esters adopt a 
conformation in which the trifluoromethyl, ester and oxymethine proton lie in the same plane 
(Figure 3.4).77,78 In this conformation, the phenyl group shields one side of the molecule 










131: 1,2-syn aldol 132: 1,2-anti aldol























































the diastereomeric (R) and (S) MTPA esters thus allows the absolute configuration of 
secondary alcohols to be determined. The experimental 1H NMR data for 134 and 135 is 
tabulated in  
Table 3.1, and confirms the configurational assignment of the newly formed C5 stereocentre 
as expected. 
 
Figure 3.4: Assignment of absolute configuration using MTPA esters. Shielding effects in the dominant 
conformers of MTPA esters, and the expected δS - R sign.  
Table 3.1: NMR data for diastereomeric MTPA esters 134 and 135 (500 MHz, CDCl3).   
Proton  δS-MTPA δR-MTPA δ(S-R) 
 3  3.61 3.52 +0.09 
4’/4”  1.83 1.79 +0.04 
6  2.81 2.86 -0.05 
8’  2.53 2.62 -0.09 
8”  2.21  2.33 -0.12 
9  2.28 2.33 -0.05 
10’  3.18 3.22 -0.04 
10”  2.35 3.28 -0.03 
28  1.04 1.08 -0.04 
29  0.86 0.91 -0.05 
Chemical shifts are taken as the midpoint of multiplets for the purpose of the MTPA analysis.  
 





3.2.2.2 ELABORATION TO THE C3 – C10 ACETONIDE   
The conversion of aldol adduct 109 into the C3 – C10 acetonide 106 needed to explore the 
modified macro-Heck route was accomplished in three steps, using a 1,3-anti Evans-
Tischenko reduction as a key step to introduce the remaining stereocentre at C7. Treatment 
of 109 with SmI2 in the presence of propanal followed by solvolysis (K2CO3, MeOH) of the 
propionate ester and acetonide formation (Me2C(OMe)2, PPTS) provided 106 in excellent 
yield of 86% (Scheme 3.13). This three-step transformation was carried out without 
purification of the intermediates, which have previously been characterised by Haslett.53,56  
 
Reagents and conditions: [a] SmI2, EtCHO, THF, -78 °C ⟶ 30 °C. [b] K2CO3, MeOH, rt. [c] CH3C(OMe)2, PPTS, CH2Cl2, 
rt. 
Scheme 3.13: Elaboration of aldol adduct 109 to the completed C3 – C10 acetonide 106.  
Mechanistically, the Sm first promotes a pinacol-like reductive coupling between two 
equivalents of propanal to form a Sm (iii) pinacolate species 139– this is thought to be the 
active species involved in the Evans-Tischenko reduction (Scheme 3.14).  Addition of aldol 
adduct 109 leads to the formation of a bicyclic transition state TS-138 in which the ketone and 
aldehyde substituents are equatorially arranged to minimise unfavourable steric interactions. 









































Scheme 3.14: Proposed mechanism for the 1,3-anti Evans-Tischenko reduction. Formation of the 
putative active species [(EtCHO)2SmI･SmI3] (inset).  
The anticipated relative stereochemistry was confirmed based diagnostic chemical shifts of 
the acetonide carbons in the 13C NMR spectrum (Figure 3.5). The observed values at δC 
(CDCl3) = 100.6, 24.0 and 26.1 ppm are indicative of a 1,3-anti acetonide adopting a twist-boat 
conformation 141 in which the two methyl groups are in similar environments, unlike for 1,3-
syn acetonides 140 where the axial and equatorial methyl groups are in electronically different 
environments.79  
 
Figure 3.5: A Expected 13C NMR shifts for 1,3-syn 141 and 1,3-anti 140 acetonides  


















































19.5 ± 0.21 ppm
30.0 ± 0.15 ppm











100.6 ± 0.25 ppm









140: 1,3-syn acetonide 141: 1,3-anti acetonide





3.3 ELABORATION TO THE MODIFIED C1 – C11 WESTERN FRAGMENT   
With adequate stocks of acetonide 106 to prepared, the divergent synthesis to the modified C1 
– C11 fragment 99 could be investigated (Scheme 3.5). The conversion of acetonide 106 into 
the required linear precursor 108 requires two olefinations: conversion of the C1 PMB ether 
into a terminal olefin, and conversion of the C3 TBS ether into the required α,β -unsaturated 
thioester.  
Since conditions were already optimised for the latter transformation (the Horner-
Wadsworth-Emmons olefination), attention was first focused on installation of the terminal 
olefin, which was envisioned to arise from a Wittig methylenation of the parent aldehyde. This 
would also avoid having to conduct the Wittig reaction in the presence of the thioester, which 
may be reactive under the necessary conditions.  
3.3.1 PREPARATION OF THE LINEAR C1 – C11 PRECURSOR  
Accordingly, treatment of PMB ether 106 with DDQ afforded alcohol 142 (80%), which was 
oxidised to aldehyde 143 using the Dess-Martin periodinane (DMP). In order to circumvent 
the epimerisation previously observed by Haslett when conducting the C10 oxidation 
(TEMPO/BAIB), the potentially delicate aldehyde was used immediately without 
purification. Thus, treatment of 143 with Ph3P=CH2 (generated in situ from the deprotonation 
of Ph3P+MeBr- with n-BuLi) afforded terminal olefin 144 in modest yield (33%), with the mass 
balance accounted for by unreacted aldehyde.  It was found that an excess of the ylid was 
needed to obtain good conversion, affording 144 in 78% yield over two steps from alcohol 142.  
 
Reagents and conditions:  [a] DDQ, pH 7 buffer, CH2Cl2, rt. [b] DMP 145, NaHCO3, CH2Cl2, rt. [c] Ph3PMeBr, n-BuLi, 
THF, -78 °C.  















































All that remained for the completion of the C1 – C11 linear precursor 108 was the installation 
of the α,β-unsaturated thioester moiety that would act as a Michael acceptor in the anticipated 
cyclisation step.  
The phosphonate 149 needed for the Horner-Wadsworth-Emmons olefination was prepared 
in two steps from trimethylphosphonoacetate 146 (Scheme 3.16 A). Accordingly, sodium 
hydroxide mediated saponification of 146 afforded 2-phosphonoacetic acid 147 which was 
able to undergo thioesterification with thiol 148 under Steiglich conditions (DCC, DMAP) to 
provide 149 in 60% yield from 146. This result, although not surprising, is in conflict with 
previous studies by Haslett, who observed significant degradation while attempting to form 
the thioester using the above conditions, instead installing the thioester via activation of the 
carboxylic acid as the corresponding acid chloride.56   
At this stage, the C3 TBS ether 144 was deprotected (TBAF) and oxidised to aldehyde 150 
((COCl)2, DMSO; Et3N)l The HWE olefination was conducted on 150 using modified 
Masamune-Roush conditions (LiCl, Et3N) as optimised by Haslett.56 This proceeded 
uneventfully to provide 108 in good yield (74%) as a single geometric isomer. The geometry of 
the newly formed alkene was confirmed by 1H NMR analysis, with a 3JH-H coupling constant 
of 17.2 between H3 and H4 indicative of the predicted (E)-geometry. This selectivity is 
rationalised by the reversible addition of 151 to aldehyde 150, with the anti-addition product 
153 thermodynamically favoured due to minimisation of the unfavourable steric clash 
between the thioester and the R-group of the aldehyde (Scheme 3.16 c). The formation of 
oxaphosphatanes (154 and 154) has been shown to be the rate-determining step of the 
reaction,81 thus the (E)-olefin 108 is obtained as the major geometric isomer. 






Reagents and conditions:  [a] NaOH, H2O, rt. [b] DCC, DMAP (cat.), CH2Cl2, rt. [c] TBAF, THF, rt. [d] DMP, NaHCO3, 
CH2Cl2, rt. [e] 149, LiCl, Et3N, CH2Cl2, -30 °C.  
Scheme 3.16: A Preparation of thioester 149. B Conversion of TBS ether 144 to the complete C1 – C11 
linear precursor 108. C Mechanistic rationale for the selective formation of the (E)-olefin using a 
Horner-Wadsworth-Emmons olefination.    
3.3.2 INTRAMOLECULAR OXY-CONJUGATE CYCLISATION  
The intramolecular oxy-conjugate cyclisation (IOCC) is a well-established method for the 
synthesis of tetrahydropyran rings.82–84 While the reaction often gives excellent 


































































































mechanistic understanding, making it challenging to predict which diastereomer is likely to 
dominate from a given substrate under a given set of conditions. Given the wide range of 
biologically active natural products containing THP motifs (see Figure 3.6 for selected 


























































































In 2011, Fuwa reported a ‘bio-inspired’ hetero-Michael cyclisation that provided reliable 
access to the 2,6-cis diastereomer using α,β-unsaturated thioesters in place of the oxoesters 
that have conventionally been used in synthesis.85,86 This was inspired by biosynthetic studies 
that determined pyrans found in polyketides are formed via enzyme mediated conjugate 
addition while the chain is still attached to the acyl carried protein 158 via a sulfur linkage 
(Scheme 3.17).    
 
Scheme 3.17: Pyran formation in polyketides. The heterocycle formation is catalysed by an enzyme while 
the growing chain is still bound to the acyl carrier protein of the polyketide synthase.  
Despite the excellent diastereoselectivity reported for the Bronsted acid mediated cyclisation 
of thioesters, limited examples exist of its use in the context of complex molecule synthesis: 
the Paterson C1 – C11 western fragment synthesis of madeirolide A 161/162,53 and the Clarke 
synthesis of a C20 – C32 fragment of phorboxazole A 16087 being two notable examples 
(Scheme 3.18). A further example by Romea uses stochiometric base (DBU) to afford 
cyclisation of thioester 163, however the selectivity in this case is significantly lower (2:1) than 
for the corresponding reactions using Bronsted acids.88 
Synthetic and computational studies were carried out during investigations into the 
cyclisation of 108 with the aim of gaining insight into the factors governing the selectivity and 



























Scheme 3.18: Examples of Fuwa’s thioester cyclisation in total synthesis. A Application in Clarke’s 
synthesis of a phorboxazole fragment. B Application in the Paterson synthesis of a C1 – C11 fragment of 
madeirolide A. c Example of a base-catalysed cyclisation of thioesters in the Romea synthesis of 
herboxidiene.  
 












































































3.3.2.1 SYNTHETIC STUDIES  
With the C1 - C11 linear precursor 108 to hand, the feasibility of the intramolecular oxy-
conjugate cyclisation (IOCC) could be investigated. Given the close similarity between 108 
and Haslett’s C1 – C11 linear precursor 38, bearing a PMB ether at C10, it was anticipated that 
the application of the IOCC conditions previously optimised would be successful.   
Accordingly, 118 was treated with p-TsOH in CH2Cl2 at ambient temperature. The reaction 
initially appeared to be rapid, with all the starting material consumed within 30 minutes.  
However, following column chromatography, 1H NMR revealed that the new spot was an 
inseparable mixture of desired THP 107 and deprotected starting material 165 in a 5:1 ratio 
(based on the crude 1H NMR). Attempts at re-submitting the mixture to the reaction 
conditions did not significantly change the ratio of 107 to 165, plausibly indicating that the 5:1 
ratio indicates a thermodynamic distribution of products.  
 
Scheme 3.20: Initial results for the p-TsOH mediated IOCC of 108. Products 107 and 165 were isolated 
as an inseparable mixture.  
At this juncture it became apparent that either the reaction needed to be pushed to 
completion, or a method for the separation of 107 from 165 needed to be found. In this 
instance, carrying forward the mixture was undesirable as diol 165 would likely also be 
reactive under the glycosylation conditions needed to complete the fragment, resulting in 
unnecessary attrition of material. Treatment of the crude mixture with TBSCl/imidazole did 
enable the separation of 107 from 165 by flash column chromatography (as the corresponding 
silyl ethers).  This was not investigated further as it was in no way tractable, especially given 





























Scheme 3.21: Separation of 107 from 165 by conversion to the corresponding TBS ethers.  
Despite repeated attempts at encouraging the reaction to completion, 1H NMR of the crude 
product always indicated at least 10% of 165. The best conversion was obtained using 
stoichiometric p-TsOH (1.1 eq.), doping the CH2Cl2 with 1% i-PrOH. This presumably helps 
by providing a proton source which facilitates protonation of the thioenol intermediate 168, 
which may be rate determining when the IOCC is carried out in a non-protic solvent such as 
CH2Cl2 (Scheme 3.22). Interestingly, heating the reaction mixture did not confer any increase 
in conversion. 
 
Scheme 3.22: Mechanistic outline showing the proposed thioenol intermediate 168.  
With conditions now optimised to provide maximum conversion, all that remained necessary 
was to separate away the small quantities of diol 165.  It was found that the use of a modified 
eluent (TLC: 20% Me2CO : PhMe + 0.1% HCOOH; column chromatography: 10 - 30% Me2CO 
: PhMe + 0.1% AcOH) enabled the small amounts of 165 to be separated from 107 providing 
spectroscopically pure material to be taken forward. The additive was switched from formic 
to acetic acid for the purposes of column chromatography due to formation of the formate 
ester at C5.  
Overall, this slight modification to the optimised conditions developed by Haslett enabled the 
reproducible isolation of 107 in 70% yield as a single diastereomer by NMR. The remaining 
mass balance of the reaction was largely accounted for by recovered diol which was able to be 













































The stereochemistry at the newly introduced C7 oxymethine was confirmed by analysis of 
3JHH couplings,  1D NOESY NMR experiments, and by analogy to the THP formed by Haslett, 
which differs only by the presence of a PMB ether at C10 in place of the C10 – C11 olefin 
present in 107 (Figure 3.7). Specifically, irradiation of H3 showed the expected nOe 
enhancements to the co-axial protons at H5 and H7 – a result consistent with the ring adopting 
a chair conformation.  
 
Figure 3.7: Reciprocal nOe enhancements across the newly formed THP ring confirming the anticipated 
2,6-cis stereochemistry.  
3.3.2.2 MECHANISTIC AND COMPUTATIONAL STUDIES  
To rationalise the high-levels of diastereoselectivity observed, Fuwa proposed that the 2,6-cis 
diastereomer is favoured kinetically and thermodynamically for the cyclisation of α,β-
unsaturated thioesters under Bronsted acidic conditions, proposing the diastereomeric oxy-
allyl cation transition states TS-170 and TS-171 (Scheme 3.23).85 This mechanistic pathway 
rationalises the dominant formation of the 2,6-cis diastereomer since the transition state TS-
170 leading to it places the oxy-allyl cation in the pseudo-equatorial position, minimising A1,3 
strain across the ring. Conversely TS-171 is disfavoured owing to the pseudo-axial position of 
the oxy-allyl cation.  No additional experimental data has been provided by Fuwa to support 
this hypothesis, and recent computational investigations by Ermanis failed to identify either 



















3J H7-H6 (axial) = 9.9 Hz






Scheme 3.23: Proposed transition states for Bronsted-acid catalysed IOCC used to rationalise high levels 
of 2,6-cis selectivity (Fuwa)85 
With experimental results for the cyclisation now available (§3.3.2.1), a computational studies 
of the reaction was initiated to better understand the factors governing the selectivity in the 
context of the C1 – C11 fragment of madeirolide A. These studies aimed to answer several 
questions:  
§ Is the reaction under kinetic or thermodynamic control (or both)? 
While Fuwa suggests that the 2,6-cis isomer is both the kinetic and thermodynamic 
product, this is not entirely consistent with the mechanistic evidence, which shows 
that the 2,6-trans THP is not easily isomerised into the 2,6-cis THP suggesting a high 
kinetic barrier for the reverse reaction (retro-IOCC) once the THP was formed.  
§ What role (if any) does the thioester play in the reaction? 
While the thioester moiety is certainly involved in the biosynthetic pathway during 
the construction of polyketides, there is no clear basis for its use in synthetic 
chemistry other than the claim that the reaction is ‘biomimetic’. In Haslett’s original 
work,56 the corresponding methyl ester was found to give the same 2,6-cis 
diastereomer, albeit in lower yield which may suggest that the thioester is not 
essential. The answer to this question was particularly important, as it would greatly 
influence the synthetic strategy adopted for construction of the eastern 
tetrahydropyran, with the methyl ester significantly easier to introduce than the 






























Mechanistic consideration:  
In order to simplify the calculations, diol 165 was used in place of the actual acetonide as the 
substrate for the IOCC.  This was not expected to be deleterious to the reaction, with 165 likely 
to be formed prior to the oxy-Michael step.  
General strategy:  
To find the energies of the stationary points (transition states, intermediates etc.) along the 
reaction coordinate, a starting geometry must first be obtained. This can be done manually but 
is often achieved using molecular mechanics – a computationally inexpensive method that 
allows thorough exploration of conformational space to identify the geometries of structures 
lying close to the global minimum.  
Low-energy conformers from the conformational search are then used as input geometries in 
quantum mechanical optimisations using DFT. This additional step is necessary as molecular 
mechanics energies are known to be unreliable, especially in situations where the various 
transition states are likely to be close in energy. Finally, calculation of vibrational frequencies 
characterises the structures as minima (no imaginary frequencies) or transition states (exactly 
one imaginary frequency).90  
Conformational search:  
The structures subjected to the conformational search are shown in Figure 3.8.  An additional 
conformational search was conducted to find starting geometries for the transition states 175 
in which the C3-O7 bond was artificially constrained to 1.8 Å. For the purposes of molecular 
mechanics, the bonding of the various structures needed to be specified and as such the 
protonation state had to be inferred. No further assumptions were made about the binding 
between the substrate and the acid.   
The conformational searches were implemented in Schrodinger MacroModel using the 
MMFF-94 force-field91 and implicit CHCl3.* All conformers within 50 kj mol-1 of the global 
minimum were recorded, with a sufficient number of steps used to ensure that all conformers 
 
* Chloroform was used in place of dichloromethane as a solvent model for the conformational search as 
gas-phase calculations vastly over-emphasised the significance of intramolecular interactions resulting 
in highly folded conformers for the starting material. 
 





within 10 kj mol-1 of the global minimum were found at least 10 times.* Redundant conformer 
elimination was used to remove similar conformations from the ensemble.† 
 
Figure 3.8: Structures used as inputs for the conformational search.  
 
 
* The method used for the conformational search (mixed torsional/low-mode Monte Carlo) is non-
systematic, using random displacements to generate new structures for minimisation. Finding the same 
conformation multiple times therefore gives confidence (though not certainty) that the conformational 
space has been sufficiently explored. A high cut-off (10 kj mol-1) is used since molecular mechanics (MM) 
energies are known to be prone to error and as such a high-energy conformer from MM may end up 
significantly lower (or higher) in energy when optimised using quantum mechanical (QM) techniques 
such as DFT.  
† Molecular mechanics often generates many similar conformers that will ultimately optimise to the 
same structure (e.g. Conformations that differ only by the rotation of a methyl group). Redundant 
conformer elimination helps to identify and remove these conformations to avoid the number of 







































176: 2,6-cis 177: 2,6-trans














Ground state optimisation:  
Optimisation is a general term for finding stationary points along a reaction pathway. In the 
case of ground state optimisation, the desired stationary points are minima where the first 
derivative of the reaction coordinate is zero (i.e. the point is stationary and not lying on a 
gradient). Finding local minima is relatively easy, with many algorithms available to 
accomplish the task – in the most straightforward implementation, it is always possible to 
drive a structure towards a minima by following the reaction coordinate down-hill.  
DFT Optimisation was performed in Schrodinger Jaguar at the B3LYP/6-31G**+ level of 
theory.92–94 Implicit solvent (CH2Cl2) was included in the calculations to represent the true 
reaction conditions most accurately. Since the energies from molecular mechanics are known 
to be inaccurate, it is not possible to optimise the lowest energy conformer. Accordingly, 
following redundant conformer elimination (described above), all remaining conformers 
within 10 kj mol-1 of the global minimum were subjected to optimisation with DFT and the 
lowest energy structure used for the construction of the energy diagrams (below).   
Transition state optimisation:  
Unlike ground state optimisation, where the lowest energy structure can always be found 
given sufficient time, there is no general method that will always identify a transition state. 
Various methods exist to accomplish this task, the most common of which interpolates the 
transition state based on known structures of a starting material and a product, however there 
is no universal method, and the process takes significantly longer than the corresponding 
ground state optimisations.95  
Given the increased time needed to find a transition state, the previously adopted method of 
optimising everything within a given window is not a viable strategy. *  To minimise the 
number of structures used in TS optimisation, a multi-dimensional scaling approach was used 
to ‘cluster’ the structures according to similarity (Figure 3.9) .†  
 
* Each ‘step’ of a transition state search uses an optimisation to determine if the geometry is converged. 
Accordingly, if a TS search takes 20 steps to converge this is the same as running a ground-state 
optimisation on 20 individual structures.  
† The idea for clustering conformers was demonstrated by Ermanis.89 The methodology used to cluster 
the conformers is outlined in Appendix C.  






Figure 3.9: Clustering of conformers. [Key: points are coloured by relative MMFF-94 energy; points are 
sized by the number of times the conformational search identified that conformer]. Note that the axes 
are arbitrary, and the distance between points is not a quantitative measure of how similar/different two 
structures are. 
Representative conformations corresponding to the expected transition states (i.e. chair and 
boat like conformations with sensible geometries for orbital overlap) were then subjected to 
a DFT coordinate scan (B3LYP/6-31G**+, gas-phase), fixing the bond length at 0.2 Å	intervals 
(1.2, 1.4, 1.6, 1.8, 2.0, 2.2 Å) in order to identify an approximate location of the transition state. 
These approximate geometries were subsequently refined using DFT (B3LYP/6-31G**+, 
implicit CH2Cl2) to obtain transition states shown in Figure 3.10 and Figure 3.11.  
 With transition states identified, minimum energy pathway (MEP) calculations were 
conducted. * The MEP is used to ensure that a given transition state does indeed connect the 
anticipated starting material to the anticipated product (i.e. the actual reaction of interest).† A 
priori the computer has no understanding of the reaction being carried out, so will latch onto 
a transition state (single imaginary frequency) even if this is not the one being identified. By 
following the MEP for the four transition states above, an additional set of intermediates were 
obtained corresponding to the thioenol formed upon cyclisation. There is growing evidence 
that this intermediate may be key to the outcome of the reaction, governing whether the 
cyclisation occurs under kinetic or thermodynamic control. 
 
*  The minimum energy pathway is a mass-weighted variant of the more commonly used intrinsic 
reaction coordinate (IRC).  
† One of the challenges with transition state searches is that the TS found will not necessarily be the one 
that connects two minima.  






















Figure 3.10: Chair-like transition states for the p-TsOH mediated IOCC. Tolyl rings have been faded and 
some hydrogens have been omitted for clarity. All energies calculated relative to 174 (DFT-B3LYP/6-














































Figure 3.11: Boat-like transition states for the p-TsOH mediated IOCC. Tolyl rings have been faded and 











Reaction pathway:  
Thermodynamically, DFT calculations suggest that the 2,6-cis diastereomer is 4.6 kcal mol-1 
lower in energy than the 2,6-trans diastereomer (Scheme 3.24), giving a Boltzmann 
population of >99% at 298 K. This result is consistent with experiment, in which cyclisation 
of 107 in the presence of p-TsOH affords a single diastereomer by NMR (see §3.3.2.1).*  
 
Scheme 3.24: Energy diagram for the p-TsOH mediated IOCC showing the lowest energy pathways to 
2,6-cis (orange) and 2,6-trans (blue) products. All energies relative to the neutral starting material 165. 
This thermodynamic preference for the 2,6-cis diastereomer 107 is rationalised by the 
minimisation of 1,3-diaxial strain across the ring present in the trans diastereomer 178, with 
three groups forced axial in order to keep the sterically demanding thioester group equatorial 
(Figure 3.12).    The same thermodynamic preference is observed computationally for the 
corresponding methyl ester variant, with a smaller energy gap observed between the chair-
like transition states leading to the cis and trans isomers respectively (3.2 kcal mol-1 vs 4.6 kcal 
mol-1).  
         
 
* The detection limit of NMR spectroscopy is such that the predicted 1% of the trans diastereomer would 

























   
Figure 3.12: Ground state structures and energies for the 2,6-cis and 2,6-trans THPs.  
While the 2,6-cis diastereomer 107 may be the thermodynamically favoured in this case, this 
does not explicitly determine that the reaction is under thermodynamic control — this is 
determined by the barrier to interconversion between the two products and requires 
consideration of the transition states involved in the cyclisation. Accordingly, plotting the two 
lowest energy transition states against the protonated starting material and product 
complexes gives a more complete picture of the reaction pathway (Figure 3.13). The reaction 
pathway below is still consistent with the 2,6-cis isomer being the thermodynamic product, 
however the barrier to the reverse reaction (back to the thioenol) is sufficiently high that the 



























Figure 3.13: Energy diagram for the p-TsOH mediated IOCC showing the lowest energy pathways to 
2,6-cis (orange) and 2,6-trans (blue) products. All energies relative to 174 (DFT-B3LYP/6-31G**+, 
CH2Cl2). Note: the transition state for the re-protonation of the thioenolate was not able to be found.  
 
3.3.3 COMPLETION OF THE FRAGMENT  
With the C1 – C11 aglycone 107 to hand, all that was required to complete the fragment was 














































3.3.3.1 SYNTHESIS OF THE CINERULOSE DONOR  
The l-cinerulose A moiety present in madeirolide A is relatively uncommon, present only in 
a small number of anthracycline-type natural products such as aclacinomycin A and the 
ciclamycins.4 Unlike other carbohydrates, deoxysugars (of which l-cinerulose is an example) 
are not found abundantly in nature, necessitating the use of synthesis to provide access in 
meaningful quantities.96,97   
Previous total syntheses requiring l-cinerulose have accessed the moiety via derivatisation of 
l-rhamnose or another pre-existing glycoside; while successful, these approaches often 
require upwards of six steps to obtain a suitably functionalised donor unit, with additional 
post-glycosylation steps then required to remove unwanted functionality or adjust the 
oxidation state.98–100 
A more attractive approach is the de novo synthesis of the sugar, the first asymmetric 
synthesis of which was reported in 2014 by Schmidt using a chiral-pool approach in which 
(S)-lactate was used to provide the methyl stereocentre with known absolute configuration 
(Scheme 3.25).101   
 
Scheme 3.25: Asymmetric synthesis of l-cinerulose (Schmidt). 101 
In Haslett’s work, the l-cinerulose moiety in madeirolide A was previously accessed via the 
related 2,3-dehydrocinerulose scaffold 190; available in three steps from 2-furyl methyl 
ketone102 187 via Noyori asymmetric  transfer hydrogenation103,104 followed by Achmatowitz 
rearrangement,105 with subsequent acetylation providing a stable cyclic form of the molecule 
amenable to glycosylation  (Scheme 3.26). The epimeric mixture at the anomeric position is 























Reagents & conditions: [a] Ru(p-cymene)(S,S-TsDPEN), HCOOH:Et3N, rt. [b] NBS, NaHCO3, NaOAc, THF:H2O, O °C. 
[c] Ac2O, py., DMAP. CH2Cl2, rt. 
Scheme 3.26: Synthesis of 2,3-dehydrocinerulose acetate as a precursor to the l-cinerulose moiety 
present on madeirolide A (Haslett). 56 
In the published route,53 190 was reduced using catalytic hydrogenation over Pd/C to give 42 
in modest yield (34%) with small quantities (15%) of the de-acylated product 191 also isolated. 
The remaining mass balance was unaccounted for, presumably due to the high volatility of 
both 191.  Although this provided sufficient material for preliminary studies, the yield was low 
and the reaction found to be capricious, often leading to degradation rather than the desired 
product. One possible explanation to this lies in the inherent acidity of the catalyst, leading to 
formation of an oxonium ion that subsequently gets reduced (Scheme 3.28).  
 
Scheme 3.27: Pd/C catalysed hydrogenation of 2,3-dihydrocinerulose derivative 190 (Haslett). 
 
Scheme 3.28: Mechanistic rationale for the isolation of the deacylated product 191.  
Given the poor yield of catalytic hydrogenation, an alternative tactic was explored for 
chemoselective reduction of the enone. The Stryker reagent, [(PPh3)CuH]6,106 acts as a soft 
hydride source resulting in conjugate reduction of enones to the corresponding ketones with 
excellent chemoselectivity.107  Unfortunately, the original Stryker reagent is highly air 
sensitive and requires storage and manipulation inside a glovebox.106,108 These deficiencies, 
coupled with a desire to carry out the reaction catalytically, have led  to the development of 
operationally easier copper hydride reductions.109–113 Many of these alternatives allow the 
[Cu]-H species to be prepared in situ and used catalytically as a solution, avoiding the issues 
encountered with the original methodology.  









































The Yun protocol111,112 generates a solution of the Stryker reagent from copper (ii) acetate and 
triphenyl phosphine, using Ph2SiH2 as the stochiometric reductant.* Treatment of 190 with 
this solution gave moderate yields (50 – 60%) of the desired saturated ketone 42, with none of 
the over-reduction product 191 observed, more importantly, this reaction was highly 
reproducible (Scheme 3.29). The use of benzene (in place of the toluene used in the literature) 
was found to be critical as it enabled the solvent to be removed in vacuo without significant 
loss of 42.   
 
Scheme 3.29: Conjugate reduction of enone using a copper hydride reagent.  
Detailed mechanistic studies of this copper (i) hydride reduction have not yet been reported, 
however several proposals have been made based on the known mechanism of the original 
stochiometric Stryker reduction. Initially, coordination of [Cu]-H to the enone and hydride 
insertion generates a copper enolate which undergoes metathesis to the silane, converting the 
copper enolate into a silyl enol ether with concomitant regeneration of the [Cu]-H species, 
which renders the process catalytic in [Cu], with the silane acting as the stochiometric 
reducing agent. In the absence of a proton source (t-BuOH), the silyl enol ether 193 can be 
isolated, which provides some mechanistic support for the proposed mechanistic pathway.  
 
* The solution is unable to be characterised, however evaporation in vacuo affords a red solid, the 1H 



















Scheme 3.30: Proposed mechanistic pathway for copper hydride reduction of enones using (Me2SiH)2O 
as the terminal source of hydride (Oestreich).113 
3.3.3.2 GLYCOSYLATION  
To complete the modified C1 – C11 western fragment 99, all that remained was the 
glycosylation of 107 with cinerulose donor 42. Thus, treatment of a mixture of 107 and 42 with 
BF3･Et2O in dry CH2Cl2 afforded the 99 in 64% yield as a separable 7:1 mixture of anomers in 
favour of the axially substituted cinerulose moiety (Scheme 3.31). 
 









































































Gratifyingly, detailed NMR comparison against natural madeirolide A shows excellent 
agreement with the synthetic fragment 99 (Figure 3.14 and Table 3.2). The large errors at C10 
and C11 are consistent with the terminal olefin not representing the diene present in the 
natural product, and consistent with those previously observed by Haslett. 56 
 
Figure 3.14: 1H NMR comparison of the C1 – C11 fragment 99 with natural madeirolide A.  
3.3.4 SUMMARY AND ANALYSIS  
The work described in this chapter has culminated in the synthesis of a modified C1 – C11 
fragment of madeirolide A in 13 steps from PMB protected Roche ester. The key goals outlined 
at the beginning of this chapter have been met successfully. Namely, the issue of the protecting 
group shuffling and challenging vinyl iodide have been solved based on a modified fragment 
union strategy in which a macro-Heck cyclisation is envisioned to replace the previously 
anticipated macro-Stille cross-coupling. Through this modified route, around 50 mg of the C1 
– C11 fragment 99 have been accessed. Additionally, the IOCC used to forge the western THP 
has been studied computationally. This computational study was able to successfully 









Table 3.2: NMR data for madeirolide A and the C1 – C11 fragment 99. 
















1 170.9 - - - 195.9 - - - 
2’ 
41.6 
2.45 m - 
49.9 
2.67 dd 14.6, 4.7 
2” 2.58 m - 2.92 dd 14.6, 8.3 
3 74.2 3.80 m - 72.4 3.82 m - 
4’ 
36.2 
1.26 m - 
36.4 
1.23 m - 
4” 2.14 m - 2.14 ddd 12.1, 4,5, 1.9 
5 75.9 3.56 td 10, 4 76.0 3.52 td 10.6, 4.6 
6 42.9 1.32 m - 42.1 1.37 ddq 9.8, 6.4, 3.4 
7 77.9 3.07 td 78.9 78.9 3.08 td 9.9, 2.9 
8’ 
40.5 1.44 m 40.0 40.0 
1.52 m - 
8” 1.46 dd 10.3, 3.0 
9 34.3 2.37 m - 33.3 2.51 m - 
10 142.3 5.48 dd 15, 10 145.4 5.80 ddd 17.2, 10.4, 6.8 
11’ 
122.8 6.24 dd 15, 11 112.0 
4.97 dd 17.3, 1.6 
11” 4.88 dd 10.4, 1.5 
28 13.0 0.90 d 7 13.3 0.91 d 6.5 
29 18.0 0.85 d 7 18.4 0.94 d 6.7 
32 92.6 5.15 t 6 92.6 5.15 t 5.4 
33’ 
28.8 
1.93 m - 
28.9 
1.93 ddt 14.8, 9.5, 5.6 
33” 2.28 m - 2.36 m - 
34 33.8 2.46 m - 33.8 2.45 m - 
35 211.0 - - - 211.2 - - - 
36 71.5 4.26 q 7 71.3 4.27 q 6.7 
















4. RESULTS & DISCUSSION II:   
INVESTIGATIONS INTO THE EASTERN 
TETRAHYDROFURAN 
4.1 SYNTHETIC STRATEGY FOR THE EASTERN FRAGMENT  
The proposed C12 – C27 100 fragment of madeirolide A is highly functionalised containing 
nine stereocentres (five of which are contiguous), and two saturated oxygen heterocycles, 
including the synthetically challenging all-cis C21 – C25 THP. In accordance with the 
modified macrocyclisation strategy (see §3.1), the previously anticipated C12 (Z)-vinyl 
stannane was replaced with the corresponding (Z)-vinyl iodide (Scheme 4.1).  
 
Scheme 4.1: Modified fragment union strategy showing the proposed C12 – C27 eastern fragment 100 of 














































The overall approach to the synthesis of the modified C12 – C27 eastern fragment 100 is 
outlined retrosynthetically in Scheme 4.2. Initial simplification reveals 194, with the THF 
formed through a cycloetherification of 195. Key to this strategy was the recognition that the 
diol could be disconnected to alkene 196, which provided a point of scission; thus, in a forward 
sense the C17 – C18 bond would be formed through an sp2 – sp3 Suzuki cross-coupling between 
organoborane 197 and vinyl iodide 198.   This disconnection between C17 and C18 was critical 
since logistically, it was desirable to separate the two heterocycles; this not only provided 
greater convergence to the route, but also permitted synthetic work to be conducted in 
parallel which was necessary owing to the anticipated challenges in effecting ring closure of 
the THP.  
 
































































4.2 SYNTHESIS OF THE C13 – C17 FRAGMENT  
4.2.1 RETROSYNTHESIS  
Haslett originally anticipated the C13 – C17 fragment 197 of madeirolide A to be synthesised 
in nine steps from (–)-ethyl-l-lactate (Scheme 4.3).56 Central to the strategy was the use of a 
Cy2BCl mediated lactate aldol reaction between aldehyde 199 and ethyl ketone (S)-200 to 
forge the C15 – C16 bond with concomitant installation of the required 1,2-anti relationship. 
This aldol reaction is well precedented, as illustrated in the Paterson synthesis of the  C10 – 
C29 fragment 205 of  (+)-roxaticin.114 Although the lactate aldol approach would provide the 
desired stereochemistry, the cleavage of the auxiliary and subsequent elaboration into 
organoborane 197 requires a significant number of steps, the majority of which are redox 
manipulations. As no synthetic work had been carried out on this fragment proposed by 
Haslett, an alternative approach was therefore proposed, obviating the need for an auxiliary 
altogether.   
 
 
Scheme 4.3: A Proposed synthesis of the C13 – C17 fragment 197 using a lactate aldol as the key step to 
set the necessary stereochemistry (Haslett). B Literature precedence for the selectivity of the proposed 
aldol, as used in the context of (+)-roxaticin (Paterson).114   
The revised route to the C13 – C17 fragment 197 is shown retrosynthetically in Scheme 4.4. It 
was reasoned that the 1,2-anti relationship could be installed at a late stage through a 

























































stereocentre to bias formation of the desired diastereomer. Thus, retrosynthetic 
simplification of 205 in the manner illustrated reveals 206, accessed via the readily available 
aldehyde 199 and prop-1-en-2-ylmagnesium bromide 207, itself derived from commercially 
available 2-bromopropene.  
 
Scheme 4.4: Retrosynthesis of the C13 – C17 fragment 197 using a diastereoselective hydroboration to 
set the key 1,2-anti relationship between C15 and C16.  
4.2.2 RACEMIC MODEL STUDIES 
The racemic model studies described in this section were carried out by James Thompson, a BP 
funded summer student. All experiments were designed by the author, and results are provided 
here for completeness. 
Initial studies into the proposed hydroboration/Suzuki cross-coupling approach were carried 
out on a racemic model system. This allowed investigation of the hydroboration reaction and 
subsequent Suzuki cross-coupling reaction without the need to first prepare 205 as a single 
enantiomer, which was anticipated to be a straightforward task given the wide range of 
methods available for accessing enantiomerically pure secondary alcohols.    
Accordingly, addition of prop-1-en-2-ylmagnesium bromide to 199* followed by protection as 
the corresponding TES ether (TESCl, imidazole) afforded rac-208  setting the stage for the 
projected hydroboration (Scheme 4.5). In the event, treatment of 208 with 9-BBN in THF at 
-78 °C, followed by oxidative workup (H2O2, MeOH) gave rac-210 in 68% yield as an 
inseparable 9:1 mixture of diastereomers in favour of the desired 1,2-anti product as expected 
from prior work by Still.115 
 
* A supply of aldehyde 199 was available within the Paterson group and was prepared by Ms Nadia 
































Reagents and conditions:  [a] THF, -78 °C. [b] TESOTf, 2,6-lutidine, THF, 0 °C. [c] 9-BBN, THF, -78 °C; H2O2, MeOH, 
pH 7 buffer.   
Scheme 4.5: Synthesis of the rac-210 to test the diastereoselectivity of the proposed hydroboration 
(Thompson).116 
The observed diastereoselectivity can be rationalised by analysis of the conformational 
preferences of the olefin, which bears a chiral centre in the allylic position (Figure 4.1).  To 
minimise A1,3 strain, the substrate is likely to adopt a reactive conformation in which the allylic 
proton eclipses the alkene.117 In this conformation, the two diastereotopic faces of the alkene 
are differentiated, with hydroboration taking place on the less hindered face away from the 
sterically demanding TES ether. The lowest energy conformation of alkene 208 is shown in 
Figure 4.1 B, demonstrating the ability to differentiate between the two diastereotopic faces 




Figure 4.1: Rationalisation of 1,2-anti diastereoselectivity during hydroboration. A Putative transition 
state for the reaction. B Lowest energy conformation of 208 showing the TES ether shielding the lower 





















































While the steric-driven ‘reactive conformer’ model described above adequately predicts the 
major diastereomer, it is incompatible with many experimental observations, leading to the 
suggestion that there is a stereoelectronic component involved in determining 
diastereoselectivity.118,119 Evans120 and Still115 have independently reported significant 
protecting group effects when studying the hydroboration of terminal olefins using 9-BBN. 
When comparing the hydroboration of a terminal allylic alcohol protected with a series of silyl 
ethers (-TMS, -TBS, -TBDPS), selectivity was found to decrease as the protecting group got 
larger, contrary to the expected outcome based on minimisation of A1,3 strain alone.  
 
Scheme 4.6: Studies into the diastereoselectivity of uncatalysed hydroborations using 9-BBN (Evans).120 
With the stereochemistry of the hydroboration confirmed, attention was turned to the 
proposed sp2 - sp3 Suzuki cross-coupling reaction that would be used to forge the C17 - C18 
bond of madeirolide A (Scheme 4.2). While many examples of such a reaction exist in the 
literature, including in the synthesis of complex natural products,121 the hydroboration/cross-
coupling sequence was anticipated to be challenging,122 as sp3 alkyl boranes are known to 
undergo slow transmetallation, often leading to significant amounts of the protodeboronation 
product being formed, thus requiring super-stochiometric amounts of the organoborane 
coupling partner to achieve good yields.123  
Given that work was on-going into the synthesis of the C18 – C27 fragment 128, a model vinyl 
iodide 214 was prepared (Scheme 4.7). The choice of vinyl iodide was not important since the 
challenging aspect of the sp2 - sp3 cross-coupling reaction is known to be with the sp3 
organoborane rather than the sp2 halide. Thus, Takai olefination (CrCl2, CHI3) of 
hydrocinnamaldehyde 213 afforded 214 in a modest 42% yield with the desired (E)-isomer 


















  92:  8
9-BBN
THF, 25 ºC






Scheme 4.7: Preparation of a model (E)-vinyl iodide used to investigated the proposed sp2 - sp3 Suzuki 
cross-coupling reaction (Thompson). 116 
Initial attempts at effecting the convergent union of 214 and rac-197 were met with 
disappointment, failing to return the desired product and leading to significant amounts of 
protodeboronation.  Screening of a range of conditions eventually identified Braun’s 
conditions (PdCl2(dppf), Cs2CO3, AsPh3, DMF/THF/H2O) to provide modest yields of the 
desired coupling product 215 when using a two-equivalent excess of the organoborane 
(Scheme 4.8).  
 
Scheme 4.8: Successful sp2 – sp3 Suzuki cross coupling between vinyl iodide 214 and organoborane rac-
197 (Thompson).  
Ideally, this reaction would proceed to full conversion, however the ability to recover the vinyl 
iodide starting material meant that there was no net loss of what would, in the real system, be 
the ‘valuable’ component. Given the known difficulties with sp2 - sp3 cross-couplings using 
organoboranes, it may well be the case that in future studies it would be prudent to make use 
of a more stable boron derivative, such as a MIDA boronate, which allows the reactive species 
to be released slowly over the course of the cross-coupling reaction, preventing loss to 
protodeborylation.  This will be investigated further in due course, with future directions 
discussed in Chapter 6.  
4.2.3 ENANTIOSELECTIVE SYNTHESIS THE C13 – C17 ALCOHOL 
For the planned synthesis of madeirolide A, 197 would be required as a single enantiomer. A 
particularly attractive strategy for this was the kinetic resolution of  allylic alcohol rac-206 
using a Sharpless asymmetric epoxidation.124  Treatment of a racemic allylic alcohol with 
Ti(Oi-Pr)4/(+)-DET sets up two diastereomeric transition states (Figure 5.3). The presence of 




























energies resulting in one enantiomer of the allylic alcohol undergoing rapid epoxidation, 
leaving behind the other enantiomer which is theoretically returned with complete 
enantioenrichment.   
 
Figure 4.2: Schematic representation of a kinetic resolution using a Sharpless asymmetric epoxidation.  
The Sharpless kinetic resolution of rac-206 has been used by Ghosh and co-workers in their 
synthesis of  (–)-lasonolide A, obtaining ent-206 with excellent enantioselectivity using (–)-
DIPT (Scheme 4.9).125 Despite this precedence, significant attempts at optimisation by 
Thompson failed to provide access to material with an ee > 33%.* In the authors hands, the ee 
was able to be increased to 42%, however this was not considered synthetically useful.  
Notably, Thompson also observed the formation of a by-product, proposed to be aldehyde 217 
which could arise from Lewis acid catalysed opening of the epoxide and subsequent hydride 
shift.  
 
Scheme 4.9: Kinetic resolution of racemic allylic alcohol 206  using a Sharpless asymmetric epoxidation. 
Note that Ghosh carried out the synthesis using (+)-DIPT and thus obtained the enantiomeric products.  
To quickly access enantioenriched alcohol 206, the kinetic resolution attempted by 
Thompson was abandoned in favour of a more traditional oxidation/reduction sequence. 
Accordingly, rac-206 was oxidised using the Dess-Martin periodinane to provide ketone 218 
in 82% yield (Scheme 4.10).  
 







































Scheme 4.10: Oxidation of rac-206 and proposed asymmetric reduction.   
One of the most common asymmetric reduction methods is the Corey-Bakishi-Shibata 
reaction, which uses chiral B-substituted oxazaborolidines to distinguish the enantiotopic 
faces of a prochiral ketone.126  Accordingly, treatment of ketone 218 with the (S)-CBS catalyst 
in the presence of BH3･DMS as the terminal source of hydride provided allylic alcohol 206 in 
89% yield and 97% ee (Scheme 4.11).* The selectivity of the reaction is rationalised through 
cyclic transition state TS-219 in which the large group on the ketone orients itself away from 
the methyl group on boron to avoid an unfavourable steric interaction.  
 
Scheme 4.11: CBS reduction of ketone 218 to provide access to enantiomerically enriched allylic alcohol 
206.   
In tandem with the CBS reduction, an alternative transfer hydrogenation approach was 
investigated using the Noyori Ru(p-cymene)TsDPEN catalyst system.103,104 The Noyori 
reduction has the advantage of not requiring low temperatures to be maintained, and the 
exceptionally low catalyst loadings (often <1%) allow for large quantities of ketone to be 
carried through the reaction. Although the catalyst is commercially available, it is most 
conveniently prepared from [RuCl2(p-cymene)2] by treatment with (1S, 2S)-TsDPEN in the 
presence of KOH (Scheme 4.12).127  Once formed, the bright-purple catalyst is able to be stored 
at room temperature on the bench without appreciable decomposition.  
 
Scheme 4.12: Preparation of (S,S)-Ru(p-cymene)TsDPEN for use in a Noyori asymmetric transfer 
hydrogenation. 
 
* Enantiomeric excess was determined by chiral HPLC (Chiralpak-IA®, 20% i-PrOH:n-hexane).    











































Treatment of ketone 218 with 1 mol% catalyst 220 in a mixture of triethylamine and formic 
acid at 40 °C provided allylic alcohol 206 in 78% yield, albeit with a reduced enantiomeric 
excess of 87% (Scheme 4.13).  Attempts at optimisation (lowering temperature or catalyst 
loading) failed to provide any enhancements to the enantioselectivity, as such this route was 
abandoned in favour of the successful CBS reduction route.  
 
Scheme 4.13: Noyori asymmetric transfer hydrogenation of ketone 218 to provide access to 
enantiomerically enriched allylic alcohol 206.  
The accepted catalytic cycle for the asymmetric transfer hydrogenation of ketones was first 
proposed by Noyori, and has since been validated through a combination of computational 
studies and the characterisation of the active ruthenium species via x-ray crystallography 
(Scheme 4.14).128,129 Mechanistically, the coordinatively unsaturated 16-electron ruthenium 
species is first reduced by formic acid to generate the catalytically active 18-electron 
ruthenium hydride species. The ketone is then reduced by this species via a putative six-
membered pericyclic step in which the hydride from Ru-H is delivered with simultaneous 
protonation of the oxygen using the protic N-H bond, thus regenerating the 16-electron 























Scheme 4.14: Proposed catalytic cycle of the Noyori transfer hydrogenation using a Ru(p-
cymene)TsDPEN catalyst. Crystal structures of the proposed intermediates shown below, some 
hydrogens have been omitted for clarity (Noyori).130 
The origin of enantioselectivity in the Noyori transfer hydrogenation is not well understood 
despite extensive mechanistic and computational studies. Central to the issue is the fact that 
the proposed model (Figure 4.3) is unable to unify the experimental evidence for the 
reduction of both ketones and imines, which give opposite facial selectivity when using the 
same catalyst. Most widely studied are aromatic ketones, where Noyori has proposed a non-
(S,S)-Ru(p-cymene)TsDPEN (S,S)-RuH(p-cymene)TsDPEN









covalent interaction between the aryl group and the aromatic group bound to the ketone, as is 
evident from the favoured transition state TS-221.  
 
Figure 4.3: Proposed transition states for the Noyori transfer hydrogenation of aromatic ketones 
(ArCOR) using Ru(phenyl)TsDPEN catalyst (Noyori).  
4.2.4 SUMMARY AND ANALYSIS  
The investigation of the C13 – C17 fragment described in this chapter achieved its intended 
goals. Firstly, the use of a hydroboration to generate an sp3 borane with concomitant 
introduction of the necessary 1,2-anti diastereoselectivity has been validated, precluding the 
need for a lactate auxiliary based approach which would require additional redox and 
functional group manipulations to arrive at a suitably functionalised intermediate.  
The organoborane 197 was also used to affect the desired sp2 – sp3 Suzuki cross-coupling 
reaction using a model vinyl iodide 214. Despite the modest 29% yield, the result acts as a 
‘proof of concept’ that the coupling is possible in this context, and, given the many catalysts, 
ligands, and boron derivatives developed in recent years, it will undoubtedly be possible to 
find a suitable combination that procures access to the cross-coupling product 196 in 
synthetically acceptable yields.  
Overall, over 5 g of homochiral allylic alcohol 206 is available for further studies, making use 
of a CBS reduction to install the C15 stereocentre with reliable yield and enantioselectivity. 
Given the highly oxygenated nature of the C12 – C27 fragment of madeirolide A, and on-going 
difficulties in accessing the eastern THP, alcohol 206 has not yet been elaborated to the 


























5. RESULTS & DISCUSSION III: SYNTHESIS 
OF THE EASTERN TETRAHYDROPYRAN 
5.1 GENERAL SYNTHETIC STRATEGY  
The construction of the eastern THP was anticipated to be a significant obstacle to realising a 
successful total synthesis of madeirolide A. Previous synthetic studies by Haslett56 and 
Fearnley61 failed to procure access to the required heterocycle, despite the successful 
preparing several advanced precursors (see §2.3.1.1).  
 As a means of assembling highly-substituted THPs, the intramolecular oxy-conjugate 
cyclisation (IOCC) is unmatched in terms of versatility, with numerous examples in complex 
molecule synthesis making it an encouraging strategy for construction of the pentasubstituted 
all-cis eastern THP.83,131,132 The proposed application of an IOCC to the synthesis of the C18 – 
C27 fragment 198 is shown in Scheme 5.1.  Thus, initial retrosynthetic manipulations to 
remove the vinyl iodide reveals the target THP 223, with subsequent scission of the O25 – C21 
bond revealing a linear precursor 224 in which four of the five stereocentres are present.  
 
Scheme 5.1: Intramolecular oxy-conjugate cyclisation strategy applied to the C18 – C27 eastern fragment 
198.   
The highly-oxygenated nature of the linear C19 – C27 fragment required careful consideration 

































to remain differentiable throughout the synthesis to ensure that esterification between 229 
and the western fragment takes place with site-selectivity. Additionally, it was decided to 
leave the C26 ketone as a protected alcohol prior to cyclisation to deter the possibility for 
formation of a hemiacetal through competitive attack of O23. To this end, 225 was identified 
as a suitable cyclisation precursor, bearing a silyl ether on O22 which would be easily removed 
at the end of the synthesis. Note that the concept of using an acetonide to constrain O23 and 
O25 is borrowed from the western fragment synthesis (see §2.3.1 and §3.2).  
 
Scheme 5.2: Protecting group strategy and differentiation of the C22, 23, and 26 hydroxyl groups.    
5.2 THE TARTRATE APPROACH  
The C20 – C21 olefin was recognised as a strategic disconnection for simplification of the 
linear precursor 225 (Scheme 5.3). This retrosynthetic manoeuvre traces its origins to the 
seminal work by Fuwa who screened a variety of oxy-Michael acceptors – introduced via cross 
metathesis – during the development of the 2,6-cis selective thioester methodology (see 
§3.3.2).86 In the context of madeirolide A,  a cross-metathesis reaction  could affect convergent 
union of 227 with a variety of acrylate derivatives 232 - 235 to probe the reactivity and 
diastereoselectivity of the anticipated cyclisation. The cross-metathesis is projected to give 
good selectivity as it takes place between a type i and type ii alkene,133 and the acrylate 
derivatives are readily accessible in one step from acroloyl chloride via the addition of a 















































Scheme 5.3: Retrosynthetic analysis of a linear C19 – C27 precursor to the eastern THP.  Michael 
acceptors investigated by Fuwa (inset). 
Recognising the 1,4-syn 1,2-anti relationship within 228, a lactate aldol reaction could be used 
to forge the C23 and C24 stereocentres concomitantly.134 This reveals ethyl ketone (R)-200 
and  α-siloxy-β,γ-unsaturated aldehyde 229 as sub-targets, both accessible from the chiral 
pool using lactic and tartaric acid derivatives respectively. This lactate aldol methodology, 
developed within the Paterson group,134 has been widely used in polyketide synthesis, giving 
confidence that the C22 and C23 stereocentres will be introduced with high levels of 
selectivity . Notably, unlike in the majority of cases, the lactate ‘auxiliary’ forms part of the 
natural product, providing the C27 methyl group, and thus avoiding the need for additional 
manipulations to cleave the C – C bond beteen C25 and C26.  
One downside to using chiral pool materials is that one enantiomer is often naturally 
abundant, and hence cheaper. For the construction of madeirolide A, the unnatural 
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chapter, unless otherwise noted, have been carried out in the enantiomeric series using the 
(S)-lactate derived ketone (S)-200. Given that all the intended reactions are diastereoselective 
and under substrate control, it would be possible to procure access to the correct enantiomer 
once the route had been suitably developed. Parenthetically, at this stage it is not yet known 
conclusively what the absolute stereochemistry of madeirolide A 1 is, with current synthetic 
efforts guided by the configuration of the cinerulose sugar and by comparison to mandelalide 
A for which the absolute configuration is known.   
5.2.1 PREPARATION OF THE LACTATE ETHYL KETONE  
The required ketone (S)-200 was accessed in two steps from natural (S)-(–)-ethyl-l-lactate 
(S)-231 following an improved protocol from Trauner (Scheme 5.4).135 Weinreb amide 236 
was first prepared through the action of i-PrMgCl and Weinreb salt on (S)-231, with 
subsequent addition of EtMgBr in situ furnishing ethyl ketone 232.  While this procedure 
improves on the original two-step procedure developed in our group, avoiding the isolation of 
the Weinreb amide, the resulting unprotected alcohol is highly volatile. An overall yield of 
between 30 – 40% from (S)-231  was obtained, in keeping with literature values.135  
 
Reagents and conditions: [a] i-PrMgCl, [MeO(Me)NH･HCl], THF, 0 °C; EtMgBr, 0 °C ⟶ rt. [b] Bz2O, DMAP, Et3N, 
CH2Cl2, rt.  
Scheme 5.4: Preparation of lactate derived ethyl ketone (S)-200 using Trauner’s ‘one-pot’ synthesis.  
Protection of the free hydroxyl moiety at the beginning of the synthesis would increase the 
efficiency of the subsequent steps by preventing loss of material to evaporation. While this 
lacks elegance, the transformation was deemed synthetically valuable in obtaining stocks of 
ent-200. This would be critical when conducting the reaction on the opposite (correct) 
enantiomeric series owing to the prohibitive cost of 231. (S)-(–)-ethyl-l-lactate ent-232 was 
thus converted to TBS ether 238 and subjected to the Trauner conditions to afford 239 in 
excellent yield (60 – 85% from 231). With the ketone to hand, the TBS group needed to be 
switched for the required benzoate without isolation of the intermediate unprotected 
secondary alcohol.*  This was achieved in one-pot by sequential treatment with TBAF and 
 
* The benzoate group is necessary to achieve diastereoselectivity in the lactate aldol reaction, but cannot 






















Bz2O giving quantitative yield of (S)-200. Anketell has also shown this transformation to be 
possible using catalytic TBAF and KF as an economical stochiometric fluoride source.136  
 
Reagents and conditions: [a] TBSCl, Imid., CH2Cl2, 0 °C. [b] i-PrMgCl, [MeO(Me)NH･HCl], THF, 0 °C; EtMgBr, 0 °C ⟶ 
rt. [c] TBAF, CH2Cl2, rt; Bz2O, Et3N, DMAP.  
Scheme 5.5: Modified preparation of lactate derived ethyl ketone (S)-200.  
5.2.2 SYNTHESIS OF THE ALDEHYDE  
The use of the α-siloxy-β,γ-unsaturated aldehyde 229 (Scheme 5.6) as the coupling partner 
for the lactate aldol reaction was an ambitious strategy, with the	β,γ-olefin liable to migrate to 
form the corresponding silyl enol ether/enal 240, which is thermodynamically favoured 
owing to conjugation with the carbonyl. The stability of 229 to Lewis acidic conditions has 
been investigated by Hayashi using the racemic compound rac-229, after 1 h at 0 °C, a 10:1 
ratio of rac-229 to 240 was observed, demonstrating the possibility that it may be stable 
enough to survive the lactate aldol reaction conditions.137  
 
Scheme 5.6: Possible alkene migration to convert α-siloxy-β,γ-unsaturated aldehyde 229 into the 
corresponding enal 240.   
The bis-allylic diol 244 was prepared following precedent from Danishefsky.138 Initial 
protection of 241 provided the corresponding C2 symmetric acetonide (isopropylidene ketal) 
242, which was essential for good diastereoselectivity in the subsequent steps. Conversion of 
242 to the bis-allylic alcohol 244 was achieved in two-steps: the esters were first reduced using 
DIBAL at low-temperatures, with addition of divinyl zinc to the ensuing aldehyde providing 
244 in 60% yield and 11:1 dr.  The use of a zinc organometallic in place of conventional 
magnesium or lithium reagents was necessary as the desired stereochemistry would prevail 































Reagents & conditions: [a] Me2C(OMe)2, p-TsOH, CH2Cl2, rt. [b] DIBAL-H, PhMe, -78 °C. [c] (H2C=CH)2Zn, THF, -78 
°C.  
Scheme 5.7: Synthesis of 244 as a precursor to the α-siloxy-β,γ-unsaturated aldehyde 229.  
Silyl protection of the C22 hydroxyls using TBSOTf occurred uneventfully to provide 230, 
setting the stage for removal of the acetonide and oxidative cleavage of the diol to the α-siloxy-
β,γ-unsaturated aldehyde 229 (Scheme 5.8).    
 
Scheme 5.8: TBS protection of 244 and proposed elaboration to aldehyde 229.   
Although many examples exist of chemoselective acetonide cleavage in the presence of a 
secondary TBS ether (or other silyl groups in general), 140  the methodology is not general and 
often requires extensive screening to find a suitable procedure. To this end, Table 5.1 
summarises the conditions investigated.  
Unfortunately, despite these investigations, conditions were not able to be identified that 
would permit the removal of the acetonide in the presence of the TBS ethers. To overcome 
the above difficulties, one of two changes needed to be made: replacement of the TBS ethers 
with a more stable derivative, or replacement of the acetonide with a more labile derivative. 
The latter option was preferred as, given the already challenging cyclisation it was not 
desirable to further increase the steric bulk at C22, as would be necessary if the TBS was 
replaced with a more acid-stable derivative such as a TBDPS. Accordingly, the 
cyclopentylidene analogue 251 of 230 was targeted. The cyclopentylidene ketal has been 
shown to have roughly one-third of the half-life of the corresponding isopropylidene ketal 
(acetonide)141 which was anticipated to provide enough of a rate difference to achieve 






























































Table 5.1: Attempted removal of the 1,2-acetonide in the presence of the secondary TBS ether.  
 
Reagents Temperature Time Protecting groups cleaved  
 
TBS Acetonide 
PPTS (cat), MeOH 
rt 
24 h No reaction  
48 h   
72 h   
40 °C 
6 h    
24 h   
p-TsOH (cat), MeOH rt 24 h   
DOWEX-W50, MeOH Rt  24 h   
Amberlyst, MeOH rt 24 h   
FeCl3/SiO2, CHCl3 142,143 rt 3 h   
I2, MeOH 144 rt  
3 h  No reaction  
6 h No reaction  
24 h   
TFA - 78 °C 10 min    
All reactions carried out in dry CH2Cl2 unless otherwise stated  



































To this end, 241 was first protected as the cyclopentylidene ketal 248 by condensation with 
cyclopentanone under Dean-Stark conditions (Scheme 5.9). From 248, the bis-TBS ether 251 
could be accessed following an analogous sequence of reactions to those used for the 
acetonide providing access to 251 in 13% from 241. Disappointingly, treatment of 251 with the 
conditions described in Table 5.1 failed to provide the projected chemoselectivity.  
 
Reagents & conditions: [a] Cyclopentanone, p-TsOH, PhMe, reflux. b] DIBAL-H, PhMe, -78 °C. [c] (H2C=CH)2Zn, THF, 
-78 °C. [d] TBSOTf, 2,6-lutidine, CH2Cl2, rt.  
Scheme 5.9: Synthesis of cyclopentylidene ketal 251.   
In an attempt to rationalise the above results, a 1:1 mixture of isopropylidene ketal 244 and 
cyclopentylidene ketal 250 was treated with catalytic PPTS. After 2 h, NMR analysis of the 
crude product showed essentially complete deprotection to the tetra-ol 247, with around 10% 
of 244 remaining. This facile deprotection points to the involvement of the TBS ethers in 
retarding deprotection, possibly due to a steric effect in which the silyl groups are essentially 
shielding the molecule preventing effective nucleophilic attack. This would also explain why 
tetra-ol 247 was so frequently observed during screening of deprotection conditions, as, once 
the TBS groups were cleaved there was nothing impeding the subsequent hydrolysis of the 
acetonide.  
 
Scheme 5.10: Competitive hydrolysis of the isopropylidene ketal 244 and cyclopentylidene ketal 250.  
Rather than persist with the existing protecting group strategy, it appeared prudent at this 
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under the conditions required to remove the acetonide. In addition to permitting the 
investigation of the proposed lactate aldol, this would also avoid the same issue of 
chemoselectivity arising when attempting the IOCC, where a six-membered acetonide needs 
to be removed in the presence of a secondary TBS ether to reveal the free hydroxyl at C25 for 
cyclisation to occur (see Scheme 5.3).  
A benzyl ether was selected as a suitable replacement for the TBS ether owing to its stability 
towards acid.  The successful route to the α-benzyloxy-β,γ-unsaturated aldehyde 254 is 
shown in Scheme 5.11. Hence, 244 was first converted to bis-benzyl ether 252 prior to 
hydrolysis of the acetonide to diol 253.* With 253 to hand, the oxidative cleavage could finally 
be conducted, accordingly treatment of 253 with silica supported sodium periodate gave 254 
which was used in the subsequent lactate aldol (see §5.2.3) without purification owing to the 
dual potential for epimerisation of the α-stereocentre and migration of the β,γ-alkene.  
 
Reagents & conditions: [a] NaH, BnBr, TBAI, THF, 0 °C. [b] HCl (3 M aq.), THF, rt. [c] NaIO4 on SiO2, pH 4 buffer, 
CH2Cl2, rt.  
Scheme 5.11: Successful synthesis of the C20 – C23 α-benzyloxy-β,γ-unsaturated aldehyde 254.  
5.2.3 LACTATE ALDOL COUPLING†  
With a tractable route to the α-benzyloxy-β,γ-unsaturated aldehyde 254 developed, attention 
was turned to the lactate aldol reaction that was to set the C23 and C23 stereocentres. Ketone 
(R)-200 was first enolised using Cy2BCl and Et3N at 0 °C to afford the (E)-enolate 255 to which 
a solution of aldehyde 254 was added at -78 °C (Scheme 5.12). The result of the aldol was a 
complex mixture, with 1H NMR of the crude product showing two aldehyde resonances, and 
at least four distinct products based on the number of signals corresponding to the C31 methyl 
observed.  
 
* The conditions used for the removal of the acetonide were arbitrary, and it may well be the case that 
far milder methods would accomplish the same task – this was not investigated.  
† This aldol reaction was carried out using the ethyl ketone derived from unnatural d-lactate owing to 






































Scheme 5.12: Lactate aldol coupling between ethyl ketone (R)-200 and α-benzyloxy-β,γ-unsaturated 
aldehyde 254.  
During the protracted investigations into preparation of the tartrate-derived aldehyde, a 
modified synthetic strategy had been devised. This route, using an NHK reaction (see §5.3), 
proved successful, and accordingly the decision was taken to halt optimisation of the above 
lactate aldol reaction.  
5.3 THE NHK COUPLING APPROACH 
 
Scheme 5.13: Modified retrosynthesis using an NHK reaction to form the C21 – C22 bond.  
The failure of the tartrate-based approach prompted a re-evaluation of the proposed strategy. 
Specifically, the C22-oxymethine stereocentre and the C21 – C22 bond could conceivably be 
forged simultaneously using a Cr(ii)/Ni(ii) mediated Nozaki-Hiyama-Kishi (NHK) reaction 
between aldehyde 260 and a suitable vinyl iodide 259 (Scheme 5.13). The necessary 
stereochemistry at C22 would prevail if the reaction proceeded through a non-chelated 
Felkin-Anh transition state, which is well precedented in the literature using Cr/Ni 

































































intermediate; in a forward sense, ozonolysis would unmask the reactive aldehyde immediately 
prior to reaction to avoid the potential for epimerisation of the α-stereocentre. 262 itself 
would then be formed through a lactate aldol reaction between ketone (S)-200 and acrolein 
followed by a substrate-directed 1,3-anti Evans-Saksena reduction and subsequent protection 
as the acetonide. Vinyl iodide 259 is a known compound, prepared in two steps from methyl 
prop-2-ynoate 261 (methyl propiolate). 
5.3.1.1 LACTATE ALDOL AND PREPARATION OF THE C21 – C27 ALLYLIC ALCOHOL 
Synthesis of 262 commenced with a Cy2BCl mediated lactate aldol reaction between the 
previously described ketone (S)-200  and acrolein (Scheme 5.14). Following recrystallisation 
(Et2O in n-hexane or CH2Cl2 in benzene) the resulting aldol adduct 263 was obtained as a 
single diastereomer with a reproducible yield of 75 – 85 % on scales between 500 mg and 4 g. 
The relative stereochemistry between the C23-Me and C24-OH groups was confirmed as 1,2-
anti by measurement of the 3JHH coupling constant.  Additionally, MTPA ester analysis on the 
crude aldol adduct 263 confirmed the expected absolute configuration at the newly formed 
C23 oxymethine (see Appendix A).  
 
Scheme 5.14: Aldol reaction between ketone (S)-200  and acrolein.  
Rationalisation of the 1,4-syn 1,2-anti diastereoselectivity requires consideration of both the 
enolate formation and the aldol transition state. As previously discussed, the relative 1,2-
disastereoselectivity is a consequence of the enolate geometry, with (E) and (Z) enolates 
providing anti and syn aldol adducts respectively.  Using boron chlorides, deprotonation takes 
place prior to the departure of chloride resulting in the Lewis acid being significantly larger 
than that used in the Mukaiyama protocol in which the triflate counterion has completely 
dissociated prior to enolisation Scheme 5.15.134 Computational studies have demonstrated a 
stereoelectronic preference for the B—Cl bond to lie in the same plane as the developing 
enolate, with a weak non-covalent interaction between the α-proton and Cl facilitating 





























Scheme 5.15: Mechanistic rationale for the stereodivergent formation of (E)- and (Z)-boron enolates 
from ethyl ketones.75 
The transition state of the lactate aldol has been the subject of several computational 
investigations to rationalise the high levels of diastereoselectivity observed.74 Current 
evidence suggests the reaction takes place via the diastereomeric boat-like transition states 
TS-264 and TS-265, with the major product arising from TS-264 in which the benzoate forms 
a stabilising formyl hydrogen bonding interaction with the aldehyde and minimises the syn-










■ sterically demanding chiral ligands (Ipc)
■ excellent leaving group (OTf)
Brown conditions
Ipc2BCl, Et3N
■ sterically demanding chiral ligands (Ipc)


















































Scheme 5.16: Mechanistic rationale for the Cy2BCl mediated lactate aldol. 
With the aldol adduct 263 to hand, the remaining C25 stereocentre could be established by 
taking advantage of the proximal C23 oxygen to carry out a substrate directed 1,3-anti 
reduction.  Two methods are commonly used to achieve this process: the Evans-Saksena 
reduction using Me4NBH(OAc)3,146,147 and the Evans-Tischenko148 reduction using catalytic 
SmI2. In the event, the Evans-Saksena reduction of 263 turned out to be most convenient, 
providing access to acetonide 262 in 86% yield over two steps without purification of the 
intervening 1,3-diol. The use of an Evans-Tischenko reduction was not investigated in this 
case as the resulting propionate ester 269 would be unable to be cleaved in the presence of the 























































Scheme 5.17: Substrate directed 1,3-anti reduction of 263 and protection as a 1,3-acetonide showing the 
successful Evans-Saksena route, and an alternative Evans-Tischenko route that was not investigated.   
In agreement with the stereochemical model proposed by Evans,146 262 was obtained as a 
single diastereomer, confirmed as the 1,3-anti diastereomer using the Rychnovsky analysis (δC 
= 101.42, 24.63, 24.11 ppm).  The 1,3-anti isomer dominates via TS-271 due to the 
intramolecular delivery of hydride, with the protonated carbonyl adopting a psuedoaxial 
position to avoid 1,3-diaxial clash between the acetate on boron and the bulky R group 
(containing the benzoate protecting group) (Scheme 5.18).  
 













































































































5.3.1.2 PREPARATION OF THE VINYL IODIDE COUPLING PARTNER  
At this stage, attention was turned to the synthesis of the vinyl iodide coupling partner 259 
required to carry out the NHK reaction. Unlike with the originally planned tartrate approach, 
it would not be possible to easily introduce a range of different Michael acceptors at a later 
stage, and as such the vinyl iodide used would need to be suitably functionalised prior to 
coupling. Given this lack of flexibility, efforts were focused on the preparation of the methyl 
ester, and the 4-tolyl thioester as previously used for the C1 – C11 western fragment. 
The vinyl iodide 259 was prepared in two steps from methyl propiolate following previously 
reported procedures. Thus, treatment of methyl propiolate 261 with NaI in AcOH/MeCN 
furnished the (Z)-vinyl iodide 274 which was thermally isomerised in refluxing benzene in 
the presence of catalytic HI.  The isomerisation required several days of reflux, monitoring 
the (Z) ⟶ (E) conversion by proton NMR of a small reaction aliquot. The reaction would 
generally give an 8:1 mixture of geometric isomers (in favour of the desired isomer), however 
recrystallisation from hexane enabled geometrically pure material 259 to be isolated.   
 
Reagents & conditions: [a] NaI, AcOH:MeCN (1:1), 80 °C. [b] HI (aq.), PhH, reflux.  
Scheme 5.19: Preparation of (E)-vinyl iodide 259 from methyl propiolate.  
It was anticipated that the corresponding thioester 278 might be prepared in an analogous 
fashion starting from propiolic acid 275, with initial thioesterification furnishing 276 which 
could undergo the same sequence of hydroiodination and isomerisation (Scheme 5.20). 
Attempts at forming thioester 276 under Steiglich-type conditions (DCC, DMAP) resulted in 
an inseparable mixture of products. Analysis of the crude 1H NMR spectra and LCMS 
suggested the formation of the 1,4-addition product rather than the desired thioester (albeit 
in low yield. Thioesterification via formation of the acid chloride proved more successful, 
providing access to 276 in 50% yield, however 276 did not react under the hydroiodination 
conditions described above, leading only to hydrolysis back to the carboxylic acid 275.  
 



























5.3.1.3 NOZAKI-HIYAMA-KISHI (NHK) COUPLING 
The Nozaki-Hiyama-Kishi (NHK) reaction was first reported in the late 1970s. Since the 
initial reports, the NHK reaction has found extensive use in the synthesis of complex natural 
products145 owing to the mild and chemoselective nature of the reaction. Two examples of this 
are found in Nicolaou’s rapamycin synthesis149 and Mohapatra’s work on zeanol analogues150 
(Scheme 5.21).  
 
Scheme 5.21: Selected examples of NHK couplings in complex natural product synthesis. A Total 
synthesis of Rapamycin (Nicolaou).149 B Synthesis of 7-epi zeanol (Mohapatra).150 
The mechanism of the NHK reaction is thought to proceed via a Grignard-like addition of an 
organochromium species into a carbonyl, as outlined in Scheme 5.22.151,152 Although the exact 
identify of the species is not known, it is postulated that the active catalyst is obtained from 
Ni(ii) via reduction using two equivalents of a sacrificial Cr(ii) salt. The Ni(0) catalyst 
oxidatively inserts into the C – X bond, with X representing a halide (Br, I etc.) or 
psuedohalide (OTf). Subsequent transmetallation of the Ni(ii)  organometallic to Cr(iii) 
provides a nucleophilic vinyl chromium species which undergoes chemoselective addition 


















































Scheme 5.22: Proposed mechanism for the Ni(ii) catalysed Nozaki-Hiyama-Kishi reaction.151  
Chromium is less electropositive than lithium or magnesium, accounting for the decreased 
reactivity of organochromium species when compared to that of the analogous organolithium 
or organomagnesium reagents.153,154 This reactivity allows the discrimination of various 
carbonyl containing functional groups, with high levels of chemoselectivity for aldehydes over 
ketones or esters. Additionally, unlike for lithium or magnesium, the reactivity of the 
chromium species can be finely tuned through the choice of ligands to control the steric and 
electronic properties of the metal centre.    
Prior to investigation of the proposed organometallic addition, the required aldehyde 260 
needed to be umasked through ozonolysis of the terminal olefin 262. Of principle concern was 
the stability of aldehyde	260, with epimerisation of the	α-stereocentre possible to give the 
undesired 1,3-syn	acetonide 285. In the event epimerisation did not prove to be a problem if 
the aldehyde was used immediately following preparation (Scheme 5.19),	however upon 









































diastereomers, as determined by integration of the  diagnostic C23 oxymethine proton. Due 
to this, the ozonolysis was always conducted prior to the subsequent reaction, with the crude 
aldehyde obtained suitably clean following filtration through a plug of cotton wool to remove 
insoluble NaHCO3	and azeotroping with benzene. 
 
Scheme 5.23: Successful ozonolysis of the terminal alkene to unmask aldehyde 260. 
Initial attempts at forging the C22-C21 bond were met with disappointment, returning 
epimerised aldehyde (260 + 285) and methyl acrylate, presumably from quenching of the 
initially formed oxidative addition product. It was quickly realised that the quality of CrCl2 
was critical to success, as had been noted by Takai.154,155 While pre-heating a mixture of 
CrCl2/NiCl2 at 150 °C under high vacuum (0.5 mmHg) ameliorated the problem, the reaction 
was still found to be highly batch-dependant, with some reagents failing to return product 
even if dried prior to use. Optimisation of the reaction is shown in Table 5.3, which identified 









































Table 5.2: Optimisation of the NHK coupling between vinyl iodide 259 and aldehyde 260. Optimised 
conditions are highlighted in blue.  
 
Entry  Eq. CrCl2 
Eq. 
259 
Solvent d.r.  Yield 
1  10 3.5 DMSO - - 
2  10 1.5 DMF - - 
3  10 3.5 DMF - - 
4  10 3.5 THF  - 21% (NMR) 
5  10 3.5 DMF 3:1 60% (NMR) 
6  10 3.5 1:1 THF:DMF 5:1 71% (NMR) 
7  10 3.5 1:1 THF:DMF 5:1 87% 
8  10 1.5 1:1 THF:DMF  3:1 42% 
All reactions carried out at rt under argon using previously degassed solvent. NiCl2 (1 mol%) used relative to the 
amount of CrCl2 present.  
 
Isolated yield of pure material following column chromatography 
NMR conversion. 
 
All dr values measured from NMR spectra of crude reaction products. 
 
The diastereoselectivity of the NHK reaction was determined from the 1H NMR spectrum of 
the crude reaction product 258 prior to column chromatography. Based on literature 
precedence, it was expected that the reaction would lead to the desired 1,2-anti 
stereochemistry based on the polar Felkin-Anh model via TS-286.151  MTPA analysis 
confirmed the major product as the anticipated anti diastereomer (see Appendix A). As the 
diastereomers formed during the reaction were inseparable by column chromatography, the 
MTPA analysis had to be conducted on the 5:1 epimeric mixture, adding an additional level of 

































Scheme 5.24: Diastereoselectivity of the NHK reaction based on the polar Felkin-Anh model.  
5.3.1.4 CYCLISATION  
Having procured access to a linear C19 – C27 precursor 258, the stage was now set to 
investigate the anticipated cyclisation. Prior to this, it was necessary to protect O22 such that 
it remained differentiated from O23 post-cyclisation. In keeping with the modified protecting 
group strategy, protection of the C22 hydroxyl as the corresponding benzyl ether was 
attempted but failed to provide any of the desired product (Scheme 5.25).* It was reasoned 
that the problems encountered in protecting O22 were a result of the crowded environment, 
and indeed a similar issue was reported by Haslett when attempting to benzyl protect a similar 
intermediate in his work towards a Tsuji-Trost style cyclisation.56  
 
Scheme 5.25: Attempted protection of O22 as the corresponding benzyl ether 287.  
In the interest of investigating the IOCC, the issue of the O22 protecting group was put to one 
side temporarily, opting instead to methylate (Meerwein salt, proton sponge 289) which took 
place uneventfully to give 288 in 78% yield (Scheme 5.26). This is not a tractable solution 
(there is no possibility of removing the methyl ether), and if cyclisation were successful, 
conditions would need to be found to procure access to a suitably protected precursor. The 
methyl ether should act as a suitable surrogate for the benzyl ether in terms of sterics, and as 
such if conditions are found for the cyclisation of 288, they would be expected to apply to the 
cyclisation of 287 without complication.  
 


































































Scheme 5.26: Successful derivatisation of O22 as the corresponding methyl ether 288.  
With a suitable precursor 258 now to hand, the anticipated cyclisation could be attempted. 
Initially, 288 was subjected to the conditions that successfully affected cyclisation of 38, the 
analogous precursor used to forge the western THP (see §3.3.2).  Thus, treatment of 288 with 
p-TsOH in CH2Cl2 at rt cleanly afforded diol 290 in 82% yield; the mass balance accounted for 
by recovered starting material 288 (Scheme 5.27). The diol was subsequently re-subjected to 
p-TsOH, this time replacing CH2Cl2 for DCE to allow the reaction to be ran at higher 
temperatures. Again, this failed to provide any cyclised product, returning only diol in almost 
quantitative yield. Further screening reactions using diol 290 are summarised in Table 5.3.  
 
 
Scheme 5.27: Acetonide removal and attempted cyclisation of 288.  
With p-TsOH failing to produce any of the desired THP, a series of protic carboxylic acid 
derivatives were investigated (entries 8 – 10). Such conditions have been used successfully in 
many IOCC reactions, for instance in Clarke’s phorboxazole A fragment synthesis.87,156 




































































Table 5.3: Screening conditions for the attempted IOCC. 
 
 
Entry   Reagent Solvent  Temperature Time  Result  
1  p-TsOH (0.1 eq) CH2Cl2 rt 24 h 290 
2  p-TsOH (0.1 eq) CH2Cl2 Reflux  24 h 290 
3  p-TsOH (0.1 eq) DCE Reflux  48 h 290 
4  CSA (0.1 eq) CH2Cl2 rt 24 h  290 
5  CSA (0.1 eq) CH2Cl2 Reflux  24 h  290 
6  DOWEX-w50 CH2Cl2 rt 72 h  290 
7  DOWEX-w50 CH2Cl2 Reflux  72 h  290 
8  AcOH (1 eq) MeOH:THF rt 24 h 290 
9  TfOH (0.01 eq) CH2Cl2 - 78 °C to -20 °C 72 h  290 
10  TFA (0.1 eq) CH2Cl2 - 78 °C to +20 °C 6 h   290 
11  Zn(OTf)2 EtOH  
80 °C (sealed 
tube) 
8 h  290 +291  
12  Zn(OTf)2 MeOH 
80 °C (sealed 
tube) 
8 h  290 
13  Sc(OTf)2 MeOH 
80 °C (sealed 
tube) 
8 h  Decomposition 
14  KOtBu (1 eq) THF - 78 °C 18 h  290 
15  KOtBu (2 eq) THF - 78 °C 18 h  290 
16  KOtBu (1 eq) THF rt 5 h  290 + 291 
17  KOtBu (0.1 eq) THF rt 5 h  290 
18  DBU  Xylenes Refux  60 h 290 
19  DBU Xylenes  
100 °C (sealed 
tube) 
18 h  290 + 291 



























































In Ley’s synthesis of spongistatin II, similar difficulties were encountered with cyclisation of 
the highly substituted intermediate 294 leading to the a wide range of Lewis acids being 
screened (Scheme 5.28).157 Of the various metal triflates explored, Zn(OTf)2 was found to give 
excellent conversion, providing 295 in 75% yield a as single isomer. Encouraged by this result, 
linear precursor 290 was subjected to similar conditions (entries 11 to 13). Zn(OTf)2/EtOH 
initially looked promising, with TLC showing complete consumption of the starting material 
after 8 h, however this was a result of transesterification to the corresponding ethyl ester. The 
reaction was repeated in MeOH to supress the transesterification, leading to the clean 
recovery of 290 with no obvious degradation. Interestingly, Sc(OTf)2 caused complete 
degradation of the molecule to a complex mixture of products, with LCMS suggesting 
fragmentation of the carbon chain based on the mass ions observed.  
 
Scheme 5.28: Lewis acid mediated cyclisation of 294 en route to spongistatin II (Ley). 158 
Changing tact from the above acid-mediated cyclisations, a series of basic conditions were 
instead investigated. KOtBu was initially targeted, as the most precedent exists for its use in 
oxy-Michael cyclisations.82 It should be noted however that unlike the acid catalysed IOCC, 
which predominantly gives 2,6-cis THPs, the base catalysed reaction can lead to either 
diastereomer, and as such a priori there was no guarantee that if the molecule did cyclise it 
would lead to the desired configuration at C21.  
Both alkoxide bases (entries 14 to 17, 20) and organic bases (entries 18 and 19) were 
investigated. As previously, the cyclisation failed to occur, however an additional product was 
observed which was attributed to migration of the O26 benzoate onto the adjacent O25. This 
result was highly unusual, with benzoates generally not observed to migrate unlike the 
corresponding acetates.140 This benzoate migration was clearly a liability, as once O25 was 
esterified, cyclisation would no longer be able to take place. Removal of the benzoate from 290 
and subsequent treatment with the conditions used in entries 15, 18 and 20 (Table 5.3) did not 
provide access to the desired THP. 
The use of an IOCC to forge the C18 – C27 THP was looking increasingly unlikely at this stage. 
Although the proposed cyclisation was always anticipated to be challenging, it was expected 
that conditions could be found that would form some of the desired product, providing a basis 
for further optimisation. The disappointing lack of reactivity observed here, coupled with 





















indeed point to a deeper barrier to the cyclisation in general, rather than being linked to the 
particular set of conditions chosen.   
5.3.2 COMPUTATIONAL INVESTIGATIONS  
 
Computational studies were initiated with the aim of diagnosing the observed lack of 
reactivity encountered above. In attempting to rationalise the lack of THP formation, two 
possibilities were considered:   
§ Kinetics (activation energies): 
The most likely factor affecting cyclisation is the energy of the necessary transition 
states. It may be the case that the transition states leading to the THP are sufficiently 
high in energy that they are inaccessible, even at elevated temperatures such as those 
used when investigating Ley’s spongistatin II conditions. 
§ Thermodynamics: 
The lack of THP formation could also be explained if the products were higher in 
energy than the starting material. Thus, assuming the reaction was under 
thermodynamic control (which is likely in the cases using elevated temperatures / 
sealed tubes), the reaction would mostly give starting material. This was considered 
less likely, as even if this were to be the case, one would expect to isolate a mixture of 
starting material contaminated with the THP which would be evident from NMR 
analysis.  
The calculations were conducted using the same methodology previously outlined for the 
western fragment (see §3.3.2.1), however the additional complexity of the C19 – C27 fragment 
coupled with limited computational resources meant that additional simplifications had to be 
imposed, namely that the calculations were carried out in the gas-phase without the inclusion 
of implicit solvent. The lack of solvent is not anticipated to change the qualitative results of 
the calculations; however, it should be noted that gas-phase calculations tend to over-
emphasise the magnitude of non-covalent interactions, which may make some structures 
appear more stable than they may otherwise be if solvated.   
The acid mediated cyclisation was the first to be investigated as it most closely resembled the 
calculations carried out in the western IOCC. The exact reaction studied is shown in Figure 
5.30. Although explicit MsOH was used in the calculations, the results should be equally valid 
for any of the sulfonic or carboxylic acids screened, all of which have the ability to bind in a 
bidentate fashion as was observed during the western fragment cyclisation. Scheme 5.31 





shows the complete energy profile for the above reaction, with structures of the transition 
states provided in Figure 5.1.  
 
Scheme 5.29: MsOH mediated cyclisation of 290 used as the basis for computational investigations.  
Accordingly, the acid-mediated cyclisation of 290 is predicted to occur via the diastereomeric 
chair-like transition states TS-296 and TS-297, with the small energy gap (0.6 kcal/mol) 
suggesting that the cyclisation would be unlikely to occur with high levels of 
diastereoselectivity.  Additionally, the MsOH is predicted to act as a ‘proton shuttle’, 
coordinating to both O25 (the nucleophilic hydroxyl) and the protonated carbonyl of the 





































Scheme 5.30: Energy diagram for the MsOH mediated IOCC showing the lowest energy pathways to 
2,6-cis (orange) and 2,6-trans (blue) products. All energies given in kcal/mol relative to the complex of 













































Figure 5.1: Chair-like transition states for the p-TsOH mediated IOCC. Some hydrogens have been 













Studying the base-mediated cyclisation computationally introduced some additional 
problems. Firstly, unlike the acid-mediated conditions, where MsOH, TsOH, TfOH etc can all 
bind via a similar motif (discussed above), the bases studied are not so similar – no comparison 
can be made between DBU and sodium hydride. Secondly, several of the bases screened 
contain metallic counterions (K and Na) which are not described well by molecular mechanics 
owing to the ionic nature of the bonds formed. For simplicity, the base was eschewed entirely, 
instead studying the cyclisation of the naked anion 298. Scheme 5.31 shows the complete 
energy profile, with structures of the transition states provided in Figure 5.2.   
 
Scheme 5.31: base mediated cyclisation of 298. 
The base-mediated cyclisation of 298 is predicted to occur via the diastereomeric boat-like 
transition states TS-299 and TS-300, with the small energy gap (0.2 kcal/mol)  again 
suggesting that the cyclisation would be unlikely to occur with high levels of 
diastereoselectivity.  As expected, the base-mediated cyclisation is predicted to occur 
dominantly through a boat-like transition state owing to a hydrogen bonding interaction 





























Scheme 5.32: Energy diagram for the base mediated IOCC showing the lowest energy pathways to 2,6-
cis (orange) and 2,6-trans (blue) products. All energies given in kcal/mol relative to anion 298 (DFT-














































Figure 5.2: Chair-like transition states for the base mediated IOCC. Some hydrogens have been omitted 















Comparing the reaction profiles for both the acid- and base-mediated reactions, it is not 
apparent where the lack of reactivity observed during the attempted IOCC arises. In both, the 
products are sufficiently lower in energy than the starting material (-6.9 and -7.1 kcal/mol for 
the 2,6-cis THP) to be thermodynamically preferred, although, in both cases it should be noted 
that the 2,6-trans THP is preferred over the 2,6-cis. Notably, the transition states for both  
acid- and base-mediated reactions are lower in energy (relatively) to those found in the 
western fragment cyclisation – a barrier of under 15 kcal/mol is accessible at room 
temperature, which precludes the need for the elevate temperatures attempted during 
screening reaction.  
One major difference between the acid- and base-mediated cyclisations is the C21 – O25 bond 
length in the transition state, corresponding to the developing bond. In the acid-mediated 
reaction the C-O bond is much shorter, representing a later transition state in which the bond 
is essentially formed (with the TS structure being closed in geometry to the thioenol 
intermediate observed). Conversely, the C-O bond in the base-mediated reaction is longer, 
with the TS closer to the starting material.  
Table 5.4: C21 – O25 bond lengths in IOCC transition states:  
 
Acid-mediated Base-mediated 
cis TS 1.85 2.01 
trans TS 1.89 1.99 
 
Given that the transition state energies and thermodynamic preferences of the reactions do 
not appear to elucidate the lack of reactivity, a different rationalisation is clearly needed. One 
plausible conclusion is that the lack of reactivity observed during cyclisation of linear 
precursor 290 may be the result of a high energy barrier preventing the molecule from 
adopting the required conformation for effective orbital overlap. The calculations conducted 
on the linear system only take into account the difference in relative energy between the 
starting material complex and the transition states, but do not account for the energy required 
to connect the two points (the energy-gap between two stationary points is independent of 
the path taken between them). While comprehensive analysis of the energy landscape is 
possible for small molecules (H2O, CO2, etc), as the molecule becomes more flexible, the 
number of possible permutations makes the process uneconomical and difficult to visualise.*  
Despite this, the point may be illustrated by considering rotation about two of the central 
dihedral angles required to fold the molecule into the reactive conformation, as shown in 
 
*  This is the same reason why systematic conformational searching (which would give the desired 
information) was abandoned in favour of ‘random’ Monte Carlo based methods.    





Figure 5.3. This two-dimensional coordinate scan, while not exhaustive, shows regions of 
high energy (red), representing barriers to conformational flexibility which may prevent the 
molecule from converting from the ground state conformation of the starting material to the 
necessary conformation for the transition state.  
 
 
Figure 5.3: Contour plot showing a two-dimensional coordinate scan of linear precursor 290. All 
energies in kJ/mol relative to the lowest energy conformer. Bonds in red indicate the torsional angles 
scanned.  [MMFF-94, gas-phase].  
5.3.3 CONSTRAINED CYCLISATION  
It was hoped that by constraining the linear precursor, it would be possible to ‘lock’ the 
molecule into a more reactive conformation from which cyclisation could occur. For this 
approach to be successful, it was vital that the conformationally-controlling element did 
indeed hold the C25-hydroxyl in good proximity to the C21 enoate to ensure that the 











































Acetonide 301 was identified as a possible substrate for the constrained cyclisation, with bis-
protection of the C22/C23 diol enforcing a mutually cis arrangement of the two sidechains 
(Figure 5.4). The choice of the acetonide was somewhat arbitrary, and indeed if successful it 
may be necessary to replace the acetonide with another protecting group such as a PMP acetal 
or di-t-butylsilylene  as these are able to be cleaved to give mono-protected products, avoiding 
the potential for regioselectivity issues upon fragment union.    
 
Figure 5.4: Proposed constrained precursor 300 to investigate whether ‘locking’ the conformation of 
the starting material would promote cyclisation.  
Prior to commencing synthetic work, the feasibility of this approach was investigated 
computationally to ensure that in restricting the conformation the reactive groups weren’t 
held in such a geometry as to completely prevent the possibility of cyclisation. The optimised 
ground-state structure of 301 is consistent with the two groups being well aligned for bond-
forming, as depicted in Figure 5.5. An analogous coordinate scan was also conducted to 
determine if the molecule had free rotation about the key bonds needed to perturb the 
geometry of the structure into a form amenable to cyclisation. Interestingly, unlike the 
completely linear substrate 290, the constrained substrate appears to be more able to rotate 
about its key dihedral angles, allowing it to adopt a different conformation without incurring 
the penalty of unfavourable energetics.   
 
Figure 5.5: Lowest energy conformation of acetonide 301 showing the proximity of the C25-hydroxyl to 


























Figure 5.6: Contour plot showing two-dimensional coordinate scans of constrained precursor 301. All 
energies in kJ/mol relative to the lowest energy conformer. [MMFF-94, gas-phase].  
 


















































In addition to considering the conformation of the uncyclised structure, the relative energies 
of the resulting 2,6-cis and 2,6-trans THP products were computed (Scheme 5.33). 
Gratifyingly, the 2,6-cis product 302 is ca. 1.4 kcal/mol lower in energy than the corresponding 
trans isomer 303, with both structures adopting half-chair-like structures in order to 








Scheme 5.33: Energy diagram showing the energies of 2,6-cis (orange) and 2,6-trans (blue) products. All 
energies relative to neutral starting material 301 [DFT-B3LYP/6-31G**, gas-phase].  
The attempted synthesis of 301 commenced from the previously described lactate aldol 
adduct 263. In order to arrive at the desired 1,2-acetonide as a single isomer, it was necessary 
to ensure that the O23 and O25 remained differentiated. This precluded the use of the Evans-
Saksena reduction previously used to effect this transformation, however the related Evans-
Tischenko reduction was ideal, selectively esterifying the pre-existing C23 hydroxyl with 
concomitant introduction of the 1,3-anti relationship between C23 and C25. Initial attempts 
at the Evans-Tischenko reduction of 301 led to complex mixtures, attributed to both poor 
diastereoselectivity and migration of the acetate/propionate ester to the adjacent oxygen. In 
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immediately protecting the crude product with TESOTf/2,6-lutidine prior to column 
chromatography.  
 
Reagents & conditions: [a] SmI2, MeCHO, -78 ºC, THF. [b] TESOTf, 2,6-lutidine, CH2Cl2. [c] O3, CH2Cl2, MeOH, -78 ºC, 
[d] NiCl2/CrCl2, 259, DMF:THF, rt. [e] MeOH, K2CO3, rt.  
Scheme 5.34: Attempted preparation of constrained cyclisation precursor 301.  
With access to 304 secured, attention was turned to the NHK reaction used to forge the C20 
– C21 bond. Prior experience had suggested that this was likely to be a challenging reaction, 
with various conditions often needing to be screened to identify suitable reaction conditions. 
Following the previously established conditions, 304 was converted to the corresponding 
aldehyde via ozonolysis, which was used directly in the NHK. Unfortunately, this failed to 
provide access to 305 in synthetically useful quantities. Significantly, the major product from 
the reaction, while having the correct molecular weight by HRMS failed to show the present 
of any olefinic protons. Closer inspection of 1D and 2D NMR spectra revealed two carbonyls 
esters: the expected benzoate, and an additional ester lacking the unsaturation that would be 
expected within 305. Further evidence for the lack of the olefin was provided by the HSQC, 
which showed the introduction of a diastereotopic methylene group (CH2) with HMBC 
correlations to the non-benzoate ester. While it may be tempting to infer from this that a ring 
had been formed, C/H21 and C/H25 showed no HMBC correlation, which is indicative of the 
THP formation. Time constraints prevented further investigations into this strategy, with 
additionally work clearly warranted to determine if the use of a conformationally constraining 
group will enable successful synthesis of the desired THP. If the NHK can be successfully 









































































be achievable, as was recently demonstrated in the total synthesis of amphidinolide H by 
Kalesse and co-workers (Scheme 5.35).  
 
Scheme 5.35: Acetonide formation in the presence of a secondary TES ether in the total synthesis of 
amphidinolide H (Kalesse).159 
PALLADIUM-CATALYSED CARBONYLATIVE CYCLISATION  
In 2017, Romea and co-workers reported a total synthesis of the marine natural product (+)-
herboxidiene. During this work, a palladium (ii) catalysed carbonylative cyclisation of 
homoallylic alcohol 309 was investigated as an alternative to an IOCC, obviating the need for 
installation of a Michael acceptor (Scheme 5.36-A).88 Similar methodology has been applied 
to many complex natural products, with White’s synthesis of phorboxazole A being a notable 
example in which a pentasubstituted 2,6-cis THP 312 is accessed in excellent yield (Scheme 
5.36-A).160 In general, these reactions are highly versatile, offering excellent substrate scope 
and high-levels of atom economy owning to the incorporation of CO gas and methanol to forge 
the desired ester.  
 
Scheme 5.36: Palladium (ii) catalysed carbonylative THP synthesis. A Synthesis of herboxidiene 
(Romea).88 b Synthesis of the A ring of phorboxazole A (White). 160 
The general mechanism for palladium (ii) mediated carbonylative THP formation is shown 
in Scheme 5.37. Following π-coordination, the Pd(ii) complex 313 is attacked in an 





















































species 314.  When conducted in the presence of carbon monoxide, 314 undergoes rapid 
migratory insertion to acyl Pd(ii) species 315 which is finally trapped by MeOH (the solvent) 
to provide the product 316. The acyl Pd(ii) species 315 is highly versatile, allowing access to 
esters, aldehydes and carboxylic acids depending on the solvent system/reagents used. 
Finally, the reaction may be rendered catalytic in Pd by addition of stochiometric oxidant 
which facilitates the re-oxidation of Pd(0) to Pd(ii). The reaction reliably gives access to the 
2,6-cis diastereomer owing to the preference for the Pd to adopt a psuedoequatorial position 
in the transition state.  
 
Scheme 5.37: Mechanism for the Pd(ii)-mediated carbonylative cyclisation for the synthesis of THPs.  
This Pd(ii)-mediated carbonylative cyclisation offers a mechanistically distinct strategy to the 
IOCC strategy. As the Pd – alkene complex is formed reversibly, the molecule linear substrate 
should be better able to adopt the necessary conformation, with the Pd only binding 
equatorially. The introduction of a metal may also enable some pre-organisation of the system, 
with the Pd able to simultaneously interact with the olefin (via the pi-orbital) and the oxygen 
(via a lone pair).  
Given the tentative nature of this approach and limited time available for studies, it was 
necessary to diverge from a previously established intermediate. A suitably functionalised 
substrate 318 had been prepared during early studies into the eastern THP.  Allylic alcohol 318 
was prepared through a two-step process from alkene 262 (Scheme 5.38. See §5.3 for 


































magnesium bromide or divinyl zinc to the ensuing aldehyde 320 provided allylic alcohol 318 
which was deprotected using PPTS/MeOH to give a suitable precursor 319 for the anticipated 
cyclisation.  
This route was not investigated further at the time as the C20 stereocentre was unable to be 
introduced with high levels of diastereoselectivity – for the necessary stereochemistry to 
prevail the reaction must take place without chelation. Despite this, the available stocks of 318 
provided a convenient opportunity to attempt the aforementioned Pd(ii) catalysed 
carbonylative cyclisation to see if this approach was viable in the context of madeirolide A. If 
successful, it was aticipated that the resulting diastereomers may be separable,* with future 
preparation of allylic alcohol 318 as a single isomer possible through an oxidation-reduction 
sequence or modification of the protecting group strategy to bias the organometallic addition 
against chelation control. Specifically, the use of a silyl ether on O21 would enforce Felkin-
Anh control.  
 
Reagents and conditions: [a] O3, NaHCO3, MeOH, CH2Cl2, -78 °C; Me2S. [b] (H2C=CH)2Zn, THF, -78 °C. [c] PPTS, 
MeOH, rt.  
Scheme 5.38: Preparation of cyclisation precursor 319 from olefin 262.  
Having procured access to 319, the cyclisation could be attempted; the results of the screening 
experiments are summarised in Table 5.5. Romea’s herboxidiene conditions (Table 5.5. Entry 
1) failed to affect the cyclisation. Increasing the catalyst loading to 50 mol% (Table 5.5. Entry 
2) also led to the re-isolation of starting material in near-quantitative yield. The most 
promising result was obtained when both the catalyst and oxidant loading were increased 
 
* The cyclisation product may be a crystalline solid and may be amenable to recrystallization on larger 


































(Table 5.5. Entry 3); after 3 h, the starting material had been completely consumed by TLC, 
giving rise to a complex mixture of products.  
Table 5.5: Attempted [Pd] catalysed carbonylative cyclisation of 319.  
 
Entry  [Pd] source  Eq. [Pd] Oxidant  Eq. oxidant   Comments  
1  PdCl2  0.2 CuCl2  4.0 No reaction  
2  PdCl2  0.5 CuCl2 4.0 No reaction 
3  PdCl2 0.5 CuCl2 8.0 Complex mixture 
All reactions run at rt in MeOH (0.3 M in substrate) under 1 atm of CO / CO2  dried through CaCl2 (g) 
 
The components of the complex mixture were unable to be cleanly separated, however a 
partial assignment of the major product was possible using 2D NMR. The 13C shifts (obtained 
indirectly via HMBC and HSQC correlations) were highly diagnostic, confirming the absence 
of the terminal alkene, and showing the presence of two carbonyls: the pre-existing  benzoate 
ester (δC = 173 ppm), and what is likely to be a ketone (δC	=	210 ppm).* Additionally, HRMS 
analysis of the major product was able to determine the unsaturation present in the molecule. 
The observed parent ion at 328.1751 m/z is consistent only with a molecular formula of 
C16H26O6N, corresponding to [M+NH4]+, and requiring six degrees of unsaturation be present 
within the molecule. This suggests that the product is acyclic, given that the benzoate ester 
already accounts for five degrees of unsaturation in addition to the putative ketone observed 
in the 13C NMR.  Additionally, the molecular formula is consistent with the introduction of an 
additional oxygen relative to that of the starting material 319, however from NMR alone it is 
not possible to determine whether this oxygen has been incorporated from the methanol or 
the carbon monoxide.  
One plausible side-reaction is the Wacker-type oxidation of the terminal alkene to give the 
putative α-hydroxy ketone 322. The oxidation of simple alkenes to the corresponding methyl 
ketones is known,161,162 however the reactions are often slow, and require heat to drive the 
reaction. Romea indicates that a similar oxidation may have taken place during work on 
 

















herboxidiene, blaming the presence of an unprotected homoallylic alcohol for the low yield of 
the reaction, although no by-products are identified.   
 
Scheme 5.39: Plausible Wacker-type oxidation of 319 to convert terminal olefin into methyl ketone 322. 
Disappointingly, the data is not consistent with the formation of ketone 322, and attempts at 
repeating the reaction to get more material for structure elucidation have been met with 
failure. Despite this, the reaction still represents a mechanistically novel disconnection for the 
THP, and given the broad substrate scope of the reaction, and plentiful Pd(ii) sources 
available, it may be possible to find a system that provides more promising results.  
5.4 SUMMARY & ANALYSIS  
This chapter has explored several possible approaches for construction of the C18 – C27 
eastern tetrahydropyran, however the desired C21 – O25 bond formation has yet to be realised. 
Based on strong literature preference, an intramolecular oxy-conjugate cyclisation (IOCC) 
was investigated as the best option. Synthetically, this was approached from several angles, 
attempting both acid- and base-mediated cyclisation of various linear precursors. The lack of 
reactivity was not able to be rationalised by computational evaluation of the reaction pathway, 
however it appears likely that the molecule is unable to adopt the required conformation for 
productive C – O bond formation. Based on the above findings, two more speculative 
approaches were investigated. Firstly, attempts were made to constrain the conformational 
flexibility of the molecule, and secondly, a palladium (ii) catalysed carbonylative cyclisation 
was investigated. Neither of these investigations proved successful, however time constraints 
prevented their complete exploration and as such they may yet prove fruitful.  
At this stage, based on the above experimental and computational studies, it appears that the 
cyclisation of a fully elaborated linear precursor may not be a viable way to procure access to 
the necessary heterocycle, possibly requiring a simplified THP precursor to be elaborated 








































6. SUMMARY & FUTURE DIRECTIONS 
FOR THE TOTAL SYNTHESIS OF 
MADEIROLIDE A  
6.1 SUMMARY  
The completed synthesis of madeirolide A 1 is yet to be realised, with the synthesis of the C19 
– C27 pentasubstituted all-cis eastern THP proving to be a particularly formidable challenge. 
Despite this, several fragments of the molecule have now been completed successfully, and 
the studies towards the remaining fragment will serve as a solid foundation for future work. 
The synthetic work carried out on madeirolide A in this thesis is broken up into three 
segments, summarised below:   
§ C1 – C11 western fragment 99: 
Chapter 3 described the strategy evolution for the proposed total synthesis of 
madeirolide A. Addressing many of the issues encountered by Haslett, a modified 
fragment union strategy was proposed, changing from a ring closing macro-Stille 
cross-coupling to a Heck macrocyclisation. This change permitted the successful 
synthesis of a modified C1 – C11 western fragment 99 which was completed in 13 steps 
(LLS) providing a tractable route for material throughput should it be required for 
future studies. 
Additionally, in preparation for work on the C19 – C27 eastern THP, a computational 
model was developed using DFT calculations to rationalise the observed reactivity 
and selectivity of the pivotal IOCC reaction used to close the heterocycle.  
§ C13 – C18 eastern fragment 197:  
Chapter 4 described investigations into the C13 – C18 fragment 197 from which the 
eastern THF would ultimately derive. A short asymmetric synthesis was developed, 





cutting the step-count significantly relative to the initial proposal (see §5). The use of 
an sp2 – sp3 Suzuki cross-coupling reaction to form the C18 – C19 bond was also 
validated, which is pivotal to the intended strategy for the completion of madeirolide 
A.  
§ C19 – C27 eastern fragment 198:  
Chapter 5 described the attempted synthesis of the C19 – C27 fragment, 
encompassing the eastern THP. The construction of the pentasubstituted all-cis 
heterocycle has proved to be an arduous challenge, with no cyclisation achieved 
despite the investigation of several mechanistically different approaches.  The 
synthesis of several linear precursors has been discussed, along with computational 
studies to probe the disappointing lack of reactivity. At present, the reasons behind 
the lack of reactivity are not apparent, with further studies needed to probe the 






















6.2 FUTURE WORK  
6.2.1 COMPLETION OF THE C12 -  C27 EASTERN FRAGMENT  
6.2.1.1 CONSTRUCTION OF THE THP  
The completion of a total synthesis of madeirolide A is contingent on the ability to procure 
access to the C18 – C27 fragment 100. Although the IOCC approach has been extensively 
explored using a methyl ester as a Michael acceptor (see §5.3.1.4), there is still some scope for 
screening additional Michael acceptors as per the original plan.  Specifically, thioester 323 
was identified as a plausible cyclisation precursor based on the successful cyclisation carried 
out to forge the C21 – O25 bond of the western fragment 99 (see §3.3.2). Although 
computational work did not predict a marked difference in reactivity between the thioester 
and the methyl ester (HOMO - LUMO gap of 4.2 eV and 4.4 eV respectively), there are other 
examples of the thioester being significantly more electrophilic than the corresponding 
methyl ester.89 Parenthetically, this would not preclude the methyl ester from cyclisation, but 
would slow down the rate of the reaction by several orders of magnitude, as was observed by 
Haslett.56 The ability to compare the two substrates would prove beneficial to greater 
mechanistic understanding of the IOCC, even if it does not affect the desired cyclisation.  
The inability to screen a variety of Michael acceptors was a consequence of a the protected α-
hydroxy-β,γ-unsaturated aldehyde (229 / 254) causing difficulties in the lactate aldol reaction 
necessary to obtain the desired stereochemistry. A solution was developed by Eustache in the 
context of fumagillol.163 To avoid the double bond moving into conjugation, a selenium 
derivative 330 was prepared, masking the olefin and allowing the aldol reaction to take place 
without the concern of the alkene migration (Scheme 6.1-b). Post-aldol, once the aldehyde 
has been converted to the alcohol, the phenylselenyl group may be eliminated to give the 
desired terminal olefin. While this method achieved the desired result (obtaining the aldol 
adduct without migration of the double bond), it would introduce several undesirable steps, 
notably the use of diazomethane needed to isolate ester 329*, and the highly forcing conditions 
(NBu4IO4, reflux) needed to eliminate the phenylselenyl group to the desired alkene which 
may not be compatible with the other functionality present in the substrate.  
 
* The use of TMS-diazomethane would be a safer alternative, which may prove tractable.  






Reagents & conditions: [a] i. PhSeSePh, NaBH4, DMF, 90 °C. ii. CH2N2, 20 °C. [b] PMB-TCA, CSA, CH2Cl2, 20 °C. [c] 
DIBAL, PhMe, -78 °C.  
Scheme 6.1: A Synthetic strategy for screening Michael acceptors based on a cross-metathesis of allylic 
alcohol 325. b Alternative to protected α-hydroxy-β,γ-unsaturated aldehyde 330 to prevent migration 
of the double bond (Eustache).163 c Proposed lactate aldol incorporating aldehyde 330 which masks 
the β,γ	alkene until after the aldol has taken place.  
The preparation of allylic alcohol 325 as a single diastereomer would have the added benefit 
of permitting further investigations into the Pd(ii) catalysed carbonylative cyclisation (§5.4), 
with initial investigations severely complicated by the epimeric mixture at C22.  
The surprising lack of reactivity observed thus far (including work carried out previously by 
Haslett) may be indicative of a larger problem with the strategy of cyclising a fully elaborated 
linear precursor.  Given this, it may be judicious to abandon the de novo approach to the THP 
ring in favour of a more stepwise approach. As described in §2.3.1.1, Fearnley was successful 













































52% (two steps) 94%



























was unable to affect the necessary dihydroxylation, there is much work for future studies in 
this area.  
6.2.1.2 FRAGMENT UNION AND ELABORATION INTO THE COMPLETE C12 – C27 
FRAGMENT  
 
Scheme 6.2: Proposed union of the C13 – C17 fragment 198 and C18– C27 fragment 197 and elaboration 






























































    Sharpless dihydroxylation
9. TBSOTf, 2,6-lutidine 
10. K2CO3, MeOH
1. PdCl2(dppf) 
    Cs2CO3, AsPh3




















The proposed route for the synthesis of the protected C12 – C27 eastern fragment 100 is shown 
in Scheme 6.2. Key to the strategy is the union of the C13 – C17 organoborane 197 and the C18 
– C27 vinyl iodide 198 using an sp2 – sp3 Suzuki cross coupling to form the C18 – C19 (E)-alkene 
333. Early investigations into this cross-coupling using a model system were promising (see 
§4.2.2), however the option remains open to investigate more stable coupling partners should 
the need arise (Scheme 6.3):  
 
Scheme 6.3: Conversion of organoborane 197 into more stable derivatives for use in the sp2 – sp3 Suzuki 
cross-coupling.  
The (Z)-vinyl iodide is proposed to be installed in three steps from 333 through removal of the 
benzyl ethers at C13 and C22, chemoselective oxidation of the primary C13 alcohol 
(TEMPO/BAIB), and a Stork-Zhao-Wittig olefination to complete the sequence. Finally, the 
C22 hydroxyl would be protected as a TBS ether to prevent reactivity in the subsequent steps.  
The presence of the internal alkene precludes the use of catalytic hydrogenation over 
palladium for removal of the benzyl ethers at C13 and C22, however LiDBB was utilised 
successfully in the second-generation synthesis of aplyronine A by Paterson, cleaving the C27 
benzyl ether in the presence of an alkene and several other protecting groups (Scheme 6.4).164  
This sequence of reactions may, on initial inspection, show close parallels to those used by 
Haslett in the synthesis of the original C1 – C11 fragment of madeirolide A (see §2.3.1). 
However, the aldehyde used in this case has no α-stereocentre, and as such is not prone to 
epimerisation.  If necessary, the C13 – C17 fragment could be prepared with a PMB ether at 
C13, which would enable completely regioselective cleavage. This was not investigated 
further as without the C18 – C27 fragment prepared, the complete protecting group strategy 
















































Scheme 6.4: Precedent for selective debenzylation in the presence of a disubstituted alkene and silyl 
ethers (Paterson).164 
The THF is anticipated to form from an in situ Williamson etherification of mesylate 335, 
similar to that used in Reddy’s synthesis of the mandelalide A aglycone.58 Selective removal of 
the C15 TES ether using PPTS should be possible in the presence of the secondary TBS using 
conditions developed by Boger (Scheme 7.5),165 with mesylation of the ensuing hydroxyl 
converting it into a good leaving group. A Sharpless dihydroxylation (SAD) would thus 
introduce the C18 and C19 stereocentres with high-levels of selectivity under reagent control. 
Upon dihydroxylation it is anticipated that mesylate 335 will undergo rapid in situ cyclisation 
to the resulting THF, however it may be necessary to heat 335 in the presence of a weak amine 
base (i.e. pyridine) to facilitate the desired ring closure. Finally, the completion of the fully 
protected C12 – C27 fragment 100 ready for fragment union requires conversion of the C18 
hydroxyl to the TBS ether and hydrolysis of the C23 acetate.  
 
Scheme 6.5: Precedent for deprotection of a secondary TES ether in the presence of a secondary TBS 
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6.2.2 END-GAME AND COMPLETION OF MADEIROLIDE A  
 
Scheme 6.6: Completion of madeirolide A through convergent union of the C1 – C11 western fragment 
99 and the C12 – C27 eastern fragment 100. 
The convergent union of the eastern and western fragments of madeirolide A is anticipated to 
arise from a Yamaguchi esterification followed by Heck macrocyclisation, as discussed in §3.1. 
Thus, thioester 99 would initially be hydrolysed to carboxylic acid 344 to enable formation of 
the C1 – OC22 ester;* this has been demonstrated on a small scale using Haslett’s C1 – C11 
fragment 38 and occurred without any deleterious effects to the remainder of the fragment 
 
*  The formation of an ester directly from a thioester has been reported, however strong alkoxide 
nucleophiles are required. Hydrolysis of the thioester to the carboxylic acid enables for milder 
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(Scheme 6.6). With the two fragments tethered together by the ester, the C11 – C12 bond could 
be forged using the conditions developed by Smith III in the total synthesis of mandelalide A 
(Pd(OAc)2, Cs2CO3, Et3N).69The proposed route leaves some flexibility as to the order of steps, 
such that a Heck reaction could first be used to join 344 and 100, using a Yamaguchi 
esterification to close the macrocycle. Finally, the C18 and C21 protecting groups will be 
removed, completing the total synthesis and providing access to madeirolide A 1. The exact 
conditions required to achieve this deprotection will be determined in due course, however, 
the ideal scenario would involve the C18 and C21 hydroxyls both being protected with silyl 
ethers, thus allowing a single-step deprotection with HF･Py.  
6.3 CONCLUSIONS 
Madeirolide A 1 remains an important target for total synthesis. It is hoped that the completed 
synthetic work coupled with lessons learnt from unsuccessful attempts at forming the eastern 
THP may facilitate the first total synthesis. The availability of synthetic material would not 
only permit much-needed biological evaluation, but also serve to validate the stereochemical 














APPENDIX A: EXPERIMENTAL  
GENERAL EXPERIMENTAL DETAILS  
NMR spectroscopy:  
NMR spectra were recorded with an internal deuterium lock and referenced to the residual 
non-deuterated solvent peak (CHCl3: dH 7.26 ppm, dC 77.16 ppm; C6H6: dH 7.16 ppm, dC 128.06 
ppm)166 using one of the following spectrometers: Bruker Avance BB (500 MHz), Bruker 
Avance TCI (500 MHZ) and Bruker DRX (400 MHz). 1H NMR data are presented as follows: 
chemical shift (in ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint. = 
quintet, sext. = sextet, sept. = septet, m = multiplet, br. = broad, obs. = obscured, app. = 
apparent), coupling constants (J / Hz), integration and assignment. Diastereotopic protons 
are indicated as (‘) or (“). Proton shift assignments were determined on the basis of 
unambiguous chemical shift data, coupling constants, and 2D experiments (COSY, HSQC, 
HMBC, NOESY), or by analogy to fully interpreted spectra for known compounds.   
IR spectroscopy:  
Infrared spectra were recorded neat as thin films on a Perkin Elmer Spectrum One (FT-IR) 
machine fitted with an ATR accessory with wavelengths of maximum absorbance (vmax) 
quoted in wavenumbers (cm−1).  
Optical rotation measurements:  
Optical rotations were measured using either a Perkin-Elmer 343 polarimeter or an Anton 
Parr MCP100 polarimeter at the sodium d-line (589 nm) in chloroform and are reported as an 
[α] value together with the concentration of solution (c in g/100 mL).  
Melting points:  
Melting points were measured on a hot-stage apparatus and are uncorrected.   





Mass spectrometry:  
High-resolution mass spectra (HRMS) were recorded by the EPSRC Mass Spectrometry 
Service (Swansea, UK) or Department of Chemistry (Cambridge, UK) using electrospray 
(ES+) and electron ionisation (EI) techniques. The parent ion (M+) is quoted with the 
indicated cation where applicable.  
Chromatography:  
All solvent mixtures are reported as %vol unless otherwise stated. Analytical thin layer 
chromatography (TLC) was carried out on Merck Kieselgel 60 F254 plates, with visualisation 
using Goofy’s dip (phosphomolybdic acid/Ce2(SO4)3), potassium permanganate (KMnO4) dip, 
vanillin dip (vanillin, EtOH, H2SO4) or ultra-violet light. Preparative thin layer 
chromatography (PLC) was carried out using either Merck Kieselgel 60 F254 plates. Unless 
otherwise stated flash column chromatography was carried out using Merck Kieselgel 60 
(230-400 mesh) silica gel under a positive pressure by means of compressed air.  
Purification of reagents and solvents:   
Reagents and solvents were purified by standard methods where appropriate.167 All solvents 
used for reactions, chromatograph and workup were distilled prior to use. Tetrahydrofuran 
(THF) and diethyl ether (Et2O) were pre-dried over sodium wire and distilled from 
potassium/benzophenone or sodium wire/benzophenone ketyl respectively. 
Dichloromethane (CH2Cl2), triethylamine (Et3N), hexamethylphosphoramide (HMPA), 
benzene and toluene were distilled from CaH2. DMSO was distilled from MgSO4 and stored 
over molecular sieves. Diisopropylethylamine (i-Pr2NEt) was distilled sequentially from 
ninhydrin and KOH before being stored over molecular sieves. N,N’-Dimethylformamide 
(DMF) was distilled from and stored over activated 4Å molecular sieves. DDQ was 
recrystallised from a saturated solution of refluxing CHCl3 or benzene. Proton sponge was 
recrystallised from anhydrous ethanol.  Lithium chloride (LiCl) was dried by heating under 
high vacuum and cooling under argon. All other chemicals were used as received, unless 
otherwise noted. Molecular sieves were activated by heating in a microwave and allowing to 
cool under high vacuum. 
Reaction setup:  
All non-aqueous reactions were carried out at room temperature (rt) under an argon 
atmosphere using glassware flame dried under vacuum and allowed to cool under a stream of 
argon. Standard techniques were followed for handling air/moisture sensitive reagents.  





Ozone was generated using a Peak Scientific Ozone Generator using oxygen pre-dried 
through a column of drierite. Quenching of excess ozone was affected by purging the solution 
with a stream of oxygen. 
PREPARATION OF REAGENTS  
iso-Propyl magnesium chloride  
 
Magnesium turnings (9.70 g, 400 mmol) and iodine (1 crystal) were suspended in dry THF 
(200 mL) and the reaction heated under reflux until the colour dissipated. 2-Chloropropane 
(36.6 mL, 400 mmol) was added dropwise over 15 min and reflux maintained for a further 2 h 
to give a black solution of the Grignard reagent in THF. Titration against menthol in the 
presence of 1,10-phenanthroline gave an effective concentration of 1.7 m.  
Ethyl magnesium bromide  
 
To a suspension of magnesium turnings (7.00 g, 270 mmol) and iodine (1 crystal) in dry THF 
(60 mL) was added EtBr (19.0 mL, 250 mmol) dropwise over 15 min. Reflux was maintained 
for 1 h to give a grey solution of the Grignard reagent in THF. Titration against menthol in the 
presence of 1,10-phenanthroline gave an effective concentration of 3.0 m. 
Divinyl zinc168 
Vinyl magnesium bromide (3.40 mL, 1 m soln in THF, 3.40 mmol) was added dropwise to  a 
suspension of ZnCl2 (250 mg, 1.83 mmol) THF (1.1 mL). The deep-orange reaction mixture 
was stirred for 1 h before being used in the subsequent reaction directly.  
Samarium diiodide  
1,2-diiodoethane (0.362 g, 1.28 mmol) and powdered Sm (0.378 g, 2.52 mmol) were suspended 
in THF (6.8 mL) in a Schlenk tube under Ar. The mixture was sonicated for 1.5 h to give a 
deep-blue solution of SmI2 which was treated as a 0.4 m solution in THF and used immediately 











Stryker’s solution  
To a solution of Cu(OAc)2 (25 mg, 0.13 mmol) and PPh3 (65 mg, 0.25 mmol) in benzene (2 mL) 
was added (Me2SiH)2O. The resulting blue solution was stirred vigorously for 18 h to give a 
red/wine coloured solution (ca. 0.06 M in Cu(OAc)2).  
(–)-diisopinocampheyl borane   
 
To a solution (+)-α-pinene (47.1 mL, 296 mmol, 98% ee, freshly distilled from CaH2) in THF 
(40 mL) was added BH3･DMS (11.7 mL, 124 mmol) in a single portion at rt. Following addition, 
the solution was left standing without stirring for 17 h over which time a white crystalline 
solid precipitated. The solvent was removed via cannula and the crystals washed with n-
pentane (5 x 15 mL) before being dried under high-vacuum to give (–)-ipc2BH (32.5 g, 114 
mmol, 92%). The ipc2BH was able to be stored at -20 °C under Ar without appreciable loss of 
activity.  
The enantiomeric (+)-ipc2BH was prepared from (–)-α-pinene using an analogous procedure.   
(–)-diisopinocampheyl boron triflate  
 
To a suspension of (–)-ipc2BH (7.60 g, 26.6 mmol) in hexane (13 mL) was added TfOH* (2.35 
mL, 26.5 mmol) dropwise, resulting in a biphasic solution. The reaction mixture was stirred 
for 2.5 h, and the upper (clear) layer removed via cannula to give a solution of (–)-ipc2BOTf in 
hexane which was used immediately in the subsequent boron aldol reaction.  




* The quality of the TfOH was found to be critical to the successful preparation of ipc2BOTf, with best 














To a solution of 4-methoxybenzyl alcohol (15.5 mL, 125 mmol) and tetrabutylammonium 
hydrogensulfate (424 mg, 1.25 mmol) in CH2Cl2 at 0 °C was added KOH (150 mL, 50% wt in 
H2O) and 2,2,2-trichloroacetonitrile (14.4 mL, 144 mmol) sequentially. The reaction was 
warmed to rt and stirred for 2 h before the phases separated. The aqueous phase was extracted 
with EtOAc (3 x 50 mL) before the combined organic extracts dried (Na2SO4) and 
concentrated in vacuo. The product was purified by flash column chromatography (Al2O3, 10% 
EtOAc:PE40-60) afforded 4-methoxylbenzyl-2,2,2-trichloroacetimidate (29.1 g, 82%) as a 
colourless oil.  
1H NMR (500 MHz, CDCl3): d 8.35 (br s, 1H, NH), 7.35 (d, J = 8.7 Hz, 2H, Ar-H), 6.93 (d, J = 
8.7 Hz, 2H, Ar-H), 5.25 (s, 2H, Ar-CH2-O), 3.80 (s, 3H, Ar-OCH3).  
Benzyl-2,2,2-trichloroacetimidate (Bn-TCA) 
 
To a solution of benzyl (12.9 mL, 125 mmol) and tetrabutylammonium hydrogensulfate (424 
mg, 1.25 mmol) in CH2Cl2 at 0 °C was added KOH (150 mL, 50% wt in H2O) and 2,2,2-
trichloroacetonitrile (14.4 mL, 144 mmol) sequentially. The reaction was warmed to rt and 
stirred for 2 h before the phases separated. The aqueous phase was extracted with EtOAc (3 x 
50 mL) before the combined organic extracts dried (Na2SO4) and concentrated in vacuo. The 
product was purified by flash column chromatography (Al2O3, 5% EtOAc:PE40-60) afforded 
benzyl-2,2,2-trichloroacetimidate (25.2 g, 80%) as a colourless oil.  
1H NMR (500 MHz, CDCl3): d 8.39 (br s, 1H, NH), 7.45 – 7.20 (m, 5H, ArH), 5.32 (s, 2H,  Ar-
CH2-O).  
 [RuCl2(p-cymene)]2 169 
A solution of RuCl3･xH2O (3.6 g, 17.4 mmol) and α-phellandrene (18 mL, 112 mmol) in EtOH 
(180 mL) was heated under reflux for 4 h before EtOH (ca. 100 mL) was distilled off and the 
solution allowed to cool to rt. Et2O (100 mL) was added and reaction filtered under vacuum. 
After drying the resulting solid in vacuo, [RuCl2(p-cymene)]2 (5.86 g, 55%) was obtained as an 
amorphous red solid.   
1H NMR (500 MHz, CDCl3): δ 5.50 (d, J = 5.8 Hz, 2H), 5.36 (d, J = 5.8 Hz, 2H), 2.94 (hept, J = 











 (S,S)-Noyori catalyst for transfer hydrogenation  
Powdered KOH (0.195 g, 3.48 mmol) was added to a solution of (S,S)-TsDPEN (0.180 g, 0.490 
mmol) and [RuCl2(p-cymene)]2 (0.150 g, 0.145 mmol) in CH2Cl2 to give a deep-orange solution.  
After 10 min, H2O (3.5 mL) was added resulting in a purple suspension. The layers were 
separated and the organic phase dried over CaH2, filtered, and concentrated in vacuo to give 
the Noyori catalyst as a free-flowing purple crystalline solid (279 mg  g, 95%). 
The enantiomeric catalyst was prepared from (R,R)-TsDPEN using an analogous procedure.  
GENERAL PROCEDURES  
General procedure 1: MTPA ester formation 
 
For the (S)-MTPA ester: To a solution of the chiral alcohol in CH2Cl2 (0.1 m) was added (S)-
3,3,3-trifluoro-2-methoxy-2-phenylpropanoic acid (5 eq), DCC (5 eq) and DMAP (0.1 eq). The 
reaction mixture was stirred for 18 h at rt before Et2O (0.5 mL) was added. The reaction 
mixture was filtered through a plug of cotton wool and concentrated in vacuo. Unless 
otherwise stated, the crude MTPA ester was used in the analysis directly without purification.  
The (R)-MTPA ester was prepared following an analogous procedure, using (R)-3,3,3-





















EXPERIMENTAL PROCEDURES FOR THE WESTERN FRAGMENT OF 
MADEIROLIDE A   
 (R)-3-((4-methoxybenzyl)oxy)-2-methylpropan-1-ol 
 
Methyl-(S)-3-((4-methoxybenzyl)oxy)-2-methylpropanoate (20.0 g, 83.9 mmol) was added to 
a slurry of LiAlH4 (3.50 g, 92.3 mmol) in THF (200 mL) at -78 °C. The reaction mixture was 
allowed to warm to rt and stirred for a further 2.5 h before addition of EtOAc (100 mL) and 
Na/K tartrate (100 mL). After 18 h the supernatant was decanted from the grey precipitate, 
diluted with H2O (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic 
extracts were dried (MgSO4), concentrated in vacuo, and purified by flash column 
chromatography (SiO2, 30% EtOAc:PE40-60) to give alcohol 113 as a pale-yellow oil (14.7 g, 
83%). 
1H NMR (500 MHz, CDCl3) d 7.24 (d, J = 8.6 Hz, 2H, PMB Ar-H), 6.88 (d, J= 8.7 Hz, 2H, PMB 
Ar-H), 4.44 (s, 2H, PMB Ar-CH2O-), 3.80 (s, 3H, PMB O-CH3), 3.60 (dd, J= 10.8, 4.6 Hz, 1H,  
H8’), 3.57 (dd, J= 10.8, 7.1 Hz, 1H, H8”), 3.51 (dd, J=9.1, 4.7 Hz, 1H, H10’), 3.89 (dd, J= 9.0, 8.1 
Hz, 1H, H10”), 2.64 (br. s, 1H, C8-OH), 2.01-2.09 (m, 1H, H9), 0.87 (d, J= 7.1 Hz, 3H, H29). 
HRMS (ES+) calcd for C12H19O3 [M+NH4]+ 211.1329, found 211.1330.  
Data consistent with that reported in the literature.53 
 (S)-1-((3-iodo-2-methylpropoxy)methyl)-4-methoxybenzene  
 
Alcohol 113 (8.00 g, 38.1 mmol) in CH2Cl2 (80 mL) was added to a pre-stirred suspension of I2 
(10.6 g, 41.9 mmol), PPh3 (11.9 g, 45.6 mmol) and imidazole (3.90 g, 57.1 mmol) in CH2Cl2 (300 
mL) at 0 °C. The reaction mixture was stirred for 1 h before Et2O (100 mL) added and the 
reaction mixture filtered.  Na2S2O4 (100 mL) was added and the layers separated. The aqueous 
phase was back-extracted with Et2O (3 x 100 mL) and the combined organic extracts dried 
(MgSO4), concentrated in vacuo, and the crude residue purified by flash column 


















1H-NMR (400 MHz, CDCl3) d 7.29 (d, J= 8.6 Hz, 2H, PMB Ar-H), 6.91 (d, J= 8.6 Hz, 2H, PMB 
Ar-H), 4.48 (s, 2H, PMB Ar-CH2O-), 3.84 (s, 3H, PMB O-CH3), 3.27-3.41 (m, 4H, H8, H10), 1.79 
(m, 1H, H9), 1.01 (d, J= 6.7 Hz, 3H, H29). HRMS (ES+) calcd for C12H21O2NI [M+NH4]+ 
338.0611, found 388.0612. 
Data consistent with that reported in the literature.53 
2-ethyl-1,3-dithiane  
 
To a solution of propanal (5.00 mL, 69.3 mmol) in THF (5 mL) at -78 °C  was added BF3･OEt2 
(8.60 mL, 69.3 mmol) and 1,3-propanedithiol (7.00 mL, 69.3 mmol).  The reaction mixture was 
warmed to rt over 2 h before Et3N (1 mL) added and the solution concentrated in vacuo. 
Purification by flash column chromatography (SiO2, 15% EtOAc:PE40-60) afforded 112 as a 
colourless oil (7.85 g, 90%). 
1H-NMR (500 MHz, CDCl3) d 3.99 (t, J = 6.8 Hz, 1H, C5-H), 2.80-2.91 (m, 4H, -S-CH2-CH2-
CH2-S-), 2.08-2.15 (m, 1H, -S-CH2-CH2’-CH2-S-), 1.82-1.90 (m, 1H, -S-CH2-CH2”-CH2-S-), 1.79 
(quin, J = 6.8 Hz, 2H, H6), 1.08 (t, J = 7.5 Hz, 3H, H28).  HRMS (ES+) calcd for C6H13Ss [M+H]+ 
149.0453, found 149.0450.  
Data consistent with that reported in the literature.53 
(R)-2-ethyl-2-(3-((4-methoxybenzyl)oxy)-2-methylpropyl)-1,3-dithiane  
 
Iodide 114 (8.53 g, 26.6 mmol) in THF (20 mL) was added to a solution of dithiane 112 (5.93 g, 
40.0 mmol), t-BuLi (21 mL, 1.4 m in pentane, 29.3 mmol) and HMPA (6 mL) in THF (100 mL) 
at – 78 °C. Stirring was continued at this temperature for 4 h before the addition of NH4Cl 
(100 mL). After warming to rt, the mixture was diluted with EtOAc (80 mL) and the layers 
separated. The aqueous phase was extracted sequentially with EtOAc (3 x 80 mL) and CH2Cl2 
(80 mL) before the combined organic extracts dried (Na2SO4), concentrated in vacuo and the 
crude residue purified by flash column chromatography (SiO2, 10% EtOAc:PE40-60) to give 115 



















1H NMR (400 MHz, CDCl3) δ	7.26 (d, J = 8.4 Hz, 2H, PMB Ar-H), 6.87 (d, J = 8.4 Hz, 2H, PMB 
Ar-H), 4.44 (s, 2H, PMB Ar-CH2O-), 3.80 (s, 3H, PMB ArO-CH3), 3.34 (dd, J = 9.1, 5.7 Hz, 1H, 
H10’), 3.27 (dd, J = 9.1, 6.2 Hz, 1H, H10”), 2.73 – 2.83 (m, 4H, -S-CH2-CH2-CH2-S-), 2.03 – 2.12 
(m, 2H, H9, H8’), 1.87 – 2.00 (m, 4H, H6, -S-CH2-CH2-CH2-S-), 1.63 (dd, J = 15.6, 6.6 Hz, 1H, 
H8”), 1.06 (d, J = 6.6 Hz, 3H, H29), 0.99 (t, J = 7.4 Hz, 3H, H28).  HRMS (ES+) calcd for 
C18H32O2S2N [M+NH4]+ 358.1860, found 358.1863.   
Data consistent with that reported in the literature.53 
(R)-6-((4-methoxybenzyl)oxy)-5-methylhexan-3-one  
 
Dithiane 115 (55.8 g, crude) was added to a solution of I2 (80.0 g, 315 mmol) in MeCN (1500 
mL) and NaHCO3 (1000 mL). After 2.5 h, the reaction mixture was diluted with CHCl3* (500 
mL) and solid Na2S2O3 (ca. 250 g) was added until a colour change from brown to colourless 
was observed. The layers were separated and the aqueous phase extracted with CHCl3 (3 x 
500 mL) before the combined organic extracts dried (Na2SO4), concentrated in vacuo and the 
crude residue purified by flash column chromatography (SiO2, 10 ⟶	30% EtOAc:PE40-60) to 
give 110 as a yellow oil (20.1 g, 49% over two steps) plus starting material 110 (10.2 g) which 
was able to be resubjected to the reaction conditions to obtain a further 6.2 g of product.  
1H NMR (400 MHz, CDCl3) δ	7.23 (d, J = 8.7 Hz, 2H, PMB Ar-H), 6.87 (d, J = 8.6 Hz, 2H, PMB 
Ar-H), 4.39 (s, 2H, PMB Ar-CH2O-), 3.80 (s, 3H, PMB Ar-CH3), 3.32 (dd, J = 9.2, 5.4 Hz, 1H, 
H10’), 3.22 (dd, J = 9.2, 7.0 Hz, 1H, H10”), 2.56 (dd, J = 15.9, 5.7 Hz, 1H, H8’), 2.29-2.46 (m, 3H, 
H9, H6), 2.22 (dd, J = 15.9, 7.6 Hz, 1H, H8”), 1.01 (t, J = 7.3 Hz, 3H, H28), 0.92 (d, J = 6.8 Hz, 
3H, H29). HRMS (ES+) calcd for C15H22O3Na [M+Na]+ 273.1461, found 273.1458. 
Data consistent with that reported in the literature.53 
3-((tert-butyldimethylsilyl)oxy)propan-1-ol   
 
 
* CHCl3 was used in place of CH2Cl2 owing to the increased density which aided in the separation of the 

















1,3-propanediol (9.00 g, 118 mmol) was added dropwise to a slurry of NaH (4.70 g, 60% wt 
dispersion in mineral oil, 118 mmol) in THF (200 mL) at 0 °C. Upon complete addition the 
cooling bath was removed and TBS-Cl (16.0 g, 107 mmol) added portion-wise. After stirring 
for 2 h, NaHCO3 (50 mL) and EtOAc (100 mL) were added and the layers separated. The 
aqueous phase was extracted with EtOAc (3 x 100 mL) and the combined organic extracts 
dried (Na2SO4) and concentrated in vacuo to afford the mono-TBS protected diol 119 as a 
colourless oil (21.2 g, ca. 94%) which was used directly in the subsequent step without 
additional purification.  
For the purposes of characterisation, an analytical sample was purified by flash column 
chromatography (SiO2, 5% EtOAc:PE40-60) to provide the following data:  
1H NMR (400 MHz, CDCl3) δ 3.91 – 3.72 (m,  4H, H5, H3), 2.60 (t, J = 5.4 Hz, 1H, OH), 1.78 (p, 
J = 5.5 Hz, 2H, H4), 0.90 (s, 9H, Si-C(CH3)3), 0.08 (s, 6H, Si-(CH3)2).HRMS (ES+) calcd for 
C9H23SiO2 [M+H]+ 191.1462, found 191.1460.  
Data consistent with that reported in the literature.53 
3-((tert-butyldimethylsilyl)oxy)propanal  
 
DMSO (3.50 mL, 49.8 mmol) was added dropwise to a solution of (COCl)2 (2.10 mL, 24.9 
mmol) in CH2Cl2 at -78 °C and the reaction mixture stirred for 10 min before a solution of 119 
(2.50 g, 13.1 mmol) in CH2Cl2 (20 mL) was added dropwise, followed immediately by Et3N 
(15.8 mL, 113.1 mmol). The cooling bath was removed and the reaction mixture stirred for 20 
min while warming to rt. Water (30 mL) was added and the layers separated. The aqueous 
phase was extracted with EtOAc (3 x 20 mL) before the combined organics layers dried 
(Na2SO4)and concentrated in vacuo. Purification by flash column chromatography (SiO2, 5% 
EtOAc:PE30-40) afforded 59 (2.40 g, 96%) as a colourless oil.  
1H NMR (400 MHz, CDCl3) d 9.78 (t, J = 2.0 Hz, 1H, H5), 3.96 (t, J = 6.0 Hz, 2H, H3), 2.58 (td, 
J= 6.0, 2.1 Hz, 2H, H4), 0.86 (s, 9H, Si-C(CH3)3), 0.05 (s, 6H, Si-(CH3)2). HRMS (ES+) calcd 
for C9H21SiO2 [M+H]+ 189.1305, found 189.1307.  














A solution of ketone 110 (2.00 g, 7.90 mmol) in CH2Cl2 (8 mL) was added dropwise to a pre-
stirred solution of (–)-ipc2BOTf (10.0 mL, ca. 1.2 m in hexane, 12.0 mmol) and i-Pr2NEt (4.20 
mL, 23.9 mmol) in CH2Cl2 (5 mL) at -78 °C, and the resulting mixture stirred for 2.5 h while 
warming to -30 °C. A solution of aldehyde 59 (4.50 g, 23.9 mmol) in CH2Cl2 (5 mL) was dried 
over CaH2 before being added to the enolate solution at -78 °C and stirred for a further 18 h at 
this temperature. MeOH (5 mL), pH 7 buffer (5 mL) and H2O2 (2 mL) were added and the 
reaction stirred vigorously while warming to rt. The layers were separated and the aqueous 
phase extracted with CH2Cl2 (3 x 10 mL) before the combined organic extracts dried (MgSO4), 
concentrated in vacuo, and the crude residue purified by flash column chromatography (SiO2, 
10% EtOAc:PE40-60 then 25% Et2O:CH2Cl2 + 0.1% AcOH) to give 109 as a colourless oil (2.30 g, 
65%).  
1H-NMR (500 MHz, CDCl3) δ 7.23 (d, J = 8.6 Hz, 2H, PMB Ar-H), 6.86 (d, J = 8.6 Hz, 2H, PMB 
Ar-H), 4.41 (s, 2H, PMB Ar-CH2O-), 4.04-4.09 (m, 1H, H5), 3.80 (s, 3H, PMB Ar-OCH3), 3.70-
3.83 (m, 2H, H2), 3.44 (s, 1H, C5-OH), 3.32 (dd, J = 9.3, 5.3 Hz, 1H, H10’), 3.23 (dd, J= 9.3, 6.8  
Hz, 1H, H10”), 2.67 (d, J = 5.1 Hz, 1H, H8’), 2.57-2.65 (m, 1H, H6), 2.32-2.41 (m, 1H, H9), 2.31 
(d, J = 7.6 Hz, 1H, H8”), 1.60-1.69 (m, 1H, H4’), 1.51-1.58 (m, 1H, H4”), 1.12 (d, J= 7.2 Hz, 3H, 
H8), 0.92 (d, J = 6.6 Hz, 3H, H29), 0.9 (s, 9H, Si-C(CH3)3), 0.1 (s, 6H, Si-(CH3)2). HRMS (ES+) 
calcd for C24H42O3SiNa [M+Na]+ 461.2694, found 461.2682. 
Data consistent with that reported in the literature.53 
(3R,4S,7R)-1-((tert-butyldimethylsilyl)oxy)-8-((4-methoxybenzyl)oxy)-4,7-dimethyl-5-
oxooctan-3-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate  
 
(S)-MTPA ester 135 was prepared from aldol adduct 109 (10.0 mg, 0.02 mmol) following 
general procedure A and purified by preparative layer chromatography (SiO2, 20% 






























1H NMR (500 MHz, CDCl3) δ 7.54 (dd, J = 7.0, 3.0 Hz, 2H, MTPA Ar-H), 7.41 – 7.35 (m, 3H, 
MTPA Ar-H), 7.25 – 7.19 (m, 2H, PMB Ar-H), 6.89 – 6.83 (m, 2H, PMB Ar-H), 5.56 (dt, J = 7.4, 
5.0 Hz, 1H, H5), 4.38 (s, 2H, PMB Ar-CH2O-), 3.80 (s, 3H, PMB-OCH3), 3.69 – 3.56 (m, 2H, 
H3), 3.52 (d, J = 1.2 Hz, 3H, MTPA -OCH3), 3.25 (dd, J = 9.2, 5.6 Hz, 1H, H10'), 3.18 (dd, J = 9.2, 
6.6 Hz, 1H, H10''), 2.81 (qd, J = 7.0, 4.5 Hz, 1H, H6), 2.53 (dd, J = 16.7, 5.2 Hz, 1H, H8'), 2.35 – 
2.25 (m, 1H, H9), 2.21 (dd, J = 16.4, 7.8 Hz, 1H, H8''), 1.90 – 1.79 (m, 2H, H4),  1.04 (d, J = 7.1 
Hz, 3H, H28), 0.88 (s, 9H, Si-C(CH3)3), 0.86 (d, J = 6.6 Hz, 3H, H29), 0.03 (s, 6H, Si-(CH3)2). 
HRMS (ES+) calcd for C34H53O7NF3Si [M+NH4]+ 672.3538, found 672.3537. 
Data consistent with that reported in the literature.53 
 (3R,4S,7R)-1-((tert-butyldimethylsilyl)oxy)-8-((4-methoxybenzyl)oxy)-4,7-dimethyl-5-
oxooctan-3-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate  
 
(R)-MTPA ester 134 was prepared following an analogous procedure to that used for the (S)-
MTPA ester 135 using the enantiomeric (R)-(+)-α-methoxy-α-trifluoromethylphenylacetic 
acid to give 134  as a colourless residue (8.5 mg, 65%).   
1H NMR (500 MHz, CDCl3) δ 7.53 (dd, J = 6.8, 3.0 Hz, 2H, MTPA Ar-H), 7.42 – 7.35 (m, 3H, 
MTPA Ar-H), 7.22 (d, J = 8.6 Hz, 2H, PMB Ar-H), 6.86 (d, J = 8.6 Hz, 2H, PMB Ar-H), 5.59 
(dt, J = 7.6, 4.7 Hz, 1H, H5), 4.39 (s, 2H, PMB Ar-CH2O-), 3.80 (s, 3H, PMB-OCH3), 3.59 – 3.44 
(m, 2H, H3), 3.50 (s 3H, MTPA -OCH3), 3.28 (dd, J = 9.2, 5.2 Hz, 1H, H10'), 3.22 (dd, J = 9.2, 
6.2 Hz, 1H, H10''), 2.86 (qd, J = 7.1, 4.2 Hz, 1H, H6), 2.68 – 2.56 (m, 1H, H8'), 2.40 – 2.29 (m, 
2H, H9, H8''), 1.84 – 1.73 (m, 2H, H4), 1.08 (d, J = 7.1 Hz, 3H, H28), 0.91 (d, J = 6.3 Hz, 3H, 
H29), 0.88 (s, 9H, Si-C(CH3)3), 0.02 (s, 3H, Si-CH3), 0.01 (s, 3H, Si-CH3). HRMS (ES+) calcd 
for C34H53O7NF3Si [M+NH4]+ 672.3538, found 672.3533. 





















Proton  δS-MTPA δR-MTPA δ(S-R) 
 3  3.61 3.52 +0.09 
4  1.83 1.79 +0.04 
6  2.81 2.86 -0.05 
8’  2.53 2.62 -0.09 
8”  2.21  2.33 -0.12 
9  2.28 2.33 -0.05 
10’  3.18 3.22 -0.04 
10”  2.35 3.28 -0.03 
28  1.04 1.08 -0.04 
29  0.86 0.91 -0.05 





Aldol adduct 109 (1.00 g, 2.30 mmol) in THF (11 mL) was added dropwise to a pre-stirred 
solution of SmI2 (5.00 mL, 0.1 m soln in THF, 0.50 mmol)  and EtCHO (1.72 mL, 10mmol) at -
30 °C. The reaction mixture was stirred at -30 °C for 18 h before being quenched by addition 
of NaHCO3 (10 mL) and diluted with EtOAc (20 mL). They layers were separated, the aqueous 
phase extracted with EtOAc (3 x 20 mL), dried (Na2SO4) and concentrated in vacuo to afford 
propionate ester 136 a yellow oil (1.10 g) which was used directly in the subsequent step 
without additional purification due to observed migration of the propionate ester during flash 
column chromatography.  
For the purposes of characterisation, an analytical sample was purified by flash column 
chromatography (SiO2, 10% EtOAc:PE40-60) to provide the following data:  
1H NMR (500 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 2H, PMB Ar-H), 6.86 (d, J = 8.7 Hz, 2H, PMB 
Ar-H), 5.40 (ddd, J = 9.4, 3.7, 2.2 Hz, 1H, H5), 4.44 (s, 2H, PMB Ar-CH2O-), 3.81 (s, 3H, PMB 
OCH3), 3.65 – 3.63 (m, 2H, H3), 3.32 (dd, J = 9.2, 6.6 Hz, 2H,  H10’), 3.28 (dd, J = 9.2, 6.3 Hz, 
















– 1.89 (m, 1H, H4’), 1.75 – 1.64 (m. 1H, H4”), 1.55 – 1.50 (m, 1H, H6), 1.42 (ddd, J = 14.0, 10.1, 4.4 
Hz, 1H, H8’),  1.33 (ddd, J = 14.0, 8.9, 2.2 Hz, 1H, H8”), 1.14 (t, J = 7.5 Hz, -CH2CH3), 0.91 (d, J 
= 6.8 Hz, H29), 0.88 (s, 9H, Si-C(CH3)3), 0.84 (d, J = 6.8 Hz, 3H, H28), 0.03 (s, 6H, Si-(CH3)2). 
HRMS (ES+) calcd for C26H47O6Si [M+H]+ 497.3293, found 497.3283.  




To a solution of crude ester 136 (1.10 g) in MeOH (10 mL) was added K2CO3 (500 mg, 3.60 
mmol). The suspension was stirred for 48 h before being filtered through a plug of cotton 
wool. Concentration of the organic filtrate in vacuo afforded diol 137 as a colourless oil (987 
mg) which was used directly in the subsequent step without additional purification.   
For the purposes of characterisation, an analytical sample was purified by flash column 
chromatography (SiO2, 50% EtOAc:PE40-60) to provide the following data:  
1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H, Ar-H), 6.90 (d, J = 8.6 Hz, 2H, Ar-H), 
4.47 (s, 2H, Ar-CH2-O), 4.15 (d, J = 9.7 Hz, 1H, H5), 3.90 – 3.79 (m, 2H, H3), 3.81 (s, 3H, Ar-
OCH3), 3.70 – 3.66 (m, 1H, H7), 3.37 (dd, J = 9.0, 5.3 Hz, 1H, H10’), 3.28 (dd, J = 9.0, 8.1 Hz, 1H, 
H10”), 2.03 – 1.97 (m, 1H, H9), 1.88 – 1.81 (m, 1H, H4’), 1.64 – 1.50 (m, 3H, H8’, H6, H4”), 1.42 
– 1.40 (m, 1H, H8”), 0.95 (d, J = 6.9 Hz, 3H, H29), 0.93 (d, J = 6.9 Hz, 3H, H28), 0.91 (s, 9H, Si-
C(CH3)3), 0.09 (s, 6H, Si-(CH3)2). HRMS (ES+) calcd for C24H45O5Si [M+H]+ 441.3031, found 
441.3020.   



























To a solution of crude diol 137 (850 mg) in CH2Cl2 (5 mL) and Me2C(OMe)2 (5 mL, 40.6 mmol) 
was added PPTS (cat.) and the reaction stirred for 2.5 h. NaHCO3 (5 mL) was added, the layers 
separated and the aqueous phase extracted with CH2Cl2 (4 x 5 mL). The combined organic 
extracts were dried (MgSO4), concentrated in vacuo and purified by flash column 
chromatography (SiO2, 30% EtOAc:PE40-60) to afford acetonide 106 as a colourless oil (942 mg, 
86% over three steps from aldol adduct 109). 
1H NMR (500 MHz, CDCl3) δ 7.26 (d, J = 8.6 Hz, 2H, Ar-H), 6.87 (d, J = 8.7 Hz, 2H, Ar-H), 
4.43 (s, 2H, Ar-CH2-O), 4.04 (ddd, J = 9.4, 5.2, 3.7 Hz, 1H, H5), 3.80 (s, 3H, Ar-OCH3), 3.72 – 
3.55 (m, 2H, H3), 3.35 (dd, J = 9.1, 5.6 Hz, 1H, H10''), 3.30 (ddd, J = 10.5, 8.1, 2.4 Hz, 1H, H7), 
3.21 (dd, J = 9.1, 7.0 Hz, 1H, H10'), 2.10 – 1.93 (m, 1H, H9), 1.73 – 1.48 (m, 5H, H6, H8, H4), 1.31 
(s, 3H, C(CH3)2), 1.30 (s, 3H, C(CH3)2), 0.94 (d, J = 6.7 Hz, 3H, H28), 0.89 (s, 9H, Si-C(CH3)3), 
0.81 (d, J = 6.9 Hz, 3H, H29), 0.04 (s, 6H, Si-(CH3)2). 13C NMR (126 MHz, CDCl3) δ 159.18, 
131.05, 129.29, 113.84, 100.58, 76.10, 72.70, 72.47, 65.53, 59.85, 55.41, 40.73, 38.57, 34.05, 30.19, 
26.10, 25.09, 23.98, 18.42, 16.62, 11.86, -5.17, -5.21. HRMS (ES+) calcd for C27H49O5Si [M+H]+ 
481.3344, found 481.3336.  




To a solution of PMB ether 106 (150 mg, 0.312 mmol) in CH2Cl2 (15 mL) and pH 7 buffer (0.75 
mL) was added DDQ (105 mg, 0.468 mmol). The resulting deep-red suspension was stirred 
for 2 h before being quenched by addition of NaHCO3 (2 mL). The reaction mixture was 
diluted with H2O (30 mL), EtOAc (30 mL) and MeOH (0.5 mL) and the layers separated. The 
aqueous phase was extracted with EtOAc (5 x 10 mL) before the combined organic layers dried 
(MgSO4), concentrated in vacuo, and the resulting orange residue purified by flash column 
chromatography (SiO2, 10 ⟶ 25% EtOAc:PE40-60 then 10% CH2Cl2:PhMe) to afford 142 as a 
colourless oil (115 mg, 77%).  
Rf (SiO2, 10% EtOAc:PE40-60) 0.2.  1H NMR (500 MHz, CDCl3) δ 4.05 (ddd, J = 9.4, 5.2, 3.7 Hz, 
1H, H5), 3.73 – 3.61 (m, 2H, H3), 3.58 – 3.51 (m, 1H, H10''), 3.44 – 3.34 (m, 1H, H10'), 3.29 (ddd, 
J = 10.2, 8.1, 1.9 Hz, 1H, H7), 1.81 – 1.71 (m, 1H, H9), 1.57 – 1.53 (m, 5H, H6, H4, H8), 1.35 (s, 3H, 















J = 6.8 Hz, 3H, H29), 0.04 (s, 6H, Si-(CH3)2). 13C NMR (126 MHz, CDCl3) δ 100.97, 77.16, 74.50, 
68.48, 65.57, 59.71, 40.93, 39.78, 34.71, 33.95, 26.10, 24.99, 23.90, 18.42, 18.15, 11.97, -5.18, -5.21. 
HRMS (ES+) calcd for C19H41O4Si [M+H]+ 361.2769, found 361.2774. IR (thin film) vmax 3438, 
2987, 2955, 2906, 1514, 1502, 1305, 1219, 1182, 1094, 1053, 952, 934, 820 cm-1. [𝜶𝜶]25
𝐷𝐷
(c 0.50, 





To a solution of alcohol 142 (92 mg, 0.255 mmol) in CH2Cl2 (20 mL) and H2O (0.1 mL) was 
added solid NaHCO3 (171 mg, 2.04 mmol) and DMP (432 mg, 1.02 mmol) sequentially and the 
resulting suspension stirred for 1 h. Na2S2O3 (5 mL) was added and the layers separated. The 
aqueous phase was extracted with CH2Cl2 (3 x 15 mL) before the combined organic layers 
washed with NaHCO3, dried (Na2SO4) and concentrated in vacuo to give 143 as a colourless 
oil (106 mg) that was used directly in the subsequent reaction without additional purification 





n-BuLi (0.52 mL, 1.6 m in hexane, 0.832 mmol) was added to a suspension of Ph3PMeBr (297 
mg, 0.832 mmol) in THF (8 mL) at 0 °C to give a bright yellow solution which was stirred for 
2 h. After cooling to -78 °C, a solution of aldehyde 143 (106 mg, crude) in THF (10 mL) was 
added and the reaction stirred overnight whilst warming to rt. NH4Cl (10 mL) was added and 
the layers separated. The aqueous phase was extracted with EtOAc (3 x 20 mL) before the 
combined organic phases dried (MgSO4), concentrated in vacuo, and the resulting residue 
purified by flash column chromatography (SiO2, 10 ⟶	30% EtOAc:PE40-60) to afford 144 as a 






















Rf (SiO2, 10% EtOAc:PE40-60) 0.35.  1H NMR (500 MHz, CDCl3) δ 5.83 (ddd, J = 17.2, 10.4, 6.8 
Hz, 1H, H10), 5.00 (dt, J = 17.3, 1.6 Hz, 1H, H11'), 4.92 (dt, J = 10.4, 1.5 Hz, 1H, H11''), 4.08 (ddd, 
J = 9.4, 5.1, 3.7 Hz, 1H, H5), 3.74 – 3.62 (m, 2H, H3), 3.33 (ddd, J = 10.4, 7.9, 2.9 Hz, 1H, H7), 
2.46 – 2.35 (m, 1H, H9), 1.72 – 1.51 (m, 5H, H8, H6. H4), 1.35 (s, 6H, C(CH3)2), 1.01 (d, J = 6.8 
Hz, 3H, H29), 0.91 (s, 9H, Si-C(CH3)3), 0.88 – 0.76 (m, 3H, H28), 0.06 (s, 6H, Si-(CH3)2).  13C 
NMR (125 MHz, CDCl3) δ 144.93, 111.87, 100.45, 72.42, 65.36, 59.68, 41.33, 40.48, 33.92, 33.53, 
25.95, 25.02, 23.93, 18.54, 18.26, 11.76, -5.32, -5.36. HRMS (ES+) calcd for C20H40O4Si [M+H]+ 
357.2819, found 357.2821. IR (thin film) vmax 2955, 2899, 1642, 1276, 1135, 1104, 997, 913, 847, 
840, 677, 669 cm-1.[𝜶𝜶]25
𝐷𝐷
(c 0.50, CHCl3) -22.3.  
2-((4R,5R,6R)-2,2,5-trimethyl-6-((R)-2-methylbut-3-en-1-yl)-1,3-dioxan-4-yl)ethan-1-ol  
 
To a solution of 144 (65.3 mg, 0.183 mmol) in THF (10 mL) was added TBAF (1 mL, 1 m in 
THF, 1 mmol). The reaction was stirred at rt for 1 h before NaHCO3 (5 mL) and CH2Cl2 (10 
mL) added and the phases separated. The aqueous phase was extracted with CH2Cl2 (3 x 10 
mL) before the combined organic layers dried (Na2SO4), concentrated in vacuo and purified 
by flash column chromatography (SiO2, 20% EtOAc:PE40-60) to give the title compound (41.0 
mg, 93%) as a colourless residue.  
Rf (SiO2, 20% EtOAc:PE40-60) 0.30.  1H NMR (500 MHz, CDCl3) δ 5.82 (ddd, J = 17.2, 10.4, 6.8 
Hz, 1H, H10), 5.00 (dt, J = 17.3, 1.6 Hz, 1H, H11'), 4.93 (dt, J = 10.4, 1.5 Hz, 1H, H11''), 4.12 (ddd, 
J = 10.9, 5.1, 2.7 Hz, 1H, H5), 3.84 – 3.64 (m, 2H, H3), 3.35 (ddd, J = 9.9, 7.9, 2.8 Hz, 1H, H7), 
2.51 – 2.44 (m, 1H, H9), 2.43 – 2.33 (m, 1H, H6), 1.81 (dddd, J = 14.5, 10.9, 7.7, 4.9 Hz, 1H, H4'), 
1.70 – 1.57 (m, 2H, H8), 1.53 (dddd, J = 14.5, 5.5, 4.1, 2.7 Hz, 1H, H4''), 1.40 (s, 3H, C(CH3)2), 1.36 
(s, 3H, C(CH3)2), 1.01 (d, J = 6.8 Hz, 3H, H29), 0.87 (d, J = 6.9 Hz, 3H, H28). 13C NMR (125 
MHz, CDCl3) δ 144.98, 112.16, 100.81, 72.50, 69.75, 62.20, 41.49, 40.78, 33.68, 32.86, 25.28, 
24.01, 18.76, 12.05. HRMS (ES+) calcd for C14H30O3N [M+NH4]+ 260.2220, found 260.2216. IR 
(thin film) vmax 3360, 3335, 2950, 2887, 1642, 1633, 1271, 1135, 1075, 989, 918, 840, 678, 669, 625 
cm-1. [𝜶𝜶]25
𝐷𝐷

















Alcohol (41.0 mg, 0.169 mmol) in CH2Cl2 (1.5 mL) was added to a pre-mixed solution of 
(COCl)2 (87 μL,	1.01	mmol)and DMSO (144 μL, 2.03 mmol) in CH2Cl2 (2.5 mL) at -78 °C. After 
15 min, Et3N (0.5 mL, 4.05 mmol) was added and the reaction mixture stirred for 30 min at -
78 °C then 30 min at rt. H2O (2 mL) was added, the layers separated, and the organic layer 
concentrated in vacuo to give 150 (47 mg) as a yellow oil that was used directly in the 
subsequent Horner-Wadsworth-Emmons reaction without additional purification. 
2-(dimethoxyphosphoryl)acetic acid  
 
 
Trimethyl phosphonoacetate (16.0 mL, 111 mmol) was added to a solution of NaOH (4.88 g, 
122 mmol) in H2O (40 mL) and the reaction mixture stirred for 18 h before the addition of HCl 
(10 mL, 37% aq.) at 0 °C. The solution was extracted with EtOAc (6 x 20 mL), the combined 
organic layers dried (MgSO4) and concentrated in vacuo to give carboxylic acid 147 (13.0 g, 
77.3 mmol, 70%) which was used without further purification.  
An analytical sample was purified by flash column chromatography (SiO2, 80% EtOAc:PE40-
60) to provide the following data:  
1H NMR (500 MHz, CDCl3) δ 10.55 (br s, 1H, OH), 3.80 (d, 3JP-H = 11.6 Hz, 6H, O-CH3), 3.00 
(d, 2JP-H = 21.8 Hz, 2H, H2). HRMS (ES+) calcd for C4H10PO5 [M+H]+ 169.0260, found 
169.0256.  




To a solution of acid 147 (10.0 g, 59.4 mmol) and 4-methylbenzenethiol (7.38 g, 59.4 mmol) in 





























suspension was stirred for 18 h before being diluted with Et2O (100 mL) and filtered through 
a short plug of celite. The filtrate was concentrated in vacuo, with the resulting residue 
purified by flash column chromatography (SiO2, 40 ⟶	 60% EtOAc:PE40-60) to give 
thiophosphonate 149 (12.8 g, 46.7 mmol, 79%) as a colourless oil.  
1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 8.2 Hz, 2H, Ar-H), 7.22 (d, J = 8.2 Hz, 2H, Ar-H), 
3.82 (d, 3JP-H  = 11.3 Hz, 6H, O-CH3), 3.30 (d, 2JP-H  = 21.2 Hz, 2H, H2), 2.37 (s, 3H, Ar-CH3). 
HRMS (ES+) calcd for C11H16PO4S [M+H]+ 275.0507, found 275.0502.  




Phosphonate 149 (41.0 mg, 0.156 mmol) in THF (0.5 mL) was added dropwise to a suspension 
of LiCl (6 mg, 0.156 mmol) in THF (1.5 mL) at – 10 °C, followed immediately by Et3N (0.02 mL, 
0.156 mmol). After 20 min, a solution of aldehyde 150 (25.0 mg, 0.104 mmol) in THF (2 mL) 
was  added dropwise and the reaction mixture stirred at -10 °C for 23 h. EtOAc (5 mL) and 
H2O (5 mL) were added and the phases separated. The aqueous layer was extracted 
sequentially with EtOAc (2 x 10 mL) and CH2Cl2 (10 mL) before the combined organic extracts 
dried (Na2SO4), concentrated in vacuo and purified by flash column chromatography (SiO2, 10 
⟶	30% EtOAc:hexanes) to give 108 (45 mg, 74%) as a white solid. 
Rf (SiO2, 20% EtOAc:PE40-60) 0.10. 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.1 Hz, 2H, Ar-
H), 7.23 (d, J = 7.9 Hz, 2H, Ar-H), 6.95 (ddd, J = 15.6, 7.5, 6.4 Hz, 1H, H3), 6.30 – 6.20 (m, 1H, 
H2), 5.81 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H, H10), 4.99 (dd, J = 17.3, 1.6 Hz, 1H, H11'), 4.93 – 4.76 
(m, 1H, H11''), 3.99 (dt, J = 9.5, 5.0 Hz, 1H, H5), 3.44 – 3.25 (m, 1H, H7), 2.39 – 2.35 (m, 1H, H9), 
2.38 (s, 3H, Ar-CH3), 2.30 – 2.19 (m, 1H, H6), 1.71 – 1.59 (m, 2H, H4), 1.35 – 1.29 (m, 8H, H8, 
C(CH3)2), 1.00 (d, J = 6.7 Hz, 3H, H29), 0.86 (d, J = 6.8 Hz, 3H, H28). 13C NMR (126 MHz, 
CDCl3) δ 189.15, 144.95, 141.00, 139.01, 134.52, 133.83, 130.15, 125.48, 113.05, 100.78, 71.80, 71.59, 
40.93, 37.76, 36.54, 35.92, 25.46, 24.19, 18.97, 12.07. HRMS (ES+) calcd for C23H33O3S [M+H]+ 
389.2145, found 389.2142. IR (thin film) vmax 3021, 2950, 2887, 1945, 1854, 1730, 1690, 1649, 
1631. 1623, 1271, 1195, 1135, 1075, 989, 918, 840, 678, 669, 625 cm-1. [𝜶𝜶]25
𝐷𝐷


















To a solution of 108 (37 mg, 0.145 mmol) in CH2Cl2 (5 mL) was added p-TsOH (2 mg, 0.011 
mmol) and i-PrOH (0.1 mL). The reaction was stirred for 36 h before H2O (5 mL) added and 
the phases separated. The organic layer was dried (Na2SO4), concentrated in vacuo and 
purified by flash column chromatography (SiO2, 10% Me2CO:PhMe) to afford 107 (23 mg, 
70%) as a colourless residue.  
Rf (SiO2, 10% Me2CO:PhMe + 0.1% HCOOH) 0.40. 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 
7.2 Hz, 2H, Ar-H), 7.24 (d, J = 8.1 Hz, 2H, Ar-H), 5.85 (ddd, J = 17.2, 10.4, 6.7 Hz, 1H, H10), 5.01 
(dd, J = 17.3, 1.6 Hz, 1H, H11'), 4.92 (dd, J = 10.4, 1.5 Hz, 1H, H11''), 3.88 (dddd, J = 15.7, 13.9, 6.9, 
4.3 Hz, 1H, H3), 3.44 – 3.35 (m, 1H, H5), 3.07 (td, J = 9.9, 2.9 Hz, 1H, H7), 2.94 (dd, J = 14.6, 8.6 
Hz, 1H, H2''), 2.70 (dd, J = 14.6, 4.5 Hz, 1H, H2'), 2.60 – 2.50 (m, 1H, H9), 2.40 (s, 3H, Ar-CH3), 
2.11 – 1.97 (m, 1H, H6), 1.64 – 1.43 (m, 2H, H4), 1.41 – 1.31 (m, 2H, H8), 0.98 (m, 6H, H29, H28). 
13C NMR (126 MHz, CDCl3) δ 195.65, 145.24, 139.72, 134.60, 134.39, 130.04, 124.19, 111.73, 78.43, 
73.35, 72.36, 44.27, 40.65, 39.64, 33.12, 21.35, 18.20, 12.78. HRMS (ES+) calcd for C20H28O3SNa 
[M+Na]+ 371.1561, found 371.1558. IR (thin film) vmax 3411, , 2980, 2957, 2930, 2901, 2869, 2848, 
1853,  1703, 1622, 1514, 1464, 1303, 1247, 1173, 1058, 1022, 1014, 975, 809, 743 cm-1. [𝜶𝜶]25
𝐷𝐷
 (c 0.50, 
CHCl3) -12.2.  
(6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl acetate  
 
To (6S)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl acetate 190 (485 mg, 2.85 mmol) was 
added Strykers reagent solution (8.0 mL, 0.025 m in copper/0.46 m in hydride) and t-BuOH 
(1.20 mL, 12.5 mmol) sequentially. After 3.5 h, the reaction was diluted with pentane (15 mL) 
and passed through a plug of SiO2, eluting with pentane (10 mL) then Et2O (60 mL). The 






















(SiO2, 30% Et2O:PE30-40) to give 42 (118 mg, >15:1 α:β; 141 mg, 1:1 α:β,	62% total) as colourless 
residues.    
The following data is provided for the major α-anomer: 
1H NMR (500 MHz, CDCl3) δ 6.27 (t, J =  5.1 Hz, 1H, H32), 4.35 (q, J = 6.7 Hz, 1H, H36), 2.58 – 
2.47 (m, 2H, H34), 2.44 – 2.38 (m, 1H, H33’), 2.13 – 2.05 ( m, 1H, H33”), 2.11 (s, 3H, Ac CH3), 
1.30 (d, J = 6.7 Hz, 3H, H37). HRMS (ES+) calcd for C8H12O4Na [M+Na]+ 15.0628, found 
195.0625.  




A mixture of 107 (100 mg, 0.29 mmol) and 42 (197 mg, 1.15 mmol) were azeotroped with PhH 
(5 x 10mL), dissolved in THF (10 mL), cannulated onto powdered molecular sieves, and stirred 
for 1 h. The solution was cooled to -78 °C and freshly distilled BF3･Et2O (one drop) added. The 
reaction mixture was stirred for 16 h at -78 °C then quenched by addition of Et3N (0.5 mL). 
Concentration in vacuo and purification by flash column chromatography (SiO2, 40% 
EtOAc:hexanes) afforded the modified C1 – C11 fragment 99 (85 mg, 64%, dr 7:1) as a 
colourless oil.  
Rf (SiO2, 40% EtOAc:PE40-60) 0.5. 1H NMR (500 MHz, CDCl3)* δ 7.25 (d, J = 7.2 Hz, 2H, Ar-H), 
7.20 (d, J = 8.1 Hz, 2H, Ar-H), 5.80 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H, H10), 5.14 (t, J = 5.4 Hz, 1H, 
H32), 4.97 (dd, J = 17.3, 1.6 Hz, 1H, H11'), 4.88 (dd, J = 10.4, 1.5 Hz, 1H, H11''), 4.27 (q, J = 6.7 
Hz, 1H, H36), 3.86 – 3.78 (m, 1H, H3), 3.52 (td, J = 10.6, 4.6 Hz, 1H, H5), 3.08 (td, J = 9.9, 2.9 
Hz, 1H, H7), 2.92 (dd, J = 14.6, 8.3 Hz, 1H, H2''), 2.67 (dd, J = 14.6, 4.7 Hz, 1H, H2'), 2.56 – 2.47 
(m, 1H, H9), 2.49 – 2.41 (m, 2H, H34), 2.35 (s, 3H, Ar-CH3), 2.30 – 2.23 (m, 1H, H33'), 2.14 (ddd, 
J = 12.1, 4.5, 1.9 Hz, 1H, H4''), 1.93 (ddt, J = 14.8, 9.5, 5.6 Hz, 1H, H33''), 1.54 – 1.50 (m, 1H, H8'), 
 
*  NMR spectra were recorded with an internal deuterium lock and referenced to the residual non-
deuterated solvent peak using modified values to allow comparison with the spectral data recorded by 




















1.46 (dd, J = 10.3, 3.0 Hz, 1H, H8''), 1.37 (ddq, J = 9.8, 6.4, 3.4 Hz, 1H, H6), 1.26 (d, J = 6.8 Hz, 
3H, H37), 1.24 – 1.22 (m, 1H, 4') (s, 1H, H4'), 0.94 (d, J = 6.7 Hz, 3H, H29), 0.91 (d, J = 6.5 Hz, 
3H,  H28).  13C NMR (126 MHz, CDCl3) δ 211.24 (C35), 195.78 (C1), 145.44 (C10), 140.00, 134.62, 
130.29, 124.35, 112.00 (C11), 92.59 (C32), 78.87 (C7), 77.44, 77.23, 76.04 (C5), 72.44 (C3), 71.34 
(C36), 49.92 (C2), 42.13 (C6), 39.98 (C8), 36.38 (C4), 33.84 (C34), 33.32 (C9), 28.85 (C33), 21.57, 
18.44 (C29), 15.09 (C37), 13.31 (C28). HRMS (ASAP, +) calcd for C26H37O5S [M+H]+ 461.2356, 
found 461.2349 also C26H40O5SN [M+NH4]+ 478.2622, found 478.2614. IR (thin film) vmax 3011, 
2953, 2889, 2850, 1730, 1708, 1483, 1451, 1449, 1390, 1324, 1221, 1139, 1123, 1109, 1100, 1072, 1053, 
724, 630, 625 cm-1. [𝜶𝜶]25
𝐷𝐷
























NMR data for madeirolide A and the C1 – C11 fragment 99:  
















1 170.9 - - - 195.9 - - - 
2’ 
41.6 
2.45 m - 
49.9 
2.67 dd 14.6, 4.7 
2” 2.58 m - 2.92 dd 14.6, 8.3 
3 74.2 3.80 m - 72.4 3.82 m - 
4’ 
36.2 
1.26 m - 
36.4 
1.23 m - 
4” 2.14 m - 2.14 ddd 12.1, 4,5, 1.9 
5 75.9 3.56 td 10, 4 76.0 3.52 td 10.6, 4.6 
6 42.9 1.32 m - 42.1 1.37 ddq 9.8, 6.4, 3.4 
7 77.9 3.07 td 78.9 78.9 3.08 td 9.9, 2.9 
8’ 
40.5 1.44 m 40.0 40.0 
1.52 m - 
8” 1.46 dd 10.3, 3.0 
9 34.3 2.37 m - 33.3 2.51 m - 
10 142.3 5.48 dd 15, 10 145.4 5.80 ddd 17.2, 10.4, 6.8 
11’ 
122.8 6.24 dd 15, 11 112.0 
4.97 dd 17.3, 1.6 
11” 4.88 dd 10.4, 1.5 
28 13.0 0.90 d 7 13.3 0.91 d 6.5 
29 18.0 0.85 d 7 18.4 0.94 d 6.7 
32 92.6 5.15 t 6 92.6 5.15 t 5.4 
33’ 
28.8 
1.93 m - 
28.9 
1.93 ddt 14.8, 9.5, 5.6 
33” 2.28 m - 2.36 m - 
34 33.8 2.46 m - 33.8 2.45 m - 
35 211.0 - - - 211.2 - - - 
36 71.5 4.26 q 7 71.3 4.27 q 6.7 











EXPERIMENTAL PROCEDURES FOR THE EASTERN FRAGMENT OF 
MADEIROLIDE A  
COMPOUNDS TOWARDS THE THF 
5-(benzyloxy)-2-methylpent-1-en-3-one  
 
To a solution of DMSO (1.38 mL, 19.4 mmol) in CH2Cl2 (5 mL) at -78°C was added (COCl)2 
(0.83 mL, 9.70 mmol). After stirring for 15 min, a solution of (±)-5-(benzyloxy)-2-methylpent-
1-en-3-ol (1.00 g, 4.85 mmol) in CH2Cl2 (5 mL) was added. The reaction mixture was stirred 
for 30 min then Et3N (4.50 mL, 29.1 mmol) was added. The reaction mixture was stirred for 
10 min at -78 °C then warmed to rt before being quenched by addition of H2O (50 mL). The 
layers were  separated and the aqueous phase extracted with Et2O (3 x 50 mL) before the 
combined organic extracts were dried (Na2SO4), concentrated in vacuo and purified by flash 
column chromatography (SiO2, 5% EtOAc:PE40-60) to give ketone 218 (860 mg, 87%) as a 
colourless oil.   
Rf (SiO2, 30% EtOAc:PE40-60) 0.6. 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.28 (m, 5H, Ar-H), 6.01 
(s, 1H, H17’), 5.83 (s, 1H, H17”), 4.56 (s, 2H, -O-CH2-Ar), 3.83 (t, J = 6.5 Hz, 2H, H13), 3.04 (t, J 
= 6.5 Hz, 2H, H14), 1.91 (s, 3H, H30). 13C NMR (126 MHz, CDCl3) δ 200.05, 144.76, 138.34, 
128.51, 127.83, 125.29, 73.42, 65.92, 37.92, 17.61. HRMS (ES+) calcd for C13H17O2 [M+H]+ 
205.1223, found 205.1221. IR (thin film, vmax) 3540, 2933, 1700, 1453, 1365, 1274, 1204, 1099, 
1073, 1004, 743.  
 (R)-5-(benzyloxy)-2-methylpent-1-en-3-ol  
  
 
(S)-CBS catalyst (0.25 mL, 1 m soln in PhMe, 0.250 mmol) was added to a solution of enone 
218 (691 mg, 3.38 mmol) in THF (5 mL) at  -78 °C. BH3･DMS (0.64 mL, 6.74 mmol) was added 




















being quenched by addition of MeOH (5mL). The solution was warmed to rt and concentrated 
in vacuo. The resulting residue was redissolved in MeOH (10 mL) and concentrated in vacuo 
– this procedure was repeated five times. Purification by flash column chromatography (SiO2, 
25% EtOAc:PE40-60) afforded allylic alcohol 206 (592 mg, 89%, er 97:3) as a pale-yellow oil.  
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H, Ar-H), 5.05 – 4.98 (m, 1H, H17’), 4.90 – 4.81 
(m, 1H, H17”), 4.52 (s, 2H, -O-CH2-Ar), 4.26 (dd, J = 7.3, 4.3 Hz, 1H, H15), 3.70 (ddd, J = 9.4, 
6.3, 5.0 Hz, 1H, H13’), 3.63 (ddd, J = 9.4, 7.0, 5.0 Hz, 1H, H13”), 1.86 (m, 2H, H14), 1.73 (s, 3H, 
H30). HRMS (ES+) calcd for  C13H19O2 [M+H]+ 207.1380, found 207.1379. Chiral HPLC 
(Chiralpak-IA, 2% i-PrOH:n-hex, 1 μL/min) Rt (major) = 12.2 min, Rt (major) = 13.1 min, er 97:3. 
[𝜶𝜶]25
𝐷𝐷
 (c 1.05, CHCl3) +5.9 (lit. -5.54 for ent-206).*  
Data consistent with that reported in the literature.125 
(R)-5-(benzyloxy)-2-methylpent-1-en-3-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate  
 
The (R)-MTPA ester S-1 was prepared from  206 (3.1 mg, 0.015 mmol) following general 
procedure A and purified by flash column chromatography (SiO2, 0 ⟶	10% EtOAc:PE40-60) to 
give (R)-MTPA ester S-1 (4.9 mg, 77%) as a colourless residue.   
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.27 (m, 10H, Ar-H), 5.63 (dd, J = 8.5, 5.2 Hz, 1H, H15), 
5.12 – 5.05 (m, 1H, H17'), 5.01 – 4.92 (m, 1H, H17''), 4.45 – 4.34 (m, 2H, -O-CH2-Ar), 3.51 (s, 3H, 
MTPA O-CH3), 3.44 – 3.28 (m, 2H, H13), 2.07 – 1.95 (m, 2H, H14), 1.74 (s, 3H, H30). HRMS 
(ES+) calcd for  C23H29F3O4N [M+NH4]+ 440.2043, found 440.2034.  
(R)-5-(benzyloxy)-2-methylpent-1-en-3-yl (S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate  
 
 






















(S)-MTPA ester S-2 was prepared from  206 (3.1 mg, 0.015 mmol) following general procedure 
A and purified by flash column chromatography (SiO2, 0 ⟶	10% EtOAc:PE40-60)  to give (S)-
MTPA ester S-2 (5.2 mg, 81%) as a colourless residue.  
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 2H, Ar-H), 7.44 – 7.41 (m, 1H, Ar-H), 7.40 – 7.27 
(m, 7H, Ar-H), 5.58 (dd, J = 8.3, 5.4 Hz, 1H, H15), 5.00 – 4.96 (m, 1H, H17'), 4.94 – 4.90 (m, 1H, 
H17''), 4.47 (s, 2H, -O-CH2-Ar), 3.49 (s, 3H, MTPA O-CH3), 3.49 – 3.43 (m, 2H, H13), 2.08 – 
1.92 (m, 2H, H14), 1.61 (s, 3H, H30). HRMS (ES+) calcd for  C23H29F3O4N [M+NH4]+ 440.2043, 
found 440.2033.   
Proton  δS-MTPA δR-MTPA δ(S-R) 
 13  3.47 3.36 +0.38 
14  2.05 2.03 +0.02 
15  5.58 5.63 -0.05 
17’  4.98 5.08 -0.10 
17”  4.92 4.98 -0.06 
30  1.61 1.74 -0.13 
Chemical shifts are taken as the midpoint of multiplets for the purpose of the MTPA analysis.  
 
6.3.1 COMPOUNDS TOWARDS THE THP  
Dimethyl (4R,5R)-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate  
 
To a solution of l-(+)-dimethyltartrate (15.0 g, 84.2 mmol) in CH2Cl2 (170 mL) was added 2,2-
dimethoxypropane (20.0 mL, 168 mmol) and p-TsOH (8.00 g, 42.1 mmol). The reaction 
mixture was heated under reflux for 72 h before being diluted with H2O (200 mL) and the 
layers separated. The organic layer was dried (Na2SO4), concentrated in vacuo and purified by 
flash column chromatography (SiO2, 30 ⟶ 70% EtOAc:PE40-60) to give 242 (7.31 g, 60%) as a 
yellow oil.  
1H NMR (500 MHz, CDCl3) δ 4.77 (s, 2H, CH), 3.78 (s, 6H, O-CH3), 1.45 (s, 6H, C(CH3)2). 13C 
NMR (125 MHz, CDCl3) δ 170.11, 113.90, 77.04, 52.86, 26.35. HRMS (ES+) calcd for  C9H14O6Na 














Data consistent with that reported in the literature.170 
(1S,1'S)-1,1'-((4S,5S)-2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(prop-2-en-1-ol)  
  
To a solution of 242 (1.00 g, 4.58 mmol) in PhMe (12 mL) at -78 °C was added DIBAL (9.16 
mL, 1 m soln in hexane, 0.92 mmol) dropwise. The reaction mixture was stirred for 3 h at  -78 
°C  before a solution of divinyl zinc (40.0 mL, 0.3 m soln in THF, 12.0 mmol) was added 
dropwise. The reaction mixture was warmed to rt and stirred for 18 h before the addition of 
NH4Cl (30 mL), Na/K tartrate (30 mL) and EtOAc (50 mL) sequentially. The layers were 
separated and the aqueous phase extracted with EtOAc (3 x 50 mL) before the combined 
organics dried (Na2SO4), concentrated in vacuo and purified by flash column chromatography 
(SiO2, 30% EtOAc:PE40-60) to give 244 (590 mg, 60%, dr 11:1) as a viscous yellow oil.  
The following data was collected for the major diastereomer:   
1H NMR (500 MHz, CDCl3) δ 5.99 (ddd, J = 17.2, 10.5, 6.0 Hz, 2H, H21), 5.39 (dt, J = 17.3, 1.5 
Hz, 2H, H20’), 5.29 (dt, J = 10.5, 1.4 Hz, 2H, H20”), 4.25 – 4.15 (m, 2H, H22), 3.95 – 3.86 (m, 
2H, H23), 2.58 (s, 2H, OH), 1.41 (s, 6H, C(CH3)2). HRMS (ES+) calcd. for C11H22O4N [M+NH4]+ 
232.1543, found 232.1547.  




To a solution of 244 (100 mg, 0.47 mmol) in CH2Cl2 (5 mL) was added TBSOTf (200 µL, 1.12 
mmol) and 2,6-lutidine (160 µL, 1.40 mmol) sequentially. The reaction mixture was stirred at 
rt for 1.5 h then quenched by addition of NaHCO3 (5 mL). The layers were separated and the 
aqueous phase extracted with CH2Cl2 (3 x 5 mL) before the combined organics dried (Na2SO4), 
concentrated in vacuo, and purified by flash column chromatography (SiO2, 5% EtOAc:PE40-
















Rf (SiO2, 10% EtOAc:PE40-60) 0.7. 1H NMR (500 MHz, CDCl3) δ 5.87 (ddd, J = 17.1, 10.4, 6.5 Hz, 
1H, H21), 5.23 (d, J = 17.1 Hz, 1H, H20'), 5.19 (d, J = 10.4 Hz, 1H, H20''), 4.23 (d, J = 6.5 Hz, 1H, 
H22), 3.96 (s, 1H, H23), 1.38 (s, 3H, C-CH3), 0.91 (s, 9H, Si-C(CH3)3), 0.08 (s, 3H, Si-CH3), 0.04 
(s, 3H, Si-CH3). 13C NMR (126 MHz, CDCl3) δ 138.04, 116.78, 109.18, 80.77, 74.42, 27.79, 26.17, 
18.48, -4.06, -4.36. HRMS (ES+) calcd. for C23H50O4Si2N [M+NH4]+ 460.3273, found 460.3271. 
IR (thin film, vmax) 2899, 2875, 2164, 1640, 1300, 1294, 1241, 1235, 1200, 1164, 1076, 924, 725, 
643 cm-1.  [𝜶𝜶]25
𝐷𝐷
 (c 1.00, CHCl3) -30.9. 
 (4S,5S)-4,5-bis((S)-1-(benzyloxy)allyl)-2,2-dimethyl-1,3-dioxolane 
 
NaH (34.0 mg, 60% dispersion in mineral oil, 1.40 mmol) was added to a solution of diol 244 
(100 mg, 0.467 mmol) in THF (5 mL) at 0 °C. The reaction mixture was stirred for 30 min 
before BnBr (0.16 mL, 1.40 mmol) and TBAI (8 mg, 0.023 mmol) were added sequentially and 
the reaction warmed to rt. The reaction mixture was stirred for a further 18 h then 
concentrated in vacuo and purified by flash column chromatography (SiO2, 10% EtOAc:PE40-
60) to give 252 (156 mg, 85%) as a yellow oil.  
Rf (SiO2, 10% EtOAc:PE40-60) 0.5. 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.19 (m, 5H, Ar-H), 5.83 
(ddd, J = 17.4, 10.4, 8.0 Hz, 1H, H21), 5.35 (dd, J = 10.4, 1.8 Hz, 1H, H20'), 5.23 (dd, J = 17.3, 1.8 
Hz, 1H, H20''), 4.60 (d, J = 12.0 Hz, 1H, Ar-O-CH’2), 4.34 (d, J = 12.1 Hz, 1H, Ar-O-CH”2), 3.98 
(dd, J = 2.9, 1.5 Hz, 1H, H22), 3.89 – 3.81 (m, 1H, H23), 1.36 (s, 3H, C(CH3)2). 13C NMR (126 
MHz, CDCl3) δ 138.26, 134.67, 128.43, 128.02, 127.67, 120.44, 110.10, 81.13, 80.44, 70.38, 27.20. 
HRMS (ES+) calcd for C25H34O4N [M+NH4]+ 412.2482, found 412.2475.  IR (thin film, vmax)  
2891, 1642, 1369, 1243, 1217, 1213, 1164, 1076, 924 cm-1. [𝜶𝜶]25
𝐷𝐷
 (c 1.00, CHCl3) +29.9 
(3S,4R,5R,6S)-3,6-bis(benzyloxy)octa-1,7-diene-4,5-diol 
 
To a solution of 252 (40.0 mg, 0.101 mmol) in MeOH (2 mL) was added HCl (1 mL, 12 m aq., 12 
mmol) and the reaction mixture stirred at 35 °C for 3 h then rt for 1 h. NaHCO3 (20 mL) was 
















organics were dried (Na2SO4), concentrated in vacuo, and purified by flash column 
chromatography (SiO2, 20% EtOAc:PE40-60) to give diol 253 (22 mg, 60%).  
Rf (SiO2, 30% EtOAc:PE40-60) 0.3. 1H NMR (400 MHz, CDCl3) δ 7.39 – 7.27 (m, 5H, Ar-H), 5.84 
(ddd, J = 17.1, 10.6, 7.3 Hz, 1H, H21), 5.44 – 5.30 (m, 2H, H20), 4.64 (d, J = 11.5 Hz, 1H, Ar-O-
CH’2), 4.39 (d, J = 11.5 Hz, 1H, Ar-O-CH’2), 4.11 – 4.00 (m, 1H, H22), 3.94 – 3.79 (m, 1H, H23), 
2.98 (d, J = 5.5 Hz, 1H, C23-OH). 13C NMR (126 MHz, CDCl3) δ 138.10, 134.00, 128.49, 128.03, 
127.98, 120.90, 81.51, 73.27, 71.82. HRMS (ES+) calcd for C25H34O4N [M+NH4]+ 412.2482, found 
412.2475. IR (thin film, vmax)  3510 (br), 3021, 2820, 1945, 1864,  1840, 1808, 1622, 1449, 1372, 
895, 760, 690 cm-1.  [𝜶𝜶]25
𝐷𝐷
 (c 1.00, CHCl3) +25.1  
(S)-2-(benzyloxy)but-3-enal 
 
To a solution of diol 253 (10 mg, 0.028 mmol) in CH2Cl2 (1 mL) was added NaIO4/SiO2 (30 mg) 
and pH 4 buffer (0.05 mL). The reaction mixture was stirred for 1 h before being filtered 
through a plug of cotton wool and concentrated in vacuo to give a colourless oil (7.3 mg, ca. 
73%).  
The following data was obtained from the crude product:  
1H NMR (400 MHz, CDCl3) δ 10.02 (s, 1H, CHO), 7.43 – 7.11 (m, 5H, Ar-H), 6.16 (ddd, J = 16.5, 
10.3, 6.2 Hz, 1H, H21), 5.32 – 5.06 (m, 2H, H20), 4.90 (d, J = 6.3 Hz, 1H, H22), 4.47 (d, J = 11.8 
Hz, 1H, Ar-O-CH2’), 4.07 (d, J = 11.8 Hz, 1H, Ar-O-CH2”). HRMS (ES+) calcd for C11H12O2 
[M+H]+ 177.0910, found 177.0919.   
dimethyl (2R,3R)-1,4-dioxaspiro[4.4]nonane-2,3-dicarboxylate 
 
To a solution of l-(+)-dimethyltartrate (10 g, 57.1 mmol) in PhMe (120 mL) was added 
cyclopentanone (22 mL, 261 mmol) and 10-(±)-CSA (1.10 g, 4.74 mmol). The reaction mixture 
was heated under reflux for 5 h, during which time the liberated H2O was removed by 



















separated. The organic phase was dried (MgSO4), concentrated in vacuo and purified by flash 
column chromatography (SiO2, 10% EtOAc:PE40-60) to give cyclopentylidene acetal 248 (2.6 g, 
19%) as a colourless oil. The remaining mass was accounted for by recovered l-(+)-
dimethyltartrate.  
Rf (SiO2, 10% EtOAc:PE40-60) 0.2. 1H NMR (500 MHz, CDCl3) δ 4.78 (s, 1H, H23), 4.14 – 3.43 
(m, 3H, O-CH3), 2.05 – 1.93 (m, 1H, Ha’), 1.92 – 1.82 (m, 1H, Ha”), 1.77 – 1.68 (m, 2H, Hb). 13C 
NMR (126 MHz, CDCl3) δ 170.03, 123.18, 76.80 (obscured by CDCl3), 52.78, 38.34, 23.45. 
HRMS (ES+) calcd for C11H17O6 [M+H]+ 245.1020, found 245.1018. IR (thin film, vmax) 2958, 
2876, 1760, 1741, 1437, 1338, 1206, 1125, 973, 867 cm-1.  [𝜶𝜶]25
𝐷𝐷
 (c 1.06, CHCl3) -28.1.  
(1S,1'S)-1,1'-((2S,3S)-1,4-dioxaspiro[4.4]nonane-2,3-diyl)bis(prop-2-en-1-ol) 
 
To a solution of 248 (2.00 g, 8.19 mol) in PhMe (24 mL) at -78 °C was added DIBAL (16.3 mL, 
1 m soln in hexane, 16.3 mmol) dropwise. The reaction mixture was stirred for 5 h at  -78 °C  
before a solution of divinyl zinc (80 mL, 0.3 m soln in THF, 24.0 mmol) was added dropwise. 
The reaction mixture was warmed to rt and stirred for 2 h before the addition of NH4Cl (70 
mL), Na/K tartrate (30 mL) and EtOAc (50 mL) sequentially. The layers were separated and 
the aqueous phase extracted with EtOAc (3 x 150 mL) before the combined organics dried 
(Na2SO4), concentrated in vacuo and purified by flash column chromatography (SiO2, 10 ⟶ 
50% EtOAc:PE40-60) to give 250 as a pale-yellow oil (1.56 g, 79%, dr 8:1).  
The following data was collected for the major diastereomer:   
Rf (SiO2, 30% EtOAc:PE40-60) 0.15. 1H NMR (500 MHz, CDCl3) δ 5.98 (ddd, J = 17.3, 10.5, 5.9 
Hz, 1H, H21), 5.38 (dd, J = 17.3, 1.5 Hz, 1H, H20'), 5.28 (dd, J = 10.5, 1.5 Hz, 1H, H20''), 4.20 – 
4.10 (m, 1H, H23), 3.92 – 3.81 (m, 1H, H22), 1.89 – 1.81 (m, 1H, Ha'), 1.80 – 1.72 (m, 1H, Ha''), 1.71 
– 1.60 (m, 2H, Hb). 13C NMR (126 MHz, CDCl3) δ 137.13, 119.76, 117.22, 81.46, 73.62, 37.42, 
23.66. HRMS (ES+) calcd for C13H20O4Na [M+Na]+ 263.1254, found 263.1254. IR (thin film, 
vmax) 3412, 2960, 2880, 2873, 1645, 1433, 1336, 1205, 994, 926 cm-1.  [𝜶𝜶]
25
𝐷𝐷
















To a solution of 250 (250 mg, 1.04 mmol) in CH2Cl2 (12 mL) at -78 °C was added TBSOTf 
(0.079 mL, 3.12 mmol) and 2,6-lutidine (0.48 mL, 4.16 mmol) sequentially. The reaction 
mixture was warmed to rt and stirred for 6 h then MeOH (1 mL) added and the solvent 
removed in vacuo. Purification by flash column chromatography (SiO2, 10% EtOAc:PE40-60) to 
afford 251 (410 mg, 84%) as a colourless oil.  
Rf (SiO2, 5% EtOAc:PE40-60) 0.2. 1H NMR (400 MHz, CDCl3) δ 5.87 (ddd, J = 17.1, 10.4, 6.7 Hz, 
1H, H21), 5.27 – 5.18 (m, 2H, H20), 4.18 – 4.12 (m, 1H, H23), 3.95 (dd, J = 3.9, 1.3 Hz, 1H, H22), 
1.79 (td, J = 6.5, 5.9, 2.4 Hz, 2H, Ha), 1.69 – 1.61 (m, 2H, Hb), 0.91 (s, 9H, Si-C(CH3)3), 0.08 (s, 
3H, Si-CH3), 0.04 (s, 3H, Si-CH3). 13C NMR (126 MHz, CDCl3) δ 138.41, 119.39, 116.53, 80.90, 
74.11, 38.20, 25.93, 23.51, 18.22, -4.13, -4.62. HRMS (ES+) calcd for C25H52O4Si2N [M+NH4]+ 
486.3249, found 486.3420. IR (thin film, vmax) 2910, 2896,  2870, 2159, 2143, 1640, 1309, 1290, 
1288, 1241, 1225, 1160, 1101, 1075, 924 cm-1.  		[𝜶𝜶]25
𝐷𝐷
(c 1.00, CHCl3) +18.3 
[All of the intermediates in this section are in the opposite enantiomeric series to the natural 
product due to the availability of (S)-ethyl lactate] 
ethyl (S)-2-((tert-butyldimethylsilyl)oxy)propanoate  
 
To a solution of ethyl (S)-2-hydroxypropanoate (31.0 g, 262 mmol) in CH2Cl2 (1000 mL) was 
added TBSCl (56.0 g, 372 mmol) and imidazole (26.0 g, 382 mmol) sequentially. The reaction 
mixture was stirred for 18 h before being filtered through a plug of SiO2 and concentrated in 
vacuo to give 238 as a colourless oil (90.4 g, 95%) which was used without additional 
purification.  
An analytical sample was purified by flash column chromatography (SiO2, 10% EtOAc:PE40-60) 

















Rf (SiO2, 10% EtOAc:PE40-60) 0.35. 1H NMR (500 MHz, CDCl3) δ 4.33 (q, J = 6.7 Hz, 1H, H26), 
4.28 – 4.13 (m, 2H, OCH2), 1.42 (d, J = 6.8 Hz, 3H, H27), 1.30 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.93 
(s, 9H, Si-C(CH3)3), 0.16 (s, 3H, Si-CH3),  0.05 (s, 3H, Si-CH3). 13C NMR (126 MHz, CDCl3) δ 
174.06, 68.40, 60.60, 25.72, 21.20, 18.25, 14.39, -4.60. HRMS (ES+) calcd. for C11H25O3Si [M+H]+ 
233.1567, found 233.1567. IR (thin film, vmax) 1732, 1730, 1455, 1310, 1211, 1093, 965, 801 cm-
1.[𝜶𝜶]25
𝐷𝐷
 (c 1.00, CHCl3) -23.1. 
(S)-3-oxopentan-2-yl benzoate  
 
To a suspension of 238 (10.0 g, 43.0 mmol) and N,O-dimethylhydroxylamine hydrochloride 
(4.40 g, 45.1 mmol) in THF (200 mL) at 0 ºC was added i-PrMgCl (44.0 mL of a 2.2 m solution 
in THF, 96.8 mmol) dropwise. The reaction mixture was stirred at 0 ºC for 2 h then cooled to 
-20 ºC and EtMgBr (40.0 mL of a 2.3 M solution in Et2O, 92.1 mmol) added dropwise. The 
reaction mixture was warmed rt and stirred for 18 h then quenched by cautious addition of 
NH4Cl (150 mL), extracted with EtOAc (3 x 150 mL), dried (MgSO4) and concentrated in 
vacuo to give (S)-2-((tert-butyldimethylsilyl)oxy)pentan-3-one. This material was used crude 
in the subsequent step.  
To a solution of the crude (S)-2-((tert-butyldimethylsilyl)oxy)pentan-3-one (13 g) in THF 
(200 mL) was added TBAF (80.0 mL of a 1.0 m solution in THF, 80.0 mmol). The reaction 
mixture was stirred for 10 min before the sequential addition of Bz2O (20.0 g, 88.4 mmol), 
Et3N (12.0 mL, 86.1 mmol) and DMAP (cat.). After 18 h, NaHCO3 (250 mL) was added and the 
reaction extracted with EtOAc (5 x 200 mL). The combined organic extracts were dried 
(Na2SO4) and concentrated in vacuo. Purification by flash column chromatography (SiO2, 20% 
EtOAc:PE40-60) afforded 200 (7.25 g, 82% over two steps) as a colourless oil.  
1H NMR (500 MHz, CDCl3) δ 8.12 – 8.03 (m, 2H, Ph-H), 7.63 – 7.56 (m, 1H, Ph-H), 7.51 – 7.41 
(m, 2H, Ph-H), 5.36 (q, J = 7.0 Hz, 1H, H26), 2.66 (dq, J = 18.3, 7.3 Hz, 1H, H24''), 2.53 (dq, J = 
18.3, 7.3 Hz, 1H, H24'), 1.53 (d, J = 7.1 Hz, 3H, H27), 1.10 (t, J = 7.3 Hz, 3H, H31). HRMS (ES+) 
calcd for C12H15O3 [M+H]+ 207.1016, found 207.1014.  














 (2S,4R,5R)-5-hydroxy-4-methyl-3-oxohept-6-en-2-yl benzoate  
 
(S)-3-oxopentan-2-yl benzoate (S)-200 (4.50 g, 21.8 mmol) in Et2O (10 mL) was added to a 
colourless solution of Cy2BCl (4.6 mL) and Et3N (4.0 mL) in Et2O (40 mL) at 0 ºC. The mixture 
was held at this temperature for 2 h before being cooled to -78 ºC and acrolein (6.0 mL, 89.9 
mmol) added dropwise. Upon complete addition the reaction was warmed to -20 ºC and held 
at this temperature for 36 h before the addition of MeOH (20 mL), pH 7 buffer (10 mL) and 
H2O2 (2 mL, 30% aq.). The layers were separated and the aqueous phase extracted with Et2O 
(5 x 50 mL), with the combined organics dried (Na2SO4), filtered, and concentrated in vacuo. 
Sequential purification by flash column chromatography (SiO2, 10 ⟶  20% EtOAc: PE40-60) 
and recrystallisation (hexanes:Et2O) afforded 263 (4.75 g, 85%) as white needle-like crystals.  
Rf (SiO2, 20% EtOAc:PE40-60) 0.2. 1H NMR (400 MHz, CDCl3) δ 8.13 – 8.04 (m, 2H, Ph-H), 7.65 
– 7.54 (m, 1H, Ph-H), 7.52 – 7.41 (m, 2H, Ph-H), 5.84 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H, H22), 5.44 
(q, J = 7.0 Hz, 1H, H26), 5.31 (dt, J = 17.1, 1.4 Hz, 1H, H21'), 5.22 (dt, J = 10.4, 1.2 Hz, 1H, H21''), 
4.33 – 4.22 (m, 1H, H23), 3.00 – 2.86 (m, 1H, H24), 2.36 (d, J = 5.3 Hz, 1H, OH), 1.57 (d, J = 7.1 
Hz, 3H, H27), 1.23 (d, J = 7.2 Hz, 3H, H31). 13C NMR (125MHz, CDCl3) δ 211.10, 165.85, 138.25, 
133.36, 129.81, 129.46, 128.47, 117.17, 75.15, 74.78, 35.56, 15.69, 14.40. HRMS (ES+) calcd for 
C15H19O4 [M+H]+ 263.1278, found 263.1274. IR (thin film, vmax) 3345, 3110, 1813, 1732, 1727, 1718, 
1430, 1377,  1104, 990, 905 cm-1. [𝜶𝜶]25
𝐷𝐷
  (c 1.00, CHCl3) +24.8. mp  122 ºC dec. 
(2S,4R,5R)-4-methyl-3-oxo-5-(((R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)hept-6-
en-2-yl benzoate  
 
(R)-MTPA ester S-3 was prepared from aldol adduct 263 (5 mg, 19 µmol) following general 
procedure A  to give (R)-MTPA ester S-3 (4 mg, 43%) as a white solid which was used crude 
in the MTPA analysis without additional purification. 
1H NMR (500 MHz, CDCl3) δ	8.07 – 8.00 (m, 2H, Ar-H), 7.62 – 7.55 (m, 1H, Ar -H), 7.49 – 7.41 
























(m, 1H, H23) , 5.55 (dd, J = 16.6, 1.2 Hz, 1H, H21’), 5.45 (dd, J = 9.9, 1.3 Hz, 1H, H21”), 5.20 (q, 
J = 7.0 Hz, 1H, H26), 3.52 (s, 3H, MTPA O-CH3), 3.11 – 3.02 (m, 1H, H24), 1.17 (d, J = 7.2 Hz, 
3H, H27), 1.15 (d, J = 7.0 Hz, 3H, H31). HRMS (ES+) calcd for C25H26F3O6 [M+H]+ 479.1676, 




(S)-MTPA ester S-4 was prepared following an analogous procedure to (R)-MTPA ester S-3 
using the enantiomeric MTPA acid to give S-4 (7mg, 80%) as a white solid which was used 
crude in the MTPA analysis without additional purification.  
1H NMR (500 MHz, CDCl3) δ 8.08 – 8.01 (m, 2H, Ph-H), 7.59 (ddt, J = 8.8, 7.4, 1.3 Hz, 1H, Ph-
H), 7.49 – 7.44 (m, 2H, Ph-H), 7.41 – 7.35 (m, 5H, MTPA Ph-H), 5.73 (ddd J = 16.7, 9.9, 8.1,  
H22), 5.71 – 5.65 (m, 1H, H23), 5.47 (dd, J = 16.6, 1.3 Hz, 1H, H21’), 5.41 (dd, J = 9.9, 1.3 Hz, 1H, 
H21”), 5.34 (q, J = 7.1 Hz, 1H, H26), 3.43 (s, 3H, MTPA O-CH3), 3.10 – 3.04 (m, 1H, H24), 1.35 
(d, J = 7.1 Hz, 3H, H27), 1.21 (d, J = 7.2 Hz, 3H, H31). HRMS (ES+) calcd for C25H26F3O6 [M+H]+ 
479.1676, found 479.1679.  
Proton  δS-MTPA δR-MTPA δ(S-R) 
 21’  5.47 5.55 -0.08 
21”  5.41 5.45 -0.04 
22  5.73 5.65 +0.08 
23  5.68 5.61 +0.07 
24  3.07  3.07 0.00 
31  1.21 1.15 +0.06 
26  5.34 5.20 +0.14 






















Aldol adduct 263 (1.90 g, 7.24 mmol) in MeCN (5 mL) was added to a solution of 
Me4NBH(OAc)3 (9.50 g, 36.2 mmol) in MeCN (10 mL) and AcOH (15 mL) at -30 ºC. The 
reaction mixture was stirred at -30 ºC for 24 h then quenched by inverse addition into cold 
NaHCO3 (100 mL). EtOAc (100 mL) was added and the layers separated before the aqueous 
phase extracted with EtOAc (3 x 100 mL). The combined organics were dried (Na2SO4) and 
concentrated in vacuo to afford 267 (1.55 g) as a crude residue which was used directly in the 
subsequent reaction without additional purification.  
An analytical sample was purified by flash column chromatography (SiO2, 2% MeOH:CH2Cl2 
+ 0.1% AcOH) to provide the following data:  
1H NMR (400 MHz, CDCl3) δ 8.14 – 7.99 (m, 2H, Ar-H), 7.63 – 7.51 (m, 1H, Ar-H), 7.50 – 7.37 
(m, Ar-H), 5.93 (ddd, J = 17.1, 10.5, 5.8 Hz, 1H, H22), 5.40 – 5.31 (m, 1H, H21'), 5.27 – 5.21 (m, 
1H, H21''), 5.26 – 5.18 (m, 1H, H26), 4.21 – 4.15 (m, 1H, H25), 4.15 – 4.07 (m, 1H, H23), 1.84 – 
1.73 (m, 1H, H24), 1.32 (d, J = 6.4 Hz, 3H, H27), 1.07 (d, J = 7.1 Hz, 3H, H31). HRMS (ES+) calcd 
for C15H20O4Na [M+Na]+ 287.1254, found 287.1251.  
(S)-1-((4S,5R,6R)-2,2,5-trimethyl-6-vinyl-1,3-dioxan-4-yl)ethyl benzoate  
 
To a solution of diol 267 (1.55 g crude) in Me2C(OMe)2  (20.0 mL, 163 mmol) and CH2Cl2 (100 
mL) was added p-TsOH (20 mg, 0.105 mmol). The reaction mixture was stirred for 18 h then 
diluted with H2O and the layers separated. The aqueous phase was extracted with CH2Cl2 (3 
x 150 mL) and the combined organics dried (MgSO4), concentrated in vacuo and purified by 
flash column chromatography (SiO2, 5 ⟶  10% EtOAc: PE40-60) to afford 262 (1.9 g, 86% over 
two steps) as a colourless oil.  
Rf (SiO2, 10% EtOAc:PE40-60) 0.4. 1H NMR (400 MHz, CDCl3) δ 8.07 – 7.97 (m, 2H, Ph-H), 7.59 
– 7.51 (m, 1H, Ph-H), 7.44 (dd, J = 8.2, 7.0 Hz, 2H, Ph-H), 5.90 (ddd, J = 17.1, 10.4, 6.5 Hz, 1H, 




















(dd, J = 9.0, 4.7 Hz, 1H, H25), 3.79 (ddt, J = 7.7, 6.6, 1.2 Hz, 1H, H23), 1.94 – 1.82 (m, 1H, H24), 
1.39 (s, 3H, C(CH3)2), 1.35 (s, 2H, C(CH3)2), 1.33 (d, J = 6.3 Hz, 3H, H27), 1.00 (d, J = 6.7 Hz, 3H, 
H31). 13C NMR (126 MHz, CDCl3) δ 166.16, 137.31, 132.84, 130.96, 129.68, 128.40, 116.07, 101.42, 
76.73, 71.59, 70.36, 37.91, 24.63, 24.11, 16.61, 11.39. HRMS (ES+) calcd for C17H24O4Na [M+Na]+ 
327.1567, found 327.1567.  IR (thin film, vmax) 3327, 3112, 1735, 1729, 1633, 1415, 1233,  987, 950, 
943, 939, 908, 880, 754 cm-1. [𝜶𝜶]25
𝐷𝐷
  (c 0.50, CHCl3) +6.2 
(2S,3S,4S,5R)-5-acetoxy-3-hydroxy-4-methylhept-6-en-2-yl benzoate 
 
SmI2 (6 mL, 0.1 m in THF, 0.6 mmol) was added to a solution of MeCHO (3 mL, 53.5 mmol)  in 
THF (70 mL) at -50 ºC. The reaction mixture was stirred at – 50 ºC for 15 min then cooled to 
-78 ºC and a solution of 263 (1.50 g, 5.71 mmol) in THF (10 mL) added dropwise. The reaction 
mixture was stirred at -78 ºC for 2 h, then 15 h at -50 ºC. The reaction was quenched by 
addition of NH4Cl (60 mL), diluted with EtOAc (100 mL), and the layers separated. The 
aqueous phase was extracted with EtOAc (3 x 100 mL), dried (MgSO4), and concentrated in 
vacuo to give S-5 (1.32 g, dr >20:1) as a white semi-solid. The crude product was used directly 
in the subsequent reaction without additional purification owing to observed migration of the 
O23 acetate.   
The following data was collected on the crude material:  
1H NMR (400 MHz, CDCl3) δ 8.05 (dd, J = 8.3, 1.4 Hz, 2H, Ar-H), 7.62 – 7.51 (m, 1H, Ar-H), 
7.45 (dd, J = 8.3, 7.0 Hz, 2H, Ar-H), 5.79 (ddd, J = 17.0, 10.4, 7.4 Hz, 1H, H22), 5.37 – 5.25 (m, 
3H, 26, H21), 5.25 – 5.16 (m, 1H, H23), 3.82 (dd, J = 6.4, 3.6 Hz, 1H, H25), 2.11 (s, 3H, Ac CH3), 
1.96 – 1.83 (m, 1H, H24), 1.33 (d, J = 6.4 Hz, 3H, H27), 0.96 (d, J = 7.0 Hz, 3H, H31). HRMS 
(ES+) calcd for C17H23O5 [M+H]+ 307.1540, found 307.1541.  
The position of the acetate was inferred based on the change in chemical shift of H23 in S-5 






















To a solution of S-5 (500 mg, crude) in THF (20 mL) was added TESOTf (0.54 mL, 2.40 mmol) 
and 2,6-lutidine (0.56 mL, 4.80 mmol) sequentially. The reaction mixture was stirred for 18 h 
then H2O (50 mL) and EtOAc (100 mL) added. The layers were separated and the aqueous 
phase extracted with EtOAc (3 x 100 mL).   The combined organics were dried (Na2SO4), 
concentrated in vacuo and purified by flash column chromatography (SiO2, 5% EtOAc:PE40-
60) to afford 304 (562 mg, 62% over two steps) as a pale-yellow oil.  
Rf (SiO2, 10% EtOAc:PE40-60) 0.7. 1H NMR (500 MHz, CDCl3) δ 8.08 (dd, J = 8.3, 1.4 Hz, 2H, 
Ar-H), 7.58 (ddt, J = 8.7, 7.0, 1.3 Hz, 1H, Ar-H), 7.47 (t, J = 7.8 Hz, 2H, Ar-H), 5.70 (ddd, J = 
17.4, 10.4, 7.2 Hz, 1H, H22), 5.30 – 5.26 (m, 1H, H21'), 5.23 (ddd, J = 10.4, 1.5, 0.8 Hz, 1H, H21''), 
5.21 – 5.15 (m, 1H, H26), 5.14 – 5.10 (m, 1H, H23), 4.04 (dd, J = 6.5, 2.4 Hz, 1H, H25), 2.03 (s, 
3H, Ac CH3), 2.02 – 1.96 (m, 1H, H24), 1.33 (d, J = 6.5 Hz, 3H, H27), 0.94 (d, J = 5.9 Hz, 3H, 
H31), 0.93 – 0.90 (m, 9H, Si-(CH2CH3)3), 0.64 – 0.51 (m, 6H, Si-(CH2CH3)3). 13C NMR (126 
MHz, CDCl3) δ 170.03, 166.09, 134.94, 132.89, 130.70, 129.60, 128.31, 118.78, 76.64, 74.41, 71.98, 
38.37, 21.27, 15.69, 10.07, 6.90, 5.21. IR (thin film, vmax) 3209, 2094, 1737, 1725, 1660, 1667, 1290, 
1262, 1109, 1004, 865 cm-1. HRMS (ES+) calcd for C23H37O5Si [M+H]+ 421.2405, found 
421.2397. [𝜶𝜶]25
𝐷𝐷
  (c 1.2, CHCl3) +2.2.  
Methyl (E)-3-iodoacrylate  
 
To a solution of methyl propiolate (5.00 mL, 56.2 mmol) in AcOH (30 mL) was added NaI (17.0 
g, 113 mmol) and the reaction mixture stirred at 70 ºC for 18 h. After cooling to ambient 
temperature H2O (20 mL) and Et2O (20 mL) were added and the layers separated. The 
aqueous phase was extracted with Et2O (3 x 50 mL) before the combined organics neutralised 
with solid KOH (ca. 5 g), dried (MgSO4) and concentrated in vacuo to give a yellow oil (10.8 g, 
ca. 51 mmol).  
The crude product (10.8 g, ca. 51 mmol) was dissolved in benzene (100 mL) and HI (1.00 mL, 
57% aq.) and the solution heated under reflux for 96 h. After cooling to ambient temperature 
H2O (20 mL) and Et2O (20 mL) were added and the layers separated. The aqueous phase was 
extracted with Et2O (3 x 50 mL) before the combined organic phase washed sequentially with 
NaHCO3 (25 mL), Na2S2O4 (25 mL) and brine (25 mL). Concentration in vacuo and 
purification by recrystallisation (hexanes:MeOH) gave geometrically pure 259 (10.2 g, 85% 









1H NMR (500 MHz, CDCl3) δ 7.91 (d, J = 14.8 Hz, 1H, H21), 6.86 (d, J = 14.8 Hz, 1H, H20), 3.72 
(s, 3H, O-CH3). HRMS (ES+) calcd for C4H6IO2 [M+H]+ 212.9412, found 212.9416.  
Data consistent with that reported in the literature.172  
 (S)-1-((4S,5S,6S)-6-formyl-2,2,5-trimethyl-1,3-dioxan-4-yl)ethyl benzoate  
 
A solution of 262 (500 mg, 1.64 mmol) in CH2Cl2 (80 mL) and MeOH (80 mL) was cooled to -
78 C and purged with O2  for 1 min. O3  was bubbled through the reaction mixture until a 
persistent deep-blue colour was achieved (ca. 5 min). The reaction mixture was purged with 
O2  to remove excess O3, then quenched by addition of Me2S (0.5 mL) and warmed to rt. 
Filtration through cotton wool and concentration in vacuo afforded aldehyde  260 as a 
colourless oil which was used directly in the subsequent reaction without additional 
purification owing to rapid epimerisation of the C23 oxymethine.  
The following data was collected on a mixture of the two C23 epimers:  
1H NMR (500 MHz, CDCl3) δ 9.86 – 9.81 (m, 1H, CHO), 8.07 – 7.99 (m, 2H, Ar-H), 7.73 – 7.65 
(m, 1H, Ar-H), 7.61 – 7.51 (m, 2H, Ar-H), 5.27 – 5.18 (m, 1H, H26), 3.96 – 3.90 (m, 1H), 3.89 – 
3.85 (m, 1H), 3.79 – 3.74 (m, 1H), 2.33 – 2.25 (m, 1H), 1.43 – 1.38 (m, 6H, C(CH3)2), 1.36 – 1.31 (m, 
3H, H27), 1.20 – 1.14 (m, 3H, H31).   
 (S)-1-((4S,5R,6S)-6-((R,E)-1-hydroxy-4-methoxy-4-oxobut-2-en-1-yl)-2,2,5-trimethyl-1,3-
dioxan-4-yl)ethyl benzoate  
 
A solution of aldehyde 260 (250 mg. 0.594 mmol) and iodide 259 (314 mg, 1.49 mmol) in 
degassed THF (15 mL) was added to a suspension of CrCl2* (584 mg, 4.75 mmol) and NiCl2 
(cat.) in degassed DMF (15 mL). The emerald green solution was stirred for 16 h before being 
 
* The quality of the CrCl2 was found to be critical to the success of the NHK reaction, with best results 
obtained using a fresh commercial material manipulated in a glovebox and dried at 100 °C under high-

























quenched with NaHCO3 (50 mL) and diluted with Et2O (50 mL). The layers were separated 
and the aqueous phase extracted with Et2O (5 x 25 mL) before the combined organics washed 
with LiCl (50 mL of a satd aq soln), dried (Na2SO4), filtered, and concentrated in vacuo to give 
a yellow oil which was purified by flash column chromatography (SiO2, 10 ⟶ 50% EtOAc: 
PE40-60) to give 258 as a colourless oil (192 mg, 87%, 5:1 dr).  
Data for the major isomer is provided below:  
Rf (SiO2, 20% EtOAc:PE40-60) 0.4. 1H NMR (500 MHz, CDCl3) δ 8.11 – 8.01 (m, 2H, Ph-H), 7.62 
– 7.53 (m, 1H, Ph-H), 7.52 – 7.42 (m, 2H, Ph-H), 6.98 (dd, J = 15.7, 4.5 Hz, 1H, H21), 6.23 (dd, J 
= 15.7, 2.0 Hz, 1H, H20), 5.28 – 5.15 (m, 1H, H22), 4.55 – 4.47 (m, 1H, H26), 3.86 (dd, J = 9.2, 4.1 
Hz, 1H, H25), 3.80 (s, 3H, H28), 3.53 (dd, J = 6.9, 3.2 Hz, 1H, H23), 2.48 (s, 1H, OH), 2.19 – 2.03 
(m, 1H, H24), 1.37 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 1.33 (d, J = 6.4 Hz, 3H, H27), 0.97 (d, 
J = 6.7 Hz, 3H, H31). 13C NMR (126 MHz, CDCl3) δ 166.74, 166.09, 144.65, 132.86, 130.87, 
129.65, 128.40, 122.17, 101.52, 77.56, 77.06, 72.36, 70.27, 51.86, 31.94, 24.73, 23.81, 16.38, 12.89. 
IR (thin film, vmax) 2905, 1736, 1729, 1713, 1624, 1605, 1510, 1390, 1125, 970, 850 cm-1. HRMS 
(ES+) calcd for C21H29O7 [M+H]+ 393.1908, found 393.1900. [𝜶𝜶]
25
𝐷𝐷
  (c 1.50, CHCl3) +19.7.  
(S)-1-((4S,5S,6S)-6-((R,E)-4-methoxy-4-oxo-1-(((R)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoyl)oxy)but-2-en-1-yl)-2,2,5-trimethyl-1,3-dioxan-4-yl)ethyl benzoate  
 
(R)-MTPA ester S-6 was prepared from 258 (10 mg, 0.025 mmol) following general procedure 
A  to give S-6  (7 mg, 45%) as a white solid which was used crude in the MTPA analysis without 
additional purification. 
1H NMR (500 MHz, CDCl3) δ 8.03 (dd, J = 8.3, 1.5 Hz, 2H, Ar-H), 7.67 – 7.61 (m, 1H, Ar-H), 
7.60 – 7.52 (m, 2H, Ar-H), 7.51 – 7.41 (m, 5H, Ar-H).6.91 (dd, J = 15.8, 5.0 Hz, 1H, H21), 5.98 
(dd, J = 15.8, 1.7 Hz, 1H, H20), 5.82 (ddd, J = 5.0, 3.1, 1.8 Hz, 1H, H22), 5.20 – 5.10 (m, 1H, H26), 
3.82 (dd, J = 9.3, 4.0 Hz, 1H, H25), 3.77 (s, 3H, O-CH3), 3.63 (dd, J = 6.8, 3.0 Hz, 1H, H23), 3.59 
(s, 3H, MTPA O-CH3), 2.09 – 2.03 (m, 1H, H24), 1.35 (s, 3H, C(CH3)2), 1.32 (s, 3H, C(CH3)2), 
1.23 (d, J = 6.4 Hz, 3H, H27), 0.95 (d, J = 6.8 Hz, 3H, H31). HRMS (ES+) calcd for C31H36F3O9 





















phenylpropanoyl)oxy)but-2-en-1-yl)-2,2,5-trimethyl-1,3-dioxan-4-yl)ethyl benzoate  
 
(S)-MTPA ester S-7 was prepared following an analogous procedure to (R)-MTPA ester S-6 
using the enantiomeric MTPA acid to give S7 (10.5 mg, 68%) as a white solid which was used 
crude in the MTPA analysis without additional purification.  
1H NMR (500 MHz, CDCl3) δ 8.09 – 7.90 (m, 2H, Ar-H), 7.60 – 7.50 (m, 8H, Ar-H), 6.93 (dd, J 
= 15.8, 5.9 Hz, 1H, H21), 6.07 (dd, J = 15.8, 1.5 Hz, 1H, H20), 5.79 – 5.75 (m, 1H, H22), 5.10 (dq, 
J = 9.4, 6.5 Hz, 1H, H26), 3.78 (s, 3H, OCH3), 3.77 – 3.74 (m, 1H, H25), 3.57 (s, 3H, MTPA-
OCH3), 3.55 – 3.49 (m, 1H, H23), 1.90 – 1.80 (m, 1H, H24), 1.27 (s, 3H, C(CH3)2), 1.21 (s, 3H, 
C(CH3)2), 1.19 (d, J = 6.4 Hz, 3H, H27), 0.86 (d, J = 6.9 Hz, 3H, H31). HRMS (ES+) calcd for 
C31H36F3O9 [M+H]+ 609.2306, found 609.2303.  
Proton  δS-MTPA δR-MTPA δ(S-R) 
OMe (ester)  3.78 3.77 +0.01 
20  6.07 5.98 +0.09 
21  6.93 6.91 +0.02 
22  5.77 5.82 -0.05 
23  3.52 3.63 -0.11 
24  1.85 2.06 -0.21 
25  3.76 3.82 -0.06 
26  5.10 5.15 -0.05 
27  1.19 1.19 0 

























yl)ethyl benzoate  
 
To a solution of (MeO)3BF4 [Meerwein salt] (282 mg, 1.91 mmol) and Proton Sponge™ (409 
mg, 1.91 mmol) in CH2Cl2 (5 mL) was added a solution 258 (0.05 g, 0.127 mmol) in CH2Cl2 (5 
mL). The reaction mixture was stirred for 3 h then quenched by addition of NaHCO3 (5 mL). 
EtOAc (20 mL) was added and the layers separated. The organic phase was washed with citric 
acid (10% wt aq., 3 x 10 mL), dried (Na2SO4) and concentrated in vacuo. Purification by flash 
column chromatography (SiO2, 10% EtOAc:PE40-60) afforded 288 as a yellow oil (40.3 mg, 
78%).  
Rf (SiO2, 20% EtOAc:PE40-60) 0.35. 1H NMR (500 MHz, CDCl3) δ 8.05 (dt, J = 8.4, 1.3 Hz, 2H, 
Ar-H), 7.60 – 7.52 (m, 1H, Ar-H), 7.49 – 7.41 (m, 2H, Ar-H), 6.94 (dd, J = 15.8, 6.3 Hz, 1H, H21), 
6.10 (dd, J = 15.8, 1.3 Hz, 1H, H20), 5.20 (ddd, J = 9.1, 6.3, 2.5 Hz, 1H, H26), 3.92 (dd, J = 9.2, 4.1 
Hz, 1H, H25), 3.82 – 3.78 (m, 4H, H22, O-CH3), 3.53 – 3.45 (m, 1H, H23), 3.41 (s, 3H, O-CH3), 
2.04 – 1.93 (m, 1H, H24), 1.39 – 1.28 (m, 9H, H27, C(CH3)2), 1.02 (d, J = 6.7 Hz, 3H, H31). 13C 
NMR (126 MHz, CDCl3) δ 166.58, 166.15, 144.91, 132.83, 130.96, 129.68, 128.40, 123.54, 101.39, 
82.66, 71.93, 70.40, 58.18, 58.16, 51.86, 34.23, 25.03, 23.53, 16.41, 12.85. HRMS (ES+) calcd for 
C22H31O7 [M+H]+ 407.2064, found 407.2064. IR (thin film, vmax) 3000, 2905, 1732, 1709, 1626, 
1600, 1510, 1405, 1391, 1125, 970, 850, 733, 640 cm-1. [𝜶𝜶]25
𝐷𝐷
  (c 1.50, CHCl3) +11.0.  
 (1S)-1-((4S,5R,6S)-6-(1-hydroxyallyl)-2,2,5-trimethyl-1,3-dioxan-4-yl)ethyl benzoate 
 
To a solution of 320 (100 mg, 0.329 mmol, crude) in THF (10 mL) at -78 ºC was added vinyl 
MgBr (0.5 mL, 1 m in THF, 0.5 mmol). The reaction mixture was warmed to rt and stirred for 
36 h before the addition of NH4Cl (10 mL) and EtOAc (10 mL) sequentially. The layers were 
separated and the aqueous phase extracted with EtOAc (3 x 25 mL) before the combined 
organics dried (Na2SO4), concentrated in vacuo and purified by flash column chromatography 
























The following data was recorded on the mixture of C22 epimers:   
1H NMR (500 MHz, CDCl3) δ 8.10 – 7.96 (m, 2H, Ar-H), 7.58 – 7.50 (m, 1H, Ar-H), 7.43 (td, J 
= 7.8, 1.6 Hz, 2H, Ar-H), 5.89 (dddd, J = 18.9, 17.0, 10.5, 6.2 Hz, 1H, H21 major + minor), 5.40 (d, J = 
17.3 Hz, 0.64H, H20’major), 5.39 (d, J = 17.2 Hz, 0.36H, H20’minor), 5.27 (ddt, J = 10.4, 8.8, 1.5 Hz, 
1H, H20”major + minor), 5.19 (dq, J = 9.1, 6.5 Hz, 1H, H26major + minor), 4.29 – 4.24 (m, 0.64H, H22 
major), 4.06 – 4.00 (m, 0.34H, H22 minor), 3.91 (dd, J = 9.2, 4.2 Hz, 0.36H, H25 minor), 3.84 (dd, J = 
9.2, 4.0 Hz, 0.64H, H25 major), 3.45 (dd, J = 6.8, 3.1 Hz, 0.64H, H23 major), 3.26 (dd, J = 7.1, 5.5 Hz, 
0.36H, H23 minor), 2.50 (d, J = 5.1 Hz, 0.36H, OH minor), 2.28 (d, J = 4.4 Hz, 0.64H, OH major), 2.10 
(ddq, J = 6.8, 4.1 Hz, 0.64H, H24major + minor), 2.02 (ddq, J = 6.7, 4.1 Hz, 0.36H, H24major + minor), 
1.37 – 1.29 (m, 9H, H31major + minor, C(CH3)2 ), 0.98 (dd, J = 6.8, 1.7 Hz, 3H, H31major + minor). HRMS 
(ES+) calcd for C19H26O5Na [M+Na]+ 357.1673, found 357.1679.  
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DQF COSY  


































































































































































































































































































































































































































































































































































































































































































































































































































































































13C NMR  
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Spectra for the unidentified product formed during the palladium catalysed carbonylative 
cyclisation:  
 


































































































































































































































APPENDIX C: DETAILS OF 
COMPUTATIONAL PROCEDURES  
 
GENERAL DETAILS  
Molecular mechanics: Conformational searches were carried out using Schrodinger 
MacroModel using the MMFF-94 forcefield in the gas-phase (unless otherwise stated). 
Mixed-torsional/low-mode sampling was used to generate conformers, using 1000 steps per 
rotatable bond and an energy cut-off of 50 kj/mol. Conformers were minimised using a 
truncated Newton conjugate gradient (TNCG) method. Following the conformational search, 
redundant conformer elimination was used to eliminate conformers with an RMSD cut-off of 
0.5Å.		
Density functional theory: DFT calculations were carried out using Schrodinger Jaguar with 
B3LYP functional and 6-31G basis set. Polarisation and diffusion corrections were used as 
indicated in the text to better describe charged structures. Frequency calculations were 
carried out on all transition state structures to confirm the presence of a single negative 
frequency.  Where indicated, gas-phase structures were re-optimised using the PBF solvent 
model, as implemented in Jaguar.  Gaussian 09 was used for all IRC/MEP calculations.  
Visualisation: Structural representations were generated using CYLView. The following 
scheme is used for atom colours:  
 H O N C S Si F





Clustering: Clustering of conformers was carried out using SPSS. An RMSD matrix was first 
exported from Schrodinger Maestro, describing the pairwise similarity between each 
conformer. This matrix was used in a multidimensional scaling calculation in combination 
with the relative energy and torsional angles for each conformer.  The results of the 
calculation were plotted using Tableau, giving rise to the clustering diagrams given within the 
body of the text.  
Structures: Cartesian coordinates (in .xyz format) for key intermediates and transition states 
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We learn wisdom from failure much more than from success.  
We often discover what will do, by finding out what will not do;  
and probably he who never made a mistake never made a discovery.  
 
